<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78383</article-id><article-id pub-id-type="doi">10.7554/eLife.78383</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Multiple ciliary localization signals control INPP5E ciliary targeting</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-273041"><name><surname>Cilleros-Rodriguez</surname><given-names>Dario</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9529-5320</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-273034"><name><surname>Martin-Morales</surname><given-names>Raquel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0933-6160</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273035"><name><surname>Barbeito</surname><given-names>Pablo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0758-0012</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208016"><name><surname>Deb Roy</surname><given-names>Abhijit</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1640-2402</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273036"><name><surname>Loukil</surname><given-names>Abdelhalim</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-273037"><name><surname>Sierra-Rodero</surname><given-names>Belen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273038"><name><surname>Herranz</surname><given-names>Gonzalo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-151687"><name><surname>Pampliega</surname><given-names>Olatz</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7924-6374</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-273039"><name><surname>Redrejo-Rodriguez</surname><given-names>Modesto</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-154643"><name><surname>Goetz</surname><given-names>Sarah C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9705-6390</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-273040"><name><surname>Izquierdo</surname><given-names>Manuel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7701-1002</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-105917"><name><surname>Inoue</surname><given-names>Takanari</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7957-7624</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-210619"><name><surname>Garcia-Gonzalo</surname><given-names>Francesc R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9152-2191</contrib-id><email>francesc.garcia@uam.es</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cby8j38</institution-id><institution>Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid (UAM)</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02gfc7t72</institution-id><institution>Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), Consejo Superior de Investigaciones Científicas (CSIC)-UAM</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01s1q0w69</institution-id><institution>Instituto de Investigación del Hospital Universitario de La Paz (IdiPAZ)</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00ca2c886</institution-id><institution>CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII)</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Department of Cell Biology, Center for Cell Dynamics, Johns Hopkins University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Department of Pharmacology and Cancer Biology, Duke University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000xsnr85</institution-id><institution>Department of Neurosciences, University of the Basque Country, Achucarro Basque Center for Neuroscience-UPV/EHU</institution></institution-wrap><addr-line><named-content content-type="city">Leioa</named-content></addr-line><country>Spain</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Pedersen</surname><given-names>Lotte B</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035b05819</institution-id><institution>University of Copenhagen</institution></institution-wrap><country>Denmark</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Sengupta</surname><given-names>Piali</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05abbep66</institution-id><institution>Brandeis University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>05</day><month>09</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e78383</elocation-id><history><date date-type="received" iso-8601-date="2022-03-04"><day>04</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-21"><day>21</day><month>08</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-01-26"><day>26</day><month>01</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.01.25.477585"/></event></pub-history><permissions><copyright-statement>© 2022, Cilleros-Rodriguez, Martin-Morales et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Cilleros-Rodriguez, Martin-Morales et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78383-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-78383-figures-v1.pdf"/><abstract><p>Primary cilia are sensory membrane protrusions whose dysfunction causes ciliopathies. INPP5E is a ciliary phosphoinositide phosphatase mutated in ciliopathies like Joubert syndrome. INPP5E regulates numerous ciliary functions, but how it accumulates in cilia remains poorly understood. Herein, we show INPP5E ciliary targeting requires its folded catalytic domain and is controlled by four conserved ciliary localization signals (CLSs): LLxPIR motif (CLS1), W383 (CLS2), FDRxLYL motif (CLS3) and CaaX box (CLS4). We answer two long-standing questions in the field. First, partial CLS1-CLS4 redundancy explains why CLS4 is dispensable for ciliary targeting. Second, the essential need for CLS2 clarifies why CLS3-CLS4 are together insufficient for ciliary accumulation. Furthermore, we reveal that some Joubert syndrome mutations perturb INPP5E ciliary targeting, and clarify how each CLS works: (i) CLS4 recruits PDE6D, RPGR and ARL13B, (ii) CLS2-CLS3 regulate association to TULP3, ARL13B, and CEP164, and (iii) CLS1 and CLS4 cooperate in ATG16L1 binding. Altogether, we shed light on the mechanisms of INPP5E ciliary targeting, revealing a complexity without known parallels among ciliary cargoes.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cilia</kwd><kwd>ciliopathies</kwd><kwd>Joubert syndrome</kwd><kwd>INPP5E</kwd><kwd>phosphoinositides</kwd><kwd>phosphatase</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004837</institution-id><institution>Ministerio de Ciencia e Innovación</institution></institution-wrap></funding-source><award-id>PID2019-104941RB-I00</award-id><principal-award-recipient><name><surname>Martin-Morales</surname><given-names>Raquel</given-names></name><name><surname>Barbeito</surname><given-names>Pablo</given-names></name><name><surname>Garcia-Gonzalo</surname><given-names>Francesc R</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004837</institution-id><institution>Ministerio de Ciencia e Innovación</institution></institution-wrap></funding-source><award-id>PID2020-114148RB-I00</award-id><principal-award-recipient><name><surname>Izquierdo</surname><given-names>Manuel</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos III</institution></institution-wrap></funding-source><award-id>CIBERER-ACCI-2020</award-id><principal-award-recipient><name><surname>Garcia-Gonzalo</surname><given-names>Francesc R</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01HD099784</award-id><principal-award-recipient><name><surname>Goetz</surname><given-names>Sarah C</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>20POST35220046</award-id><principal-award-recipient><name><surname>Deb Roy</surname><given-names>Abhijit</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012818</institution-id><institution>Comunidad de Madrid</institution></institution-wrap></funding-source><award-id>PEJD-2016/BMD-2341</award-id><principal-award-recipient><name><surname>Sierra-Rodero</surname><given-names>Belen</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004837</institution-id><institution>Ministerio de Ciencia e Innovación</institution></institution-wrap></funding-source><award-id>BES2016-077828</award-id><principal-award-recipient><name><surname>Martin-Morales</surname><given-names>Raquel</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Four conserved ciliary localization signals in the Joubert syndrome-associated INPP5E phosphoinositide phosphatase control its ciliary accumulation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Primary cilia are solitary membrane protrusions acting as cellular antennae. They emanate from the basal body, a specialized mother centriole, and consist of a microtubule shaft, or axoneme, surrounded by the ciliary membrane, which is topologically continuous with, but compositionally distinct from, the plasma membrane (PM). For cilia to perform their signaling functions, they must accumulate specific receptors and signal transducers. For this to happen, these proteins must first reach the ciliary base, from where they can enter cilia by crossing the transition zone (TZ), the border region separating the ciliary compartment from the rest of the cell. If they can make it inside cilia, the ciliary levels of these proteins will then depend on the balance between ciliary entry and exit rates, a balance that can shift over time. Ciliary entry and exit rates in turn depend on how proteins interact with TZ components, and on whether they associate with specialized ciliary trafficking machinery, such as intraflagellar transport (IFT) trains, microtubule motor-driven multiprotein assemblies whose components, like the IFT-B, IFT-A, and BBSome complexes, selectively bind ciliary cargoes to mediate their transport into or out of cilia (<xref ref-type="bibr" rid="bib73">Nachury and Mick, 2019</xref>; <xref ref-type="bibr" rid="bib81">Reiter and Leroux, 2017</xref>; <xref ref-type="bibr" rid="bib37">Garcia-Gonzalo and Reiter, 2017</xref>).</p><p>Ciliary malfunction causes ciliopathies, a diverse group of human diseases, many of which are rare autosomal recessive syndromes. One such disease is Joubert syndrome (JBTS), affecting ≈ 1 in 100,000 people worldwide and whose pathognomonic signature is the molar tooth sign (MTS), a cerebellar and midbrain malformation observable by magnetic resonance imaging (MRI). JBTS patients may also present with mild to severe intellectual disability, hypotonia, ataxia, oculomotor apraxia, apnea/hyperpnea, polydactyly, kidney cysts, and retinal dystrophy. Genetically, JBTS can be caused by mutations in over 30 different genes, all involved in ciliary function (<xref ref-type="bibr" rid="bib81">Reiter and Leroux, 2017</xref>; <xref ref-type="bibr" rid="bib11">Braun and Hildebrandt, 2017</xref>; <xref ref-type="bibr" rid="bib4">Bachmann-Gagescu et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Bachmann-Gagescu et al., 2015</xref>).</p><p>More specifically, JBTS-causative genes regulate a ciliary signaling network, one of whose main nodes is the ciliary phosphoinositide phosphatase INPP5E (Inositol polyphosphate-5-phosphatase E, formerly known as Pharbin, or as type IV 72 kDa 5-phosphatase) (<xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Bielas et al., 2009</xref>; <xref ref-type="bibr" rid="bib2">Asano et al., 1999</xref>; <xref ref-type="bibr" rid="bib56">Kisseleva et al., 2000</xref>; <xref ref-type="bibr" rid="bib57">Kong et al., 2000</xref>). Evidence for the central role of INPP5E in JBTS includes: (i) INPP5E is one of the most commonly mutated JBTS genes (<xref ref-type="bibr" rid="bib3">Bachmann-Gagescu et al., 2015</xref>); (ii) mouse models of INPP5E loss of function recapitulate key features of human JBTS, including the axon tract defects leading to MTS in humans (<xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>; <xref ref-type="bibr" rid="bib41">Guo et al., 2019</xref>); (iii) most other JBTS genes encode proteins required for INPP5E ciliary targeting (<xref ref-type="bibr" rid="bib37">Garcia-Gonzalo and Reiter, 2017</xref>; <xref ref-type="bibr" rid="bib4">Bachmann-Gagescu et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Garcia-Gonzalo et al., 2011</xref>; <xref ref-type="bibr" rid="bib82">Roberson et al., 2015</xref>; <xref ref-type="bibr" rid="bib87">Slaats et al., 2016</xref>; <xref ref-type="bibr" rid="bib1">Alkanderi et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib74">Ning et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Dowdle et al., 2011</xref>); and (iv) the few JBTS genes that may not be needed for INPP5E ciliary targeting regulate the same pathways as INPP5E, like Hedgehog (Hh) signaling or ciliary stability (<xref ref-type="bibr" rid="bib60">Latour et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Dafinger et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">De Mori et al., 2017</xref>; <xref ref-type="bibr" rid="bib94">Van De Weghe et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Frikstad et al., 2019</xref>; <xref ref-type="bibr" rid="bib55">Ki et al., 2020</xref>; <xref ref-type="bibr" rid="bib61">Lee et al., 2012</xref>). Through its effects on Hh and phosphatidylinositol 3-kinase (PI3K) signaling, INPP5E also promotes tumor progression in medulloblastoma (<xref ref-type="bibr" rid="bib17">Conduit et al., 2017</xref>).</p><p>Almost all JBTS-causing INPP5E mutations are missense mutations affecting its catalytic domain (<xref ref-type="bibr" rid="bib3">Bachmann-Gagescu et al., 2015</xref>; <xref ref-type="bibr" rid="bib91">Travaglini et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">de Goede et al., 2016</xref>). In all cases tested, these mutations impaired 5-phosphatase activity toward one or both of its main substrates, PI(4,5)P<sub>2</sub> and PIP<sub>3</sub> (<xref ref-type="bibr" rid="bib8">Bielas et al., 2009</xref>; <xref ref-type="bibr" rid="bib21">de Goede et al., 2016</xref>). INPP5E mutations can also cause other ciliopathies, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and MORM syndrome (mental retardation, obesity, retinal dystrophy, and micropenis in males). Unlike JBTS, RP and LCA, the MORM mutation does not affect the catalytic domain, instead removing INPP5E’s C-terminal CaaX box, whose farnesylation tethers INPP5E to membrane (<xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>; <xref ref-type="bibr" rid="bib21">de Goede et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Xu et al., 2015</xref>; <xref ref-type="bibr" rid="bib97">Wang et al., 2013</xref>). Besides its catalytic domain and C-terminus, INPP5E also contains a proline-rich N-terminal region, where no ciliopathy mutations have been reported (<xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Bielas et al., 2009</xref>; <xref ref-type="bibr" rid="bib2">Asano et al., 1999</xref>; <xref ref-type="bibr" rid="bib56">Kisseleva et al., 2000</xref>; <xref ref-type="bibr" rid="bib57">Kong et al., 2000</xref>; <xref ref-type="bibr" rid="bib21">de Goede et al., 2016</xref>).</p><p>INPP5E plays multiple important roles at the cilium. Among others, these roles include regulation of: (i) ciliary phosphoinositide levels, (ii) ciliary protein composition, (iii) ciliary Hedgehog and PI3K signaling, (iv) ciliary ectovesicle release, (v) ciliary stability, and (vi) ciliogenesis (<xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Bielas et al., 2009</xref>; <xref ref-type="bibr" rid="bib41">Guo et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Garcia-Gonzalo et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Chávez et al., 2015</xref>; <xref ref-type="bibr" rid="bib5">Badgandi et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Dyson et al., 2017</xref>; <xref ref-type="bibr" rid="bib77">Phua et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Hakim et al., 2016</xref>; <xref ref-type="bibr" rid="bib102">Xu et al., 2016</xref>; <xref ref-type="bibr" rid="bib103">Xu et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Constable et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Hasenpusch-Theil et al., 2020</xref>; <xref ref-type="bibr" rid="bib86">Sharif et al., 2021</xref>; <xref ref-type="bibr" rid="bib93">Ukhanov et al., 2022</xref>; <xref ref-type="bibr" rid="bib104">Yue et al., 2021</xref>). Although most of its functions are ciliary, INPP5E also plays extraciliary roles, like promoting autophagosome-lysosome fusion during autophagy (<xref ref-type="bibr" rid="bib44">Hasegawa et al., 2016</xref>).</p><p>Two motifs in INPP5E protein sequence are known to affect its ciliary targeting: the FDRxLYL motif (aa 609–615) and the CaaX box (aa 641–644), both located in the C-terminal region after the phosphatase domain (aa 297–599) (<xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>; <xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Kösling et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Fujisawa et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Qiu et al., 2021</xref>). The CaaX box is not essential for INPP5E ciliary localization, but CaaX box mutants show reduced ciliary targeting, while increasing its proportion at the ciliary base and elsewhere (<xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>; <xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Kösling et al., 2018</xref>). CaaX box farnesylation allows INPP5E to bind phosphodiesterase 6 subunit delta (PDE6D), a prenyl-binding protein that extracts INPP5E from the ciliary base membrane and ferries it across the transition zone. Once inside the cilium, the active form of the monomeric G-protein ADP ribosylation factor (ARF)-like 3 (ARL3) induces dissociation of the PDE6D-INPP5E complex, thus releasing the farnesyl group for insertion into the ciliary membrane. For this to happen, ARL3 must first be activated by a guanine nucleotide exchange factor (GEF) complex consisting of ARF-like 13B (ARL13B), an atypical small G-protein, and its cofactor Binder of ARL2 (BART) (<xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Fujisawa et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Gotthardt et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Fansa et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Ivanova et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">ElMaghloob et al., 2021</xref>).</p><p>Intriguingly, despite INPP5E farnesylation not being essential for ciliary targeting, the latter is completely dependent on PDE6D, ARL3, and ARL13B, all of them also JBTS-causative genes (<xref ref-type="bibr" rid="bib4">Bachmann-Gagescu et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Alkanderi et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). Although the reason for this apparent discrepancy is unknown, part of the answer might relate to the retinitis pigmentosa GTPase regulator (RPGR), an RP-associated protein required for INPP5E ciliary targeting, and whose own ciliary localization depends on its geranylgeranylated CaaX box binding to PDE6D (<xref ref-type="bibr" rid="bib105">Zhang et al., 2019</xref>; <xref ref-type="bibr" rid="bib80">Rao et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Dutta and Seo, 2016</xref>; <xref ref-type="bibr" rid="bib62">Lee and Seo, 2015</xref>; <xref ref-type="bibr" rid="bib27">Fansa et al., 2015</xref>; <xref ref-type="bibr" rid="bib98">Wätzlich et al., 2013</xref>; <xref ref-type="bibr" rid="bib95">Vössing et al., 2021</xref>).</p><p>Regarding ARL13B, its direct interaction with INPP5E probably explains its strong requirement for INPP5E ciliary targeting (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Fujisawa et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Qiu et al., 2021</xref>). This interaction is mediated by the FDRxLYL motif, which, unlike the CaaX box, is absolutely required for INPP5E ciliary localization (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). Ciliary localization of ARL13B is in turn dependent on Tubby-like protein 3 (TULP3), a phosphoinositide-binding adaptor that links ciliary membrane cargoes to IFT trains (<xref ref-type="bibr" rid="bib5">Badgandi et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Han et al., 2019</xref>; <xref ref-type="bibr" rid="bib70">Mukhopadhyay et al., 2010</xref>; <xref ref-type="bibr" rid="bib71">Mukhopadhyay et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Palicharla et al., 2021</xref>). This probably explains why TULP3 is also required for INPP5E ciliary targeting, although a more direct connection between TULP3 and INPP5E might also exist (<xref ref-type="bibr" rid="bib43">Han et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Palicharla et al., 2021</xref>). Other proteins needed for INPP5E ciliary targeting include the centrosomal protein of 164 kDa (CEP164), which is involved in INPP5E recruitment to the ciliary base (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib102">Xu et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Cajanek and Nigg, 2014</xref>; <xref ref-type="bibr" rid="bib85">Schmidt et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Graser et al., 2007</xref>), and the autophagy-related protein 16-like 1 (ATG16L1), also implicated in ciliogenesis and ciliary trafficking (<xref ref-type="bibr" rid="bib10">Boukhalfa et al., 2021</xref>; <xref ref-type="bibr" rid="bib76">Pampliega et al., 2013</xref>).</p><p>Although the C-terminal region of INPP5E contains both FDRxLYL motif and CaaX box, this region alone is not sufficient to target INPP5E to cilia. In contrast, a fragment containing both phosphatase domain and C-terminal region suffices for ciliary accumulation (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). This indicates that something in or near the catalytic domain is also essential for ciliary targeting, but the reasons for this requirement are unknown.</p><p>Herein, we start by elucidating why the catalytic domain is required for ciliary targeting. There are two reasons for this: (i) the FDRxLYL motif is part of the catalytic domain’s globular fold, even though the motif is outside the conserved domain as defined by primary sequence analysis; and (ii) a key catalytic domain residue, W383, which is physically adjacent to the FDRxLYL motif in the domain’s crystal structure, is also specifically and strongly required for ciliary accumulation. We then resolve another lingering question in the field: why the CaaX box is dispensable for INPP5E ciliary localization. We show that the CaaX box is partially redundant with the LLxPIR motif, located near the end of the N-terminal region. Thus, while single deletion of CaaX box or LLxPIR moderately reduces ciliary targeting, simultaneous deletion of both completely abolishes it. Therefore, we reveal that INPP5E ciliary accumulation depends on the interplay between four different ciliary localization signals (CLS1-4), the first two of which we newly identify here: the LLxPIR motif (CLS1), W383 (CLS2), the FDRxLYL motif (CLS3) and the CaaX box (CLS4). In the second half of this work, we systematically examine how each of these CLSs affects INPP5E interactions with proteins required for its ciliary targeting. Through this approach, we find that CLS2 and CLS3 function by promoting interaction with TULP3 and ARL13B, while also antagonizing CEP164 binding. On the other hand, CLS4 is needed for association to PDE6D, RPGR and, in cooperation with CLS1, to ATG16L1. Altogether, our data reveal an unprecedented degree of complexity in the ciliary targeting mechanisms of INPP5E, as compared to other known ciliary cargoes, for which a single or at most two CLSs suffice to explain ciliary accumulation (<xref ref-type="bibr" rid="bib73">Nachury and Mick, 2019</xref>; <xref ref-type="bibr" rid="bib35">Garcia-Gonzalo and Reiter, 2012</xref>; <xref ref-type="bibr" rid="bib6">Barbeito and Garcia-Gonzalo, 2021</xref>; <xref ref-type="bibr" rid="bib72">Mukhopadhyay et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">McIntyre et al., 2016</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>INPP5E catalytic domain encompasses the FDRxLYL motif and is required for ciliary targeting</title><p>Ciliary accumulation of human INPP5E requires the conserved FDRxLYL motif (aa 609–615) (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). This motif lies downstream of INPP5E’s highly conserved phosphatase domain, as defined by the InterPro protein signature database (InterPro domain IPR000300, aa 297–599) (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib9">Blum et al., 2021</xref>). However, INPP5E crystal structure reveals a more extensive globular phosphatase domain, spanning residues 282–623, on whose surface the FDRxLYL motif folds (PDB ID: 2xsw) (<xref ref-type="fig" rid="fig1">Figure 1a</xref>; <xref ref-type="bibr" rid="bib92">Tresaugues et al., 2010</xref>). Indeed, the crystallographic data show that the FDRxLYL motif, and the alpha-helix it is nested in, interact with several other catalytic domain residues (such interactions include D610-L362, Y614-P358, R620-E347, and R621-E354). Recently, a 3D model of full-length INPP5E was generated using AlphaFold, a remarkably accurate machine learning algorithm for protein structure prediction (<xref ref-type="bibr" rid="bib52">Jumper et al., 2021</xref>). The AlphaFold model closely matches the crystal structure, including the FDRxLYL motif’s structure and location. Thus, based on the structural data, we conclude that INPP5E’s catalytic domain spans residues 282–623, and therefore encompasses the FDRxLYL motif, which lies on the domain’s surface. Accordingly, from now on, when we speak of the catalytic or phosphatase domain, we will be referring to the globular domain spanning residues 282–623, unless we specify otherwise.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>INPP5E catalytic domain encompasses FDRxLYL motif and is required for ciliary targeting.</title><p>(<bold>a</bold>) Top diagram represents full length human INPP5E protein sequence (aa 1–644). Depicted are the proline-rich region (aa 10–242, Uniprot), the previously reported ciliary localization signal (FDRxLYL, aa 609–615 <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>), and the CaaX box driving farnesylation (aa 641–644). Also shown is the inositol polyphosphate 5-phosphatase catalytic domain, whose most conserved core corresponds to InterPro domain IPR000300 (aa 297–599), but which actually spans aa 282–623, as revealed by its crystal structure, available at the Protein Data Bank (PDB) and displayed below (PDB ID: 2xsw). Notice how FDRxLYL residues (in magenta above and below) are part of the catalytic domain, on whose surface they fold. The 3D structure also shows active site residues in cyan, alpha-helices in orange, and beta-strands in yellow (including the beta-sandwich at the domain’s core, and a small beta-hairpin near the active site). (<bold>b</bold>) Schematic representation of full length human INPP5E (1-644) and its deletion mutants used in (<bold>c</bold>), indicating on the right which ones localize to cilia. (<bold>c</bold>) Immunofluorescence images of cilia from hTERT-RPE1 cells transfected with the indicated EGFP-INPP5E constructs. Cells were stained with antibodies against acetylated α-tubulin (AcTub), γ-tubulin (γTub) and EGFP to detect the fusion proteins. Images are representative of at least two independent experiments per construct, with &gt;30 transfected-cell cilia visualized per construct and experiment. Scale bar, 5 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Expression levels of EGFP-INPP5E constructs from <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title><p>The indicated constructs were expressed in HEK293T cells. Lysates were analyzed by SDS-PAGE and immunoblotting with the indicated antibodies. Molecular weight markers in kilodaltons (kDa) are shown on the right. Arrows indicate locations of the 351–644, 451–644, and 551–644 constructs, whose predicted molecular weights are 61, 50, and 39 kDa, respectively. The numbers under the tubulin blots are EGFP/Tubulin band intensity ratios, normalized so that WT equals 100%.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Uncropped immunoblots from <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title><p>Relevant bands are inside rectangles. See <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig1-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> (WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig1-figsupp1-data2-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> (WB: Tubulin).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig1-figsupp1-data3-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata4"><label>Figure 1—figure supplement 1—source data 4.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> (WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig1-figsupp1-data4-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata5"><label>Figure 1—figure supplement 1—source data 5.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> (WB: Tubulin).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig1-figsupp1-data5-v1.tif"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig1-figsupp1-v1.tif"/></fig></fig-group><p>To clarify how INPP5E’s phosphatase domain controls ciliary targeting, we generated a series of INPP5E deletion mutants lacking different portions of the N or C-terminal regions, or lacking only the InterPro-defined catalytic domain (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). Interestingly, INPP5E ciliary accumulation closely correlated with the presence of an intact structurally-defined catalytic domain (aa 282–623) (<xref ref-type="fig" rid="fig1">Figure 1b–c</xref>). Deletion of the InterPro-defined catalytic domain (Δ297–599) completely abolished ciliary targeting in EGFP-INPP5E-transfected hTERT-RPE1 cells (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). N-terminal deletions not affecting the phosphatase domain did not affect ciliary localization, as was the case for constructs 100–644, 200–644, 251–644, and 274–644 (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). In contrast, 288–644 displayed strongly reduced ciliary targeting, and 351–644, 451–644 and 551–644 completely failed to localize to cilia (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). C-terminal deletions showed a similar pattern. As previously reported, the MORM mutant (1-626) was found inside cilia and at the ciliary base, and the same was true for 1–623 (<xref ref-type="fig" rid="fig1">Figure 1c</xref>; <xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>). The 1–621 mutant was only occasionally ciliary, at low levels near the ciliary base (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). Further deletions from the C-terminus resulted in complete loss of ciliary targeting, as was the case for 1–618, 1–616, 1–608, and 1–283 (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). Hence, integrity of the structurally defined catalytic domain is essential for INPP5E ciliary accumulation.</p><p>At least partly, this lack of ciliary targeting could be due to protein instability of these mutants. To assess this, we used western blot to measure the expression levels of many of these mutants in transfected HEK293T cells. Given the nature of this expression system, we expect any changes in protein levels between constructs to be likely due to changes in protein stability, at least when comparing proteins of similar sizes (if not, then slower translation rates of longer mRNAs need to be accounted for). Other factors affecting protein levels in other contexts are unlikely to play important roles in this system, including changes in transfection efficiency (always very high in HEK293T), transcriptional regulation (expression of all constructs driven by constitutive and strong cytomegalovirus promoter), or post-transcriptional mRNA regulation (no anticipated differences between constructs).</p><p>When we did these experiments, we observed a clear effect of the catalytic domain (aa 282–623) on EGFP-INPP5E protein levels (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). This was very clear, for instance, when comparing 1–626 to 1–618, and also 274–644 to 288–644. In both cases, as catalytic domain residues where removed in the second mutant of each pair, protein levels decreased sharply, by at least 4-fold. On the other hand, virtually complete removal of the catalytic domain in Δ297–599 only reduced expression moderately, about 2-fold. Yet ciliary targeting of this mutant was completely abolished, not just reduced by half (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). Altogether, these data suggest that the catalytic domain, in addition to affecting protein stability, has a specific role in promoting INPP5E ciliary accumulation.</p></sec><sec id="s2-2"><title>W383 and FDRxLYL function as specific CLSs on the catalytic domain surface</title><p>We first confirmed that, as previously reported, the FDRxLYL motif is essential for INPP5E ciliary targeting (<xref ref-type="fig" rid="fig2">Figure 2a</xref>; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). Mutation to alanines of both the FDR (aa 609–611) and LYL (aa 613–615) triplets completely abolished ciliary localization (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). To assess the relative importance of each residue within the FDRxLYL motif, we also made the individual alanine mutants (F609A, D610A, R611A, E612A, L613A, Y614A, L615A). Surprisingly, all of them still localized to cilia, indicating redundancy within the FDR and LYL triplets (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>W383 and FDRxLYL motifs act as CLSs on the catalytic domain surface.</title><p>(<bold>a</bold>) Cilia localization of the indicated FDRxLYL mutants of EGFP-INPP5E was analyzed in hTERT-RPE1 cells as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Scale bars, 5 µm. (<bold>b</bold>) Magnification from INPP5E structure (PDB ID: 2xsw) showing the FDRxLYL motif residues (pink) and adjacent catalytic domain residues shown here to affect ciliary targeting (green). Distance between W383 and F609 is indicated in angstroms. Beta-sheets and alpha-helices are shown as yellow and orange ribbons, respectively. Notice active site region on top left (cyan). (<bold>c</bold>) Cilia localization of the indicated EGFP-INPP5E constructs was analyzed as in (<bold>a</bold>). In both cases, images are representative of at least two independent experiments per construct, with &gt;30 transfected-cell cilia visualized per construct and experiment. Scale bars, 5 µm. (<bold>d</bold>) Percentage of positive cilia was quantitated for each of the indicated constructs. Data are mean ± SEM of n=3 independent experiments. Data were analyzed by one-way ANOVA followed by Tukey’s multiple comparisons tests. Significance relative to WT is shown as p&lt;0.0001(****). LYL &gt;AAA: L613A+Y614A+L615 A; FDR &gt;AAA: F609A+D610A+R611 A; RR &gt;AA: R378A+R379 A. (<bold>e</bold>) 5-phosphatase activity, expressed as picomoles of released inorganic phosphate per minute, was measured, using PI(4,5)P2 as substrate, in immunoprecipitates of HEK293T cells transfected with the indicated EGFP-INPP5E variants. Cilia-localized constructs shown as black columns, non-ciliary as grey. Data are mean ± SEM of n=9,9,5,4,3,5,3,3,2,3,3 independent experiments (from left to right). Data were analyzed by one-way ANOVA followed by Tukey’s multiple comparisons tests. Significance relative to WT is shown as small asterisks directly above each bar. Significance relative to W383A is shown as bigger asterisks as indicated. In all cases, significance is represented as: p&lt;0.05(*), p&lt;0.01(**), p&lt;0.001(***), p&lt;0.0001(****), or n.s. (not significant). (<bold>f</bold>) Protein levels in the immunoprecipitates used for the activity assays in (<bold>e</bold>). Western blot bands were quantitated and plotted as percentage of WT. Data are mean ± SEM of n=8,5,3,3,5,2,3,3,2,3 independent experiments (from left to right). One-way ANOVA revealed no significant differences.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2d</xref>.</title><p>Data from n=3 independent experiments.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78383-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2e</xref>.</title><p>Data from n=9 independent experiments.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78383-fig2-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2f</xref>.</title><p>Data from n=8 independent experiments.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78383-fig2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>FDRELYL motif residues are not individually required for INPP5E cilia localization.</title><p>Ciliary targeting of EGFP-INPP5E wild type (WT) or the indicated FDRELYL motif mutants was assessed by immunofluorescence microscopy in transfected hTERT-RPE1 cells, which were stained with antibodies against acetylated α-tubulin (AcTub), γ-tubulin (γTub) and EGFP to detect the fusion proteins. Images are representative of n=2 independent experiments, with &gt;30 transfected-cell cilia visualized per experiment. Scale bar, 5 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Expression levels of EGFP-INPP5E constructs from <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title><p>The indicated constructs were expressed in HEK293T cells. Lysates were analyzed by SDS-PAGE and immunoblotting with the indicated antibodies. Molecular weight markers in kilodaltons are shown on the right. The numbers under the tubulin blots are EGFP/Tubulin band intensity ratios, normalized so that WT equals 100%.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Uncropped immunoblots from <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title><p>Relevant bands are inside rectangles. See <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig2-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata2"><label>Figure 2—figure supplement 2—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> (WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp2-data2-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata3"><label>Figure 2—figure supplement 2—source data 3.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> (WB: Tubulin).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp2-data3-v1.tif"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Stability of W383A and FDRxLYL mutants.</title><p>(<bold>a</bold>) The indicated EGFP-INPP5E forms were expressed in HEK293T cells for 24 hr, at which time 200 µg/ml cycloheximide was added for the indicated number of hours. Cell lysates were then analyzed by western blot with antibodies against EGFP and α-tubulin. Molecular weight markers in kDa shown on the right. FDR &gt;AAA: F609A+D610A+R611 A; LYL &gt;AAA: L613A+Y614A+L615 A. (<bold>b</bold>) Protein levels at the time of cycloheximide addition for the same EGFP-INPP5E forms as in (<bold>a</bold>). EGFP/Tubulin band intensity ratios were normalized to WT and plotted as mean ± SEM from n=3 independent experiments, including one in (<bold>a</bold>). One-way ANOVA revealed no significant differences. (<bold>c</bold>) Time course of protein levels after cycloheximide addition. Amounts are EGFP/Tubulin ratios for each EGFP-INPP5E form, normalized to the ratio at 0 hr. Data are mean ± SEM (n=3 independent experiments). Unpaired t-tests reveal non-significance except for WT versus W383A at 10 hr (p=0.048).</p><p><supplementary-material id="fig2s3sdata1"><label>Figure 2—figure supplement 3—source data 1.</label><caption><title>Uncropped immunoblots from <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3a</xref>.</title><p>Relevant bands are inside rectangles. See <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig2-figsupp3-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s3sdata2"><label>Figure 2—figure supplement 3—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref> (WB: EGFP for WT and W383A).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp3-data2-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig2s3sdata3"><label>Figure 2—figure supplement 3—source data 3.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref> (WB: EGFP for FDR &gt;AAA and LYL &gt;AAA).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp3-data3-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig2s3sdata4"><label>Figure 2—figure supplement 3—source data 4.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref> (WB: Tubulin for WT and W383A).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp3-data4-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig2s3sdata5"><label>Figure 2—figure supplement 3—source data 5.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref> (WB: Tubulin for FDR &gt;AAA and LYL &gt;AAA).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp3-data5-v1.tif"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Effect of W383 mutations on ciliary targeting and activity.</title><p>(<bold>a</bold>) Cilia localization of the indicated EGFP-INPP5E variants was analyzed in hTERT-RPE1 cells as in <xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig2">2</xref>. Images are representative of n=2 independent experiments, with &gt;30 transfected-cell cilia visualized per experiment. Scale bars, 5 µm. (<bold>b</bold>) 5-phosphatase activity, expressed as picomoles of released inorganic phosphate per minute, was measured, using PI(4,5)P2 as substrate, in immunoprecipitates of HEK293T cells transfected with the indicated EGFP-INPP5E variants. Cilia-localized constructs shown as black columns, non-ciliary as grey. Data are mean ± SEM of n=3 technical replicates. (<bold>c</bold>) Western blot of the anti-EGFP immunoprecipitates used for the activity assays in (<bold>b</bold>). Molecular weight markers are on the right (kDa).</p><p><supplementary-material id="fig2s4sdata1"><label>Figure 2—figure supplement 4—source data 1.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4c</xref>.</title><p>Relevant bands are inside rectangle. See <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig2-figsupp4-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s4sdata2"><label>Figure 2—figure supplement 4—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4c</xref> (WB: EGFP).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig2-figsupp4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig2-figsupp4-v1.tif"/></fig></fig-group><p>Given that the FDRxLYL motif lies on the catalytic domain surface (<xref ref-type="fig" rid="fig1">Figure 1a</xref>), and that catalytic domain integrity is essential for ciliary targeting (<xref ref-type="fig" rid="fig1">Figure 1b–c</xref>), we hypothesized that INPP5E ciliary targeting relies on a catalytic domain surface including not only the FDRxLYL residues, but also other residues whose proximity to FDRxLYL is dependent upon a folded domain. To test this, we examined the 3D structure of INPP5E’s catalytic domain (PDB ID: 2XSW) in order to identify candidate residues for this putative surface. We did this by selecting residues meeting all or most of the following criteria: (i) located near FDRxLYL motif, on same side of domain; (ii) high exposure to solvent; and (iii) highly conserved in vertebrate INPP5E orthologs. Out of this analysis, we selected sixteen candidate residues: R345, R346, E347, W348, E349, Q353, E354, Y360, V361, R378, R379, D380, I382, W383, F384, E387. Alanine mutation of most of these residues did not affect ciliary targeting of EGFP-INPP5E in hTERT-RPE1 cells (<xref ref-type="fig" rid="fig2">Figure 2b–c</xref>). Exceptions were W348A, Y360A, W383A, and R378A+R379 A, all of which completely failed to accumulate in cilia (<xref ref-type="fig" rid="fig2">Figure 2c–d</xref>). The R378 and R379 arginines are redundant, as the double but not single mutations impeded cilia localization (<xref ref-type="fig" rid="fig2">Figure 2c–d</xref>).</p><p>Mistargeting of these four mutants could be due to loss of catalytic domain integrity, which is critical for ciliary targeting (<xref ref-type="fig" rid="fig1">Figure 1</xref>). If so, then phosphatase activity would also be disrupted in these mutants. To test this, we immunoprecipitated these EGFP-INPP5E mutants from transfected HEK293T lysates and measured their PI(4,5)P<sub>2</sub> 5-phosphatase activity in the immunoprecipitates (IPs). EGFP-INPP5E wild type was used as positive control, whereas negative controls included: (i) a reaction with substrate but no enzyme, to assess the rate of basal PI(4,5)P<sub>2</sub> dephosphorylation; and (ii) the catalytically inactive D477N INPP5E mutant, lacking a critical active site aspartate but normally localizing to cilia (<xref ref-type="bibr" rid="bib8">Bielas et al., 2009</xref>; <xref ref-type="bibr" rid="bib57">Kong et al., 2000</xref>; <xref ref-type="bibr" rid="bib36">Garcia-Gonzalo et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Kong et al., 2006</xref>; <xref ref-type="bibr" rid="bib99">Whisstock et al., 2000</xref>).</p><p>Compared to negative controls, phosphate release by WT was about 12-fold faster, a very significant difference (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). W348A and Y360A were completely inactive, and R378A+R379 A nearly so (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). Hence, lack of ciliary targeting in these mutants may be non-specific. Unlike R378A+R379 A, the cilia-localized R378A and R379A single mutants retained activity, either fully (R378A) or partially (R379A). Like R379A, W383A was half as active as WT, with a very significant ≈6-fold increase over negative controls (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). The same was true for the LYL triplet mutant, whereas the FDR mutant was somewhat less active, with a ≈3-fold increase over controls (<xref ref-type="fig" rid="fig2">Figure 2a–e</xref>). Quantitation by anti-EGFP immunoblot of the protein levels of each mutant in the IPs used to measure activities revealed no significant differences for any of the mutants (<xref ref-type="fig" rid="fig2">Figure 2f</xref>). We also analyzed expression levels of these mutants at 48 hr post-transfection by Western blot of lysates in a separate HEK293T cell experiment, in which protein levels of the W383A, LYL and FDR mutants were ≈75%, 60%, and 50% of WT, respectively. The lowest expression was seen for W348A, Y360A, R378A+R379 A, and R379A, all between 20 and40% of WT (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><p>All of this suggests that W383 and FDRxLYL function as bona fide CLSs, as their strict requirement for ciliary targeting cannot fully be accounted for by their moderate effects on enzyme activity or protein levels. Accordingly, R379A, a mutation immediately adjacent to FDRxLYL and W383, displayed similar moderate effects on activity and protein levels, but had no effect on ciliary localization (<xref ref-type="fig" rid="fig2">Figure 2b–f</xref>).</p><p>Still, the partial activity loss in W383A and FDRxLYL mutants suggests that catalytic domain integrity may be partially lost as well. To examine this further, we assessed the half-lives of these mutants in HEK293T cells using the protein translation inhibitor cycloheximide (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). After 5, 10 or 24 hr in cycloheximide, EGFP-INPP5E(WT) levels were virtually unaffected, indicating a long half-life of several days. For W383A and the triplet FDR and LYL mutants, initial levels, at 24 h post-transfection, were not significantly different from WT (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3a</xref><bold>-b</bold>). From those initial levels (100%), W383A fell to 60% in the first 10 hr, but then remained at 60% by 24 hr, rather than diminishing further (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3c</xref>). Similar results were seen for the FDR mutant, whereas LYL’s curve ran closer to WT’s (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3c</xref>).</p><p>Thus, W383A showed a biphasic kinetics, whose most parsimonious explanation appears to be the existence of two protein populations: ≈40% of W383A would be unstable with a half-life of ≈5 hr, whereas the remaining ≈60% would be stable, with a half-life of days, like WT (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3c</xref>). Presumably, the unstable form would not be properly folded and would be inactive, whereas the stable form would be folded and active, which would explain why W383A reduces activity ≈2-fold (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). Although this model remains speculative, the fact that ≈50–60% of W383A is stable and enzymatically active supports the idea that W383 is a bona fide CLS, since loss of ciliary targeting in W383A is virtually complete, and much stronger than a twofold reduction (<xref ref-type="fig" rid="fig2">Figure 2c–d</xref>). Similar points support the specificity of FDRxLYL as CLS.</p><p>We also explored how W383 substitution to residues other than alanine affects ciliary targeting and enzyme activity (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). To do this, we mutated W383 to another aromatic residue (W383F), to several aliphatic residues (W383I, W383L, W383M, W383V), or to acid (W383E) or basic (W383R) residues. Interestingly, W383F was fully active and ciliary, indicating that an aromatic ring at this position suffices for both functions (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). In contrast, all other mutations fully suppressed ciliary targeting, like W383A (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4a</xref>). Interestingly, enzyme activity of W383I, W383L, W383M, and W383V was the same as for W383A, suggesting that an aromatic ring in this position is important for both targeting and activity (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4b-c</xref>). Overall, the data in this section show that W383 and FDRxLYL, despite their moderate effects on enzyme activity, function as specific CLSs to target INPP5E to cilia.</p></sec><sec id="s2-3"><title>The LLxPIR motif cooperates with the CaaX box to target INPP5E to cilia</title><p>Besides W383 and FDRxLYL, the C-terminal CaaX box (641-CSVS-644) also modulates INPP5E ciliary targeting. Although CaaX box deletion causes mistargeting of some INPP5E molecules to the ciliary base or other cellular membranes, CaaX box mutants still accumulate in cilia (<xref ref-type="fig" rid="fig1">Figure 1c</xref>; <xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>; <xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Kösling et al., 2018</xref>). This is somewhat puzzling, as INPP5E ciliary targeting strongly depends on the farnesyl receptor PDE6D (<xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>).</p><p>In the course of our experiments, we made a serendipitous observation that led us to novel insights into how non-farnesylated INPP5E manages to still accumulate in cilia. Initially, we found that INPP5E’s N-terminus (aa 1–273), while being dispensable for ciliary targeting of INPP5E (<xref ref-type="fig" rid="fig1">Figure 1b–c</xref>), is required for ciliary targeting of INPP5E’s MORM mutant (Δ627–644) (<xref ref-type="fig" rid="fig3">Figure 3e</xref>). We subsequently saw that this effect of the N-terminus is mediated by residues 251–273, and that these residues are strongly required for ciliary targeting of the C641S mutant, in which the farnesylated CaaX box cysteine is replaced by non-farnesylatable serine (<xref ref-type="fig" rid="fig3">Figure 3a–c</xref>). Thus, while both Δ251–273 and C641S single mutants localized inside cilia, the double (Δ251–273)+C641 S mutant completely failed to do so, despite accumulating at the ciliary base (<xref ref-type="fig" rid="fig3">Figure 3a–c</xref>). Interestingly, upon careful observation and quantitation, both single mutants already showed a partial loss of intraciliary targeting, aside from their ciliary base accumulation (<xref ref-type="fig" rid="fig3">Figure 3a–c</xref>). Thus, the single Δ251–273 mutant behaves as previously reported for CaaX mutants (and as shown here for C641S), except that Δ251–273 reduces ciliary targeting even more than C641S (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). These data indicate that the CaaX box and residues 251–273 cooperate to target INPP5E inside cilia: not only are both sequences required for optimal ciliary targeting of the wild type protein, but their functions are partially redundant, each becoming essential when the other one is missing (<xref ref-type="fig" rid="fig3">Figure 3a–c</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The LLxPIR motif is a novel CLS that cooperates with the CaaX box to mediate INPP5E ciliary targeting.</title><p>(<bold>a</bold>) Schema of full length human INPP5E and its mutants used in (<bold>b–c</bold>). Cilia localization of each mutant is indicated on the right. (<bold>b</bold>) Cilia localization of WT and indicated mutants was analyzed in hTERT-RPE1 cells as in <xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig2">2</xref>. Images are representative of n=3 independent experiments, with &gt;30 transfected-cell cilia visualized per construct and experiment. Scale bar, 5 µm. (<bold>c</bold>) Quantitation of data from (<bold>b</bold>). The percentage of positive cilia in transfected cells is shown for the indicated EGFP-INPP5E constructs. Data are mean ± SEM of n=3 independent experiments. Data were analyzed by one-way ANOVA with post-hoc Tukey multiple comparisons tests. Statistical significance is depicted as p&lt;0.01(**), p&lt;0.001(***), or p&lt;0.0001(****). Significance is shown relative to WT unless otherwise indicated. (<bold>d</bold>) Schema of INPP5E deletion mutants used to map the CLS within aa 251–273. None of these mutants contains the CaaX box (aa 641–644), so their ciliary targeting is strictly dependent on residues 251–273. Cilia localization of each mutant is indicated on the right. (<bold>e</bold>) Cilia localization of the mutants from (<bold>d</bold>) was analyzed in hTERT-RPE1 cells as in <xref ref-type="fig" rid="fig1">Figures 1</xref>—<xref ref-type="fig" rid="fig3">3</xref>. (<bold>f</bold>) Sequence of aa 257–268 in wild type INPP5E and indicated mutants, whose ciliary localization in shown on the right. (<bold>g</bold>) Ciliary targeting of INPP5E(257-626) containing the mutations from (<bold>f</bold>) was analyzed as in (<bold>e</bold>). In both cases, images are representative of n=2 independent experiments, with &gt;30 transfected-cell cilia visualized per construct and experiment. Scale bars, 5 µm.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3">Figure 3c</xref>.</title><p>Data from n=3 independent experiments.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78383-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>CaaX box and the CLS-containing residues 251–273 do not affect enzyme activity.</title><p>(<bold>a</bold>) Phosphatase activity, expressed as picomoles of released inorganic phosphate per minute, was measured in immunoprecipitates of HEK293T cells transfected with the indicated EGFP-INPP5E variants, or in control buffer (no enzyme). Activity was measured using PI(4,5)P2 as substrate. Data are shown as mean ± SEM of n=3 independent experiments. Data were analyzed by one-way ANOVA followed by Tukey’s multiple comparisons tests. Significance (relative to no enzyme unless otherwise indicated) shown as p&lt;0.05(*), p&lt;0.001(***), or p&lt;0.0001(****). (<bold>b</bold>) Representative anti-EGFP immunoblot showing protein levels of EGFP-INPP5E variants in the immunoprecipitates used in (<bold>a</bold>). All three samples were run in the same SDS-PAGE gel and immunoblotted and detected in parallel. Molecular weight markers, in kDa, are shown on the right.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b</xref>.</title><p>Relevant bands are inside rectangles. See <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig3-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b</xref> (WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig3-figsupp1-data2-v1.tif"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Expression levels of EGFP-INPP5E constructs from <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title><p>(<bold>a</bold>) Constructs from <xref ref-type="fig" rid="fig3">Figure 3a–c</xref> were expressed in HEK293T cells. Lysates were analyzed by SDS-PAGE and immunoblotting with the indicated antibodies. Molecular weight markers in kilodaltons are shown on the right. The numbers under the tubulin blots are EGFP/Tubulin band intensity ratios, normalized so that WT equals 100%. (<bold>b</bold>) Same was done for the indicated constructs from <xref ref-type="fig" rid="fig3">Figure 3d–g</xref>.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Uncropped immunoblots from <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title><p>Relevant bands are inside rectangles. See <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig3-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata2"><label>Figure 3—figure supplement 2—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> (WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig3-figsupp2-data2-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata3"><label>Figure 3—figure supplement 2—source data 3.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> (WB: Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig3-figsupp2-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata4"><label>Figure 3—figure supplement 2—source data 4.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> (WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig3-figsupp2-data4-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata5"><label>Figure 3—figure supplement 2—source data 5.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> (WB: Tubulin).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig3-figsupp2-data5-v1.tif"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig3-figsupp2-v1.tif"/></fig></fig-group><p>Even though both these mutations are outside the phosphatase domain, it remains possible that their effects on ciliary targeting are due to disruption of catalytic domain integrity. To test this, we measured the PI(4,5)P<sub>2</sub> 5-phosphatase activity of the aforementioned 274–626 mutant, lacking both the N-terminus (Δ1–273) and the MORM region (Δ627–644). This mutant was fully active, with activity and protein levels indistinguishable from WT (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). In contrast, the 288–626 mutant, additionally missing residues 275–287 at the beginning of the catalytic domain, had much less activity and reduced levels (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Therefore, residues 251–273 and 627–644 are completely dispensable for enzyme activity, indicating that their effects on ciliary targeting are not caused by disruptions in the phosphatase domain. This was confirmed by Western blot of HEK293T lysates transfected with (Δ251–273)+C641 S or the single Δ251–273 and C641S mutants: in all cases protein levels were indistinguishable from WT (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Thus, residues 251–273 and the CaaX box also behave as bona fide CLSs.</p><p>We then mapped which residues within 251–273 are responsible for CLS function. To do this, we started with the 274–626 mutant, which fails to accumulate in cilia as mentioned above. To this mutant, we gradually added residues to the N-terminus, thus creating four more mutants: 269–626, 264–626, 257–626 and 251–626 (<xref ref-type="fig" rid="fig3">Figure 3d</xref>). Of these, 269–626 and 264–626 failed to accumulate in cilia, whereas 257–626 and 251–626 readily did so (<xref ref-type="fig" rid="fig3">Figure 3e</xref>). Next, starting from 257 to 626, we generated five alanine-substitution mutants within the 257-FSLLAPIRSKDV-268 region, removing residues FS, LL, PIR, SK, and DV, respectively (<xref ref-type="fig" rid="fig3">Figure 3f</xref>). Of these, residues LL and PIR were essential for ciliary targeting, whereas FS, SK and DV were fully dispensable (<xref ref-type="fig" rid="fig3">Figure 3f–g</xref>). We then created the single residue mutants spanning the 259-LLAPIR-264 motif. All these mutants (L259A, L260A, P262A, I263A, and R264A) abolished cilia localization of 257–626, although weak residual targeting was still observed only for L259A (<xref ref-type="fig" rid="fig3">Figure 3f–g</xref>). Protein levels of 257–626 and the individual LLxPIR motif point mutants were all similar to WT (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Therefore, the LLxPIR motif is a novel CLS that cooperates with the CaaX box to mediate optimal ciliary targeting of INPP5E.</p></sec><sec id="s2-4"><title>INPP5E ciliary targeting is mediated by four conserved CLSs</title><p>The above data indicate that INPP5E ciliary targeting depends on four CLSs, which we will heretofore refer to as CLS1 (the LLxPIR motif, aa 259–264), CLS2 (W383), CLS3 (the FDRxLYL motif, aa 609–615), and CLS4 (the CaaX box, aa 641–644). Our data actually show that CLS3 goes beyond the FDRxLYL motif, as deletion of residues 616–621 also interferes with ciliary targeting (<xref ref-type="fig" rid="fig1">Figure 1b–c</xref>). This is consistent with the original report on CLS3, where residues 619–621 were also shown to modulate ciliary targeting (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). Thus, CLS3 spans residues 609–621 in human INPP5E.</p><p>Since INPP5E ciliary targeting has been reported in different vertebrate species, we examined whether CLS1-4 are conserved in vertebrate evolution. To do this, we aligned the human INPP5E sequence with those of another mammal (mouse), a bird (crow), a reptile (python), an amphibian (toad), and a fish (zebrafish; <xref ref-type="fig" rid="fig4">Figure 4a</xref>). From this analysis, it is clear that all four CLSs are highly conserved in vertebrates. For CLS1, the consensus sequence is [VL]LxPIR, with only the first leucine admitting a conservative change (<xref ref-type="fig" rid="fig4">Figure 4a</xref>; <xref ref-type="fig" rid="fig3">Figure 3g</xref>). CLS2’s tryptophan is fully conserved, and so is CLS3, as previously shown (consensus: FDRxLYLxGI[KR]RR) (<xref ref-type="fig" rid="fig4">Figure 4a</xref>; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). For CLS4 the consensus is C[ST][IV]S, which in all cases encodes a farnesyl transferase-specific CaaX box (<xref ref-type="bibr" rid="bib100">Wright and Philips, 2006</xref>). Thus, the four CLSs are highly conserved. Moreover, they are all found on the same side of INPP5E according to the AlphaFold model, even though CLS1 location in this model has a low confidence score (<xref ref-type="fig" rid="fig4">Figure 4b</xref>; <xref ref-type="bibr" rid="bib52">Jumper et al., 2021</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>CLS1-4 are conserved ciliary localization signals affecting INPP5E function.</title><p>(<bold>a</bold>) CLS1-4 are highly evolutionarily conserved in vertebrates, including human (NP_063945.2), mouse (AAH80295.1), python (XP_007441606.1), crow (XP_039417670.1), toad (XP_002935265.1), and zebrafish (NP_001096089.2). Consensus sequences are shown below. (<bold>b</bold>) AlphaFold model of INPP5E 3D structure (AF-Q9NRR6-F1) depicting predicted locations of CLS1 (red), CLS2 (green), CLS3 (pink) and CLS4 (yellow). Active site in cyan. Beta-strands and alpha-helices in yellow and brown, respectively. Proline-rich N-terminal region (aa 1–200), predicted to be highly flexible, is not shown. CLS1 is probably also part of a flexible region, and its position in the AlphaFold model has a low confidence score (pLDDT). See Uniprot entry Q9NRR6 for more details. (<bold>c</bold>) Rescue assay assessing the ability of INPP5E or its mutants to lower the abnormally high TULP3 levels characteristic of INPP5E-KO cilia. The indicated constructs were transfected into INPP5E-KO RPE1 cells, generated via CRISPR-Cas9 (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Cells were fixed and stained for EGFP, acetylated tubulin (AcTub), TULP3, and DNA (DAPI), as indicated. Scale bar, 10 µm. Note how untransfected INPP5E-KO cells have high ciliary TULP3 levels, as previously described. Transfected cell cilia are labeled with asterisks in the merge panels: yellow asterisks for rescued TULP3-negative cilia, and red asterisks for non-rescued TULP3-positive cilia. (<bold>d</bold>) Quantitation of the rescue experiment shown in (<bold>c</bold>). For each construct, the percentage of TULP3-negative transfected-cell cilia was counted. Data come from five independent experiments. Each point in the graph indicates an independent transfection. Between 12 and 39 transfected-cell cilia were counted per transfection (with exception of the highest data point in ΔCLS2, where only 9 cilia could be counted). Experiments were performed in parallel with two different INPP5E-KO clones (clones 3 and 12). Graph shows individual data points, color-coded by clone as indicated, and the overall median is indicated with a line. Two-way ANOVA revealed significant differences between constructs (p&lt;0.0001) but no significant differences between the clones. All data were then analyzed by one-way ANOVA followed by Tukey tests. Significance is shown relative to EGFP unless otherwise indicated. p&lt;0.0001 (****); p&lt;0.05 (*); not significant (n.s.).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4">Figure 4d</xref>.</title><p>Data from n=5 independent experiments.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78383-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Generation of puromycin-sensitive hTERT-RPE1 cells by CRISPR/Cas9.</title><p>(<bold>a</bold>) hTERT-RPE1 cells were originally immortalized with pGRN145, a plasmid expressing both human telomerase (hTERT) and puromycin N-acetyltransferase (PAC) from Streptomyces alboniger, a 199 aa enzyme that confers puromycin resistance (top). Three single guide RNAs were selected in the region encoding aa 25–62 of PAC (bottom). A pool of these gRNAs was then used for CRISPR/Cas9-mediated knockout of PAC gene in hTERT-RPE1 cells. (<bold>b</bold>) Phase contrast images of WT and PAC-KO hTERT-RPE1 cells right before (0 hr) or after treatment for 60 hr with 2 µg/ml puromycin. This treatment was sufficient to completely kill PAC-KO cells but did not noticeably affect WT cells. (<bold>c</bold>) Dose-response curves showing percentage confluence of WT or PAC-KO cells after 60 hr treatment with the indicated puromycin doses. Approximate IC50 values are 18 µg/ml for WT and 0.6 µg/ml for PAC-KO cells, a 30-fold difference.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Generation of INPP5E-KO hTERT-RPE1 cells by CRISPR/Cas9.</title><p>(<bold>a</bold>) Top: diagram of human INPP5E gene depicting its 10 exons as boxes, with coding sequence in orange. Middle: the three indicated guide RNAs (arrows) were used to target INPP5E exon-1 in RPE-PS cells using CRISPR. Bottom: the genomic regions of interest from clones 3 and 12 were PCR-amplified, ligated into pJET1.2/blunt vector, transformed, and DNA from bacterial colonies sequenced (6 and 4 colonies for clones 3 and 12, respectively). All sequenced clones contained the same truncating mutation (P31Rfs101), which causes frameshift and only leaves intact the first 30 residues of INPP5E. (<bold>b</bold>) Immunofluorescence staining of clone-3 (INPP5E-KO) and its parental RPE-PS cells (WT) with the indicated antibodies. Ciliary staining of INPP5E is seen in WT but not INPP5E-KO cells, which only show non-specific staining outside cilia. Same results were obtained for clone-12 (not shown). (<bold>c</bold>) Immunofluorescence staining of clone-3 (INPP5E-KO) and its parental RPE-PS cells (WT) with the indicated antibodies. As previously reported, TULP3 strongly accumulates in INPP5E-KO cilia. Same results were obtained for clone-12 (not shown).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>CLS1 and CLS4 mutants are only seen at the transition zone in methanol-fixed cells.</title><p>(<bold>a</bold>) The indicated EGFP-INPP5E constructs were expressed in hTERT-RPE1 cells, which were fixed with methanol as described in Materials and methods. Immunofluorescence was carried out with antibodies against EGFP, polyglutamylated alpha-tubulin (polyE), and gamma-tubulin (γTub), as indicated. Scale bar, 5 mm. (<bold>b</bold>) Percentage of cilia with the specified EGFP-INPP5E localization was quantified for each of the constructs in (<bold>a</bold>). Data are from an individual experiment. The number of transfected cell cilia counted for each construct was, from left to right: n=31,13,15,10,12,10. (<bold>c</bold>) Pixel intensity profiles of the images in (<bold>a</bold>). A line was drawn along the cilium using Fiji/ImageJ, and the Plot Profile function of this program was used to obtain the densitometric data for each channel. Note how EGFP-INPP5E WT, ΔCLS1, ΔCLS4 and ΔCLS1 +4 accumulate at the transition zone, distal from the basal body (γTub, blue) and proximal to the axoneme (polyE, red).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig4-figsupp3-v1.tif"/></fig></fig-group><p>By affecting INPP5E ciliary targeting, these CLSs are expected to affect INPP5E ciliary function. To test this, we assessed the ability of the CLS mutants to rescue the well-documented abnormal ciliary accumulation of TULP3 in INPP5E-KO cells (<xref ref-type="bibr" rid="bib36">Garcia-Gonzalo et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Chávez et al., 2015</xref>). We performed this assay using INPP5E-KO hTERT-RPE1 cells, which we generated in two steps. First, by using CRISPR/Cas9 technology, we created puromycin-sensitive hTERT-RPE1 cells to knock out the puromycin acetyltransferase (<italic>PAC</italic>) gene, stably inserted into these cells upon their immortalization (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>). As expected, the PAC-KO clones thus obtained were highly sensitive to puromycin, in contrast to the original hTERT-RPE1 cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b-c</xref>). In the second step, using puromycin selection-based CRISPR on these cells, we generated INPP5E-KO cells, as confirmed by genomic analysis (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2a</xref>). Immunofluorescence with anti-INPP5E antibodies confirmed the absence of INPP5E from these cells, despite some non-specific non-ciliary staining (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2b</xref>). As expected, anti-TULP3 antibodies revealed a massive accumulation of this protein in the INPP5E-KO cilia (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2c</xref>).</p><p>In non-transfected or EGFP-transfected INPP5E-KO cells, the percentage of TULP3-negative cilia was very low (≈10%) (<xref ref-type="fig" rid="fig4">Figure 4c–d</xref>). As shown previously in a similar assay using Inpp5e-null mouse embryonic fibroblasts (MEFs; <xref ref-type="bibr" rid="bib36">Garcia-Gonzalo et al., 2015</xref>), transfection of EGFP-INPP5E WT into our INPP5E-KO cells effectively rescued the phenotype, driving the percentage of TULP3-negative cilia to ≈90%. Also as previously reported, the catalytically inactive D477N mutant completely failed to rescue (<xref ref-type="fig" rid="fig4">Figure 4c–d</xref>; <xref ref-type="bibr" rid="bib36">Garcia-Gonzalo et al., 2015</xref>). Having validated the assay, we assessed rescue by the following CLS mutants: Δ251–273 (ΔCLS1), W383A (ΔCLS2), F609A+D610A+R611 A (ΔCLS3), C641S (ΔCLS4), the double ΔCLS1+ΔCLS4 mutant (ΔCLS1 +4), and the catalytic domain deletion Δ297–599. Interestingly, ΔCLS4 was fully functional in this assay, ΔCLS1 a little less so, and ΔCLS1 +4 had no rescue activity whatsoever (<xref ref-type="fig" rid="fig4">Figure 4c–d</xref>). Thus, the relationship between CLS1 and CLS4 in this assay largely mirrors the redundancy observed in their ciliary targeting (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). As expected, ΔCLS3 and Δ297–599 were also completely inactive (<xref ref-type="fig" rid="fig4">Figure 4c–d</xref>). To our surprise, ΔCLS2 showed partial rescue: less than ΔCLS1, but more than ΔCLS3 (<xref ref-type="fig" rid="fig4">Figure 4c–d</xref>). The reasons for this partial rescue are still unclear to us and will require further investigation. In any case, it remains true that all non-ciliary CLS mutants showed strongly reduced functionality in the TULP3 rescue assay.</p><p>We then examined how CLS1-4 affect INPP5E cilia localization as determined by methanol fixation of hTERT-RPE1 cells (rather than fixing first with paraformaldehyde (PFA), as done so far). We did this on the basis of a recent study showing that, in these cells, live imaging of GFP-INPP5E shows a strong accumulation at the ciliary base (in addition to some intraciliary staining), and that this ciliary base accumulation is best recapitulated with methanol-only fixation (whereas PFA is better suited to visualize the intraciliary staining) (<xref ref-type="bibr" rid="bib18">Conduit et al., 2021</xref>). Indeed, with methanol fixation, EGFP-INPP5E WT was clearly accumulated at the base of most cilia (≈60%), with the remaining cilia showing a more uniform distribution along the axoneme (≈40%) (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3a-b</xref>). Regardless of cilia base-enrichment, some intraciliary axonemal staining was always seen with EGFP-INPP5E WT under these conditions. In contrast, no axonemal staining was ever observed for any of the CLS mutants (ΔCLS1, ΔCLS2, ΔCLS3, ΔCLS4, or ΔCLS1+4) (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3a-b</xref>). This confirms the importance of all these CLSs for INPP5E to reach inside cilia. It also shows that the axonemal staining seen with ΔCLS1 and ΔCLS4 in PFA-fixed cells (<xref ref-type="fig" rid="fig3">Figure 3b–c</xref>) is lost with the methanol-only fixation (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3a-b</xref>). Interestingly, with the latter fixation, ΔCLS1, ΔCLS4, and ΔCLS1+4 were all strongly accumulated at the ciliary base (in 100% of cilia). These accumulation occurred at the ciliary transition zone, distal from basal body and proximal from axoneme, as revealed by signal intensity scans along these cilia (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3c</xref>). In contrast, ΔCLS3, was never seen at the ciliary base, whereas ΔCLS2 was occasionally seen there (30% of cilia) (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3a-b</xref>). Altogether, the data in this section confirm the importance of INPP5E’s four CLSs.</p></sec><sec id="s2-5"><title>Ciliary targeting is affected by some INPP5E ciliopathy mutations</title><p>INPP5E ciliary targeting is dependent on CLS1, CLS2, CLS3, and CLS4 (<xref ref-type="fig" rid="fig2">Figures 2</xref>—<xref ref-type="fig" rid="fig4">4</xref>), and on the integrity of its catalytic domain (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The MORM mutation (Δ627–644), which deletes CLS4 and moderately reduces cilia localization, as mentioned above, is the only known INPP5E ciliopathy mutation affecting its ciliary targeting. However, whether and how other ciliopathy mutations in INPP5E also affect ciliary targeting is largely unknown. To address this, we sought ciliopathy mutations locating near a CLS, or that were likely to compromise catalytic domain integrity. In this manner, we identified twelve mutations, eleven from JBTS and one from LCA-like disease (<xref ref-type="fig" rid="fig5">Figure 5a–b</xref>; <xref ref-type="bibr" rid="bib3">Bachmann-Gagescu et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Bielas et al., 2009</xref>; <xref ref-type="bibr" rid="bib91">Travaglini et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">de Goede et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Xu et al., 2015</xref>; <xref ref-type="bibr" rid="bib97">Wang et al., 2013</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>A subset of Joubert syndrome INPP5E mutations abolishes ciliary targeting.</title><p>(<bold>a</bold>) Table of INPP5E ciliopathy mutations analyzed here. JBTS: Joubert syndrome; LCA: Leber congenital amaurosis; hom: homozygous; comp het: compound heterozygous. (<bold>b</bold>) Schema of INPP5E protein sequence indicating the locations of the ciliopathy mutations from (<bold>c</bold>) relative to its four CLSs, its catalytic domain (cyan) and its N-terminal proline-rich region (green). (<bold>c</bold>) Ciliary localization of mutants from (<bold>a–b</bold>) was analyzed in hTERT-RPE1 cells as in <xref ref-type="fig" rid="fig1">Figures 1</xref>—<xref ref-type="fig" rid="fig3">3</xref>. Images are representative of at least two independent experiments per construct, with &gt;30 transfected-cell cilia visualized per construct and experiment. Scale bar, 5 µm. (<bold>d</bold>) The mutants from (<bold>a–c</bold>) were expressed in HEK293T cells and their protein levels analyzed by SDS-PAGE and immunoblotting with anti-EGFP antibody, and anti-alpha tubulin as loading control. Molecular weight markers in kilodaltons are shown on the right. The numbers under the tubulin blots are EGFP/Tubulin band intensity ratios, normalized so that WT equals 100%. (<bold>e–g</bold>) 3D views of INPP5E catalytic domain (PDB ID: 2xsw) showing the ciliopathy-mutated residues from (<bold>a</bold>) in dark blue (other colors as in <xref ref-type="fig" rid="fig4">Figure 4b</xref>). (<bold>e</bold>) Full catalytic domain showing G286 (bottom) and D490 (top left). (<bold>f</bold>) closeup view of beta-sandwich showing W474 and V303. (<bold>g</bold>) closeup view of CLS2-3 region showing R345, T355, R378, C385, V388L, and R621.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Uncropped immunoblots from <xref ref-type="fig" rid="fig5">Figure 5d</xref>.</title><p>Relevant bands are inside rectangles. See <xref ref-type="fig" rid="fig5">Figure 5</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig5-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig5">Figure 5d</xref> (WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig5-data2-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig5">Figure 5d</xref> (WB: Tubulin).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig5-data3-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig5">Figure 5d</xref> (WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig5-data4-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig5">Figure 5d</xref> (WB: Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig5-data5-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig5-v1.tif"/></fig><p>One of the mutations, C641R, replaces the farnesylatable cysteine in CLS4 by an arginine. Not surprisingly, this mutation affected ciliary targeting in the same way as C641S or MORM, and did not affect protein levels (<xref ref-type="fig" rid="fig5">Figure 5b–d</xref>). Several other mutations affected residues located near the CLS2-CLS3 region. These included R345S, T355M, R378C, C385Y, V388L, R621Q, and R621W. None of these affected ciliary localization, despite causing moderate reductions in protein levels (<xref ref-type="fig" rid="fig5">Figure 5b–d and g</xref>). Since almost all INPP5E ciliopathy mutations affect the catalytic domain, none were found near CLS1. The closest one to CLS1 was G286R, at the beginning of the catalytic domain. Interestingly, G286R largely abolished ciliary targeting, although this is more likely due to its affecting catalytic domain integrity (<xref ref-type="fig" rid="fig5">Figure 5b–e</xref>). We also tested mutations, like W474R and V303M, that we thought likely to disrupt the catalytic domain, given their location at the core of the beta-sandwich. Indeed, W474R abolished ciliary targeting, and V303M reduced it considerably, with levels of both reduced (<xref ref-type="fig" rid="fig5">Figure 5b–d and f</xref>). Since W474R and G286R were found in homozygosis in JBTS patients, this suggests that some JBTS patients cannot target INPP5E to cilia (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). Finally, we also tested the D490Y mutation, located near a beta-hairpin close to the active site, but far from any CLS. D490Y did not affect ciliary targeting, despite a strong reduction in protein levels (<xref ref-type="fig" rid="fig5">Figure 5b–e</xref>). Altogether, these data show that INPP5E ciliary targeting is sometimes affected in Joubert syndrome, which could contribute to pathogenesis in these cases.</p></sec><sec id="s2-6"><title>INPP5E binding to PDE6D is CLS4-dependent</title><p>After identifying novel INPP5E CLSs and exploring their role in ciliopathies, we focused on the mechanisms of action of these CLSs. Presumably, these CLSs act by binding to other proteins implicated in INPP5E ciliary targeting. One such protein is PDE6D, a ciliary cargo receptor for prenylated proteins. Although PDE6D binding to INPP5E is CLS4-dependent and CLS3-independent, whether its interaction requires our newly identified CLSs (CLS1 and CLS2) is unknown (<xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib79">Qiu et al., 2021</xref>; <xref ref-type="bibr" rid="bib80">Rao et al., 2016</xref>). To test this, we cotransfected HEK293T cells with plasmids encoding Flag-PDE6D and EGFP-INPP5E in order to perform coimmunoprecipitation (co-IP) experiments (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). As expected, Flag-PDE6D robustly co-immunoprecipitated (co-IPed) with EGFP-INPP5E(WT), but not EGFP control (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). This interaction was completely dependent on CLS4, and completely independent of CLS1, CLS2, and CLS3 (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). Accordingly, ΔCLS1 +4 behaved the same as ΔCLS4, with virtually no co-IP observed, whereas ΔCLS2 and ΔCLS3 co-IPed the same as WT (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). We also tested whether the co-IP involved INPP5E’s N-terminal (aa 1–283) or C-terminal (251-644) regions, with the latter being the case for PDE6D (<xref ref-type="fig" rid="fig6">Figure 6a</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>CLS4 promotes INPP5E binding to PDE6D, RPGR and ARL13B.</title><p>(<bold>a</bold>) The indicated EGFP-INPP5E variants were coexpressed in HEK293T cells with Flag-PDE6D, as indicated. Lysates were immunoprecipitated with GFP-Trap beads and analyzed by Western blot with the indicated antibodies. Molecular weight markers in kilodaltons are shown on the right. Quantitation of Flag-PDE6D co-immunoprecipitation (co-IP), as percentage relative to WT, is shown at the bottom. Quantitations are normalized relative to both immunoprecipitated EGFP constructs and lysate amounts of Flag-PDE6D. (<bold>b</bold>) Same experiment as in (<bold>a</bold>) but Flag-RPGR was used instead of Flag-PDE6D. Quantitations at the bottom are normalized relative to immunoprecipitated EGFP constructs. (<bold>c</bold>) Coimmunoprecipitation of endogenous ARL13B with the indicated EGFP-INPP5E constructs in HEK293T cells. Asterisk points to EGFP-INPP5E(1-283) band. (<bold>d</bold>) Quantitation of ARL13B co-IP with the indicated EGFP-INPP5E constructs from n=11 independent experiments in HEK293T cells. Black and grey dots correspond, respectively, to experiments where endogenous ARL13B or exogenous ARL13B-Flag co-IP was assessed. Not all samples were present in all experiments (but EGFP, WT, ΔCLS2 and ΔCLS3 were). Two-way ANOVA revealed significant differences between constructs (p&lt;0.0001) but no significant differences between using endogenous or exogenous ARL13B. All data were then analyzed by one-way ANOVA followed by Tukey tests. Significance is shown relative to WT: p&lt;0.0001 (****). (<bold>e</bold>) Schema of chemically-inducible co-recruitment assay. Rapamycin (Rapa)-induced interaction between FKBP and FRB is used to quantitate binding of prey candidates to a bait. FKBP is fused to the prey along with a fluorescent protein, while FRB is tethered to inner leaflet of plasma membrane. Upon rapamycin addition, FKBP binds to FRB, bringing bait (red FP) and associated prey (green FP) to the plasma membrane. (<bold>f</bold>) Recruitment of bait and prey to plasma membrane can be sensitively detected by TIRF microscopy as an increased fluorescence signal. The ratio of final to initial TIRF intensity upon rapamycin addition (I/I<sub>0</sub>) for the prey provides a quantitative measure of prey’s co-recruitment to plasma membrane by bait, and hence of the prey-bait interaction. (<bold>g</bold>) TIRF microscopy images showing rapamycin-induced plasma membrane recruitment of bait constructs (left) and the corresponding co-recruitment of prey (mVenus-PDE6D, right). Intensity scales are depicted at bottom. Scale bar, 10 µm. (<bold>h</bold>) Normalized rapamycin-induced co-recruitment of mVenus-PDE6D (prey) by mCherry-FKBP-INPP5E (WT or indicated mutants), or by mCherry-FKBP (mCherry) as negative control. Individual measurements of n&gt;50 cells per condition are shown. Box and whisker plots represent median, first and third quartiles, and 95% confidence intervals. Statistical significance relative to WT is shown as *** p&lt;0.001 (unpaired Student’s t-tests). (<bold>i</bold>) Normalized rapamycin-induced co-recruitment of ARL13B-EYFP (prey) by mCherry-FKBP-INPP5E (WT or indicated mutants), or by mCherry-FKBP (mCherry) as negative control. Data acquisition, analysis and representation as in (<bold>h</bold>).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Uncropped immunoblots from <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title><p>Relevant bands are inside rectangles. (<bold>a</bold>) Immunoblots from <xref ref-type="fig" rid="fig6">Figure 6a</xref>. (<bold>b</bold>) Immunoblots from <xref ref-type="fig" rid="fig6">Figure 6b</xref>. (<bold>c</bold>) Immunoblots from <xref ref-type="fig" rid="fig6">Figure 6c</xref> (EGFP bands are also seen in ARL13B immunoblot on the left). See <xref ref-type="fig" rid="fig6">Figure 6</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig6-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig6">Figure 6a</xref> (IP: EGFP; WB: Flag).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig6-data2-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig6">Figure 6a</xref> (IP: EGFP; WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig6-data3-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig6">Figure 6a</xref> (Lysates, WB: Flag).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig6-data4-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig6sdata5"><label>Figure 6—source data 5.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig6">Figure 6b</xref> (IP: EGFP; WB: RPGR).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig6-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata6"><label>Figure 6—source data 6.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig6">Figure 6b</xref> (IP: EGFP; WB: EGFP).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig6-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata7"><label>Figure 6—source data 7.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig6">Figure 6b</xref> (Lysates, WB: RPGR).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig6-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata8"><label>Figure 6—source data 8.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig6">Figure 6c</xref> (IP: EGFP; WB: ARL13B).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig6-data8-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig6sdata9"><label>Figure 6—source data 9.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig6">Figure 6c</xref> (IP: EGFP; WB: EGFP).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig6-data9-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata10"><label>Figure 6—source data 10.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig6">Figure 6c</xref> (Lysates, WB: ARL13B).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig6-data10-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata11"><label>Figure 6—source data 11.</label><caption><title>Source data from <xref ref-type="fig" rid="fig6">Figure 6d</xref>.</title><p>Data from n=11 experiments.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78383-fig6-data11-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig6-v1.tif"/></fig><p>In addition to co-IP, we also studied the INPP5E-PDE6D interaction in vivo by means of co-recruitment assays (<xref ref-type="fig" rid="fig6">Figure 6e–f</xref>). To do this, we generated bait constructs expressing mCherry-FKBP-INPP5E fusion proteins (WT, ΔCLS1, ΔCLS2, ΔCLS3, ΔCLS4, or ΔCLS1+4), or mCherry-FKBP as negative control. Each of these bait constructs was separately co-expressed in HeLa cells with the prey construct (mVenus-PDE6D), and with FRB-CFP-CaaX, whose prenylated CaaX box tethers FRB to the inner leaflet of the plasma membrane (<xref ref-type="fig" rid="fig6">Figure 6e</xref>). Upon inducing the FKBP-FRB interaction with rapamycin, this should recruit bait constructs to the plasma membrane, a recruitment that can be monitored and quantitated by total internal reflection fluorescence (TIRF) microscopy (<xref ref-type="fig" rid="fig6">Figure 6e–f</xref>; <xref ref-type="bibr" rid="bib64">Lin et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Gallego et al., 2013</xref>). Additionally, if bait and prey interact, then prey co-recruitment to the plasma membrane will also be observed (<xref ref-type="fig" rid="fig6">Figure 6e–f</xref>). As expected, rapamycin-induced robust plasma membrane recruitment of all bait constructs (<xref ref-type="fig" rid="fig6">Figure 6g</xref>). Also as expected, mVenus-PDE6D co-recruitment was much higher with mCherry-FKBP-INPP5E(WT) than with the mCherry-FKBP control, confirming the specificity of PDE6D-INPP5E binding (<xref ref-type="fig" rid="fig6">Figure 6g–h</xref>). As observed in the co-IPs, mVenus-PDE6D co-recruitment was strongly reduced by both the ΔCLS4 and ΔCLS1+4 mutations, indicating a strong CLS4-dependence (<xref ref-type="fig" rid="fig6">Figure 6g–h</xref>). Also consistent with the co-IPs, ΔCLS1 and ΔCLS3 did not affect mVenus-PDE6D co-recruitment, whereas ΔCLS2 caused a modest reduction (<xref ref-type="fig" rid="fig6">Figure 6g–h</xref>). Altogether, the co-IP and in vivo co-recruitment data demonstrate that CLS4 is the key CLS controlling INPP5E-PDE6D binding.</p></sec><sec id="s2-7"><title>INPP5E binding to RPGR is CLS4-dependent</title><p>RPGR also interacts with INPP5E and is required for its ciliary targeting (<xref ref-type="bibr" rid="bib80">Rao et al., 2016</xref>). Moreover, RPGR ciliary targeting is also dependent on PDE6D, which binds to both its geranylgeranylated CaaX box and its RCC1-like domain (<xref ref-type="bibr" rid="bib105">Zhang et al., 2019</xref>; <xref ref-type="bibr" rid="bib80">Rao et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Dutta and Seo, 2016</xref>; <xref ref-type="bibr" rid="bib62">Lee and Seo, 2015</xref>; <xref ref-type="bibr" rid="bib27">Fansa et al., 2015</xref>; <xref ref-type="bibr" rid="bib98">Wätzlich et al., 2013</xref>; <xref ref-type="bibr" rid="bib95">Vössing et al., 2021</xref>). Despite all these connections, how RPGR mediates INPP5E ciliary targeting is unclear. To address this, we performed co-IPs between Flag-RPGR and the same EGFP-INPP5E constructs used above for the PDE6D co-IPs. As with PDE6D, the INPP5E-RPGR co-IP was abolished by ΔCLS4 and ΔCLS1+4, but was untouched by ΔCLS1, ΔCLS2 or ΔCLS3 (<xref ref-type="fig" rid="fig6">Figure 6b</xref>). Therefore, INPP5E’s farnesylated CaaX box is also key for its association to RPGR. Consistently, RPGR strongly co-IPed with INPP5E’s C-terminal fragment (251-644) but not with the N-terminal one (1-283).</p></sec><sec id="s2-8"><title>INPP5E binding to ARL13B is promoted by CLS2, CLS3, and CLS4</title><p>ARL13B is another key mediator of INPP5E ciliary targeting (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Fujisawa et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Qiu et al., 2021</xref>). ARL13B regulates INPP5E in at least two different ways. First, ARL13B acts as a guanine nucleotide exchange factor (GEF) for ARL3, whose active GTP-bound form promotes dissociation of the PDE6D-INPP5E complex after it reaches the ciliary lumen (<xref ref-type="bibr" rid="bib39">Gotthardt et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Fansa et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Ivanova et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">ElMaghloob et al., 2021</xref>). Additionally, ARL13B directly interacts with INPP5E and is required for its ciliary retention (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Fujisawa et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Qiu et al., 2021</xref>). Since the first mechanism is mediated by ARL3, we checked whether INPP5E binds ARL3. However, we detected no co-IP between EGFP-INPP5E and ARL3-myc, or its constitutively active form ARL3(Q71L)-myc, in accordance with previous data (data not shown; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). Likewise, we found no interaction between INPP5E and BART, a protein that cooperates with ARL13B as a co-GEF for ARL3 (data not shown; <xref ref-type="bibr" rid="bib26">ElMaghloob et al., 2021</xref>).</p><p>We then carried out co-IPs to assess the CLS-dependence of the ARL13B-INPP5E interaction. We readily detected co-IP of endogenous ARL13B with EGFP-INPP5E in HEK293T cells. This co-IP was much lower with ΔCLS4 and ΔCLS1+4, but not clearly affected by CLS1-3 (<xref ref-type="fig" rid="fig6">Figure 6c</xref>). As with PDE6D and RPGR, INPP5E’s C-terminal region (251-644), but not the N-terminal (1-283), sufficed for the INPP5E-ARL13B interaction (<xref ref-type="fig" rid="fig6">Figure 6c</xref>). Since CLS3 was previously reported to affect INPP5E-ARL13B co-IP, we examined this question further (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). In total, we performed 11 co-IP experiments between these proteins. In three of them (including the one in <xref ref-type="fig" rid="fig6">Figure 6c</xref>), we measured co-IP of endogenous ARL13B. In the other eight, we measured co-IP of co-transfected ARL13B-Flag. Quantitation of all these experiments showed no discernible effect of CLS1-3 on ARL13B co-IP, while largely confirming the effect of CLS4 (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). Since the previously reported effect had been observed using deletions (ΔFDR, ΔLYL) rather than alanine-substitutions (FDR &gt;AAA, LYL &gt;AAA) of the CLS3 residues, we also performed an experiment comparing ARL13B-Flag co-IP for all these four mutants. This experiment showed no differences among any of these mutants, all of which co-IPed ARL13B like WT control (data not shown). Thus, we conclude that CLS4, but not CLS1-3, affect ARL13B co-IP by INPP5E in our experiments.</p><p>We also studied INPP5E-ARL13B association by means of co-recruitment assays like those in <xref ref-type="fig" rid="fig6">Figure 6e–h</xref>. In this case, ARL13B-EYFP was used as prey instead of mVenus-PDE6D (<xref ref-type="fig" rid="fig6">Figure 6i</xref>). ARL13B-EYFP co-recruitment strongly increased with mCherry-FKBP-INPP5E(WT), as compared to mCherry-FKBP alone, demonstrating a specific interaction. This interaction was unaffected by ΔCLS1 but was strongly reduced with ΔCLS2, ΔCLS3, ΔCLS4 and ΔCLS1+4 (<xref ref-type="fig" rid="fig6">Figure 6i</xref>). Therefore, in addition to confirming the key role of CLS4, the in vivo co-recruitment data showed that CLS2-3 do affect INPP5E-ARL13B association after all. The reason why the effects of CLS2-3 are readily detectable in our co-recruitment but not out co-IP assays remains to be determined. Taken together, our data indicate that CLS2, CLS3 and CLS4 all promote INPP5E association with ARL13B.</p></sec><sec id="s2-9"><title>INPP5E binding to TULP3 is promoted by CLS2 and CLS3</title><p>TULP3 is a ciliary trafficking adapter needed for ciliary targeting of membrane proteins such as G-protein-coupled receptors, polycystins, ARL13B and INPP5E (<xref ref-type="bibr" rid="bib5">Badgandi et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Han et al., 2019</xref>; <xref ref-type="bibr" rid="bib70">Mukhopadhyay et al., 2010</xref>; <xref ref-type="bibr" rid="bib71">Mukhopadhyay et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Legué and Liem, 2019</xref>; <xref ref-type="bibr" rid="bib47">Hilgendorf et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Hwang et al., 2019</xref>). However, whether INPP5E and TULP3 interact is not known. We therefore tested this. Indeed, EGFP-INPP5E specifically co-IPed TULP3-myc (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). Such co-IP was unaffected by ΔCLS1, ΔCLS4, and ΔCLS1+4, but was clearly reduced by ΔCLS2 and ΔCLS3 (<xref ref-type="fig" rid="fig7">Figure 7a–b</xref>). Consistently, TULP3 interacted strongly with EGFP-INPP5E(251-644), and much less so with EGFP-INPP5E(1-283) (<xref ref-type="fig" rid="fig7">Figure 7a</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>CLS2 and CLS3 regulate INPP5E binding to TULP3 and CEP164.</title><p>(<bold>a</bold>) The indicated EGFP-INPP5E variants were coexpressed in HEK293T cells with TULP3-myc as indicated. Lysates were immunoprecipitated with GFP-Trap beads and analyzed by Western blot with TULP3 and EGFP antibodies, as indicated. (<bold>b</bold>) Quantitation of TULP3-myc co-IP by the indicated EGFP-INPP5E constructs in HEK293T cells. Co-IP levels, expressed as percentage of WT, are normalized by the amounts of both immunoprecipitated EGFP-INPP5Es and TULP3-myc lysate levels. Data are mean ± SEM of n=7,7,4,7,7,4,4 independent experiments and were analyzed by one-way ANOVA followed by Tukey multiple comparisons tests. Significance relative to WT is shown as p&lt;0.01(**) and p&lt;0.0001(****). (<bold>c</bold>) The indicated EGFP-TULP3 variants were coexpressed in HEK293T cells with Flag-INPP5E as indicated. Lysates were immunoprecipitated with GFP-Trap beads and analyzed by Western blot with the indicated antibodies. NTD: N-terminal domain (aa 1–183); CTD: C-terminal Tubby domain (aa 184–442). Numbers at the bottom show quantitation of Flag-INPP5E co-IP as percentage of WT, normalized by both immunoprecipitated EGFP-TULP3, and by Flag-INPP5E lysate levels. (<bold>d</bold>) Schema of INPP5E-TULP3 interaction. On INPP5E’s side, the interaction mostly involves the catalytic domain, requiring CLS2 and CLS3. On TULP3’s side, the interaction occurs mostly through the CTD and is affected by the ARL13B-binding K389, and by the phosphoinositide (PIPs)-binding K268 and R270. (<bold>e</bold>) Lysates of HEK293T cells expressing the indicated EGFP-INPP5E variants were immunoprecipitated with GFP-Trap beads and the levels of endogenous CEP164 and exogenous EGFP were analyzed by Western blot as indicated. Molecular weight markers on the right. (<bold>f</bold>) Quantitation of endogenous CEP164 co-IP by the indicated EGFP-INPP5E constructs in HEK293T cells. Co-IP levels were calculated and plotted as in (<bold>b</bold>). Data are mean ± SEM of n=5,5,3,5,5,3,3 independent experiments and were analyzed by one-way ANOVA followed by Dunnett multiple comparisons tests relative to WT. Significance is shown as p&lt;0.05(*). (<bold>g</bold>) Flag-INPP5E was coexpressed in HEK293T cells with the indicated CEP164-EGFP variants, including full length CEP164 (aa 1–1460), its N-terminal (NT, 1–467), middle (Mid, 468–1135) and C-terminal (CT, 1136–1460) regions, and NT carrying a mutated WW domain (WW: aa 56–89; mutation: Y73A+Y74 A). Arrows indicate the positions of these proteins. Lysates were immunoprecipitated with GFP-Trap beads and analyzed by Western blot with antibodies against Flag or EGFP, as indicated. Molecular weight markers are displayed on the right. (<bold>h</bold>) CLS2 and CLS3 are still required for INPP5E ciliary targeting in mutants unable to bind CEP164. Cilia localization was analyzed as in previous figures for the indicated EGFP-INPP5E variants, all of which lack aa 1–273 and hence cannot bind CEP164. Images are representative of n=2 independent experiments, with &gt;30 transfected-cell cilia visualized per construct and experiment. Scale bar, 5 µm. (<bold>i</bold>) Schema summarizing results from (<bold>e–h</bold>). CEP164-NT is sufficient for INPP5E binding provided the WW domain is intact. On INPP5E’s side, the proline-rich N-terminal region (aa 1–283) is sufficient to interact with CEP164. Moreover, INPP5E(1-283), INPP5E(∆CLS2) and INPP5E(∆CLS3) mutants all bind CEP164 more intensely than INPP5E(WT), indicating that INPP5E’s C-terminal region downregulates CEP164 binding in a CLS2/3-dependent manner. This may or may not be necessary for INPP5E ciliary targeting, but it is clearly not sufficient, as shown by the data in (<bold>h</bold>).</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Uncropped immunoblots from <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title><p>Relevant bands are inside rectangles. (<bold>a</bold>) Immunoblots from <xref ref-type="fig" rid="fig7">Figure 7a</xref>. (<bold>b</bold>) Immunoblots from <xref ref-type="fig" rid="fig7">Figure 7c</xref>. (<bold>c</bold>) Immunoblots from <xref ref-type="fig" rid="fig7">Figure 7e</xref> (EGFP bands also visible in left CEP164 blot). (<bold>d</bold>) Immunoblots from <xref ref-type="fig" rid="fig7">Figure 7g</xref>. See <xref ref-type="fig" rid="fig7">Figure 7</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig7-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7a</xref> (IP: EGFP; WB: TULP3).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-data2-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7a</xref> (IP: EGFP; WB: EGFP).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig7-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata4"><label>Figure 7—source data 4.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7a</xref> (Lysates, WB: TULP3).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-data4-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig7sdata5"><label>Figure 7—source data 5.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7c</xref> (IP: EGFP; WB: Flag).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig7-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata6"><label>Figure 7—source data 6.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7c</xref> (IP: EGFP; WB: EGFP).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig7-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata7"><label>Figure 7—source data 7.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7c</xref> (Lysates, WB: Flag).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-data7-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig7sdata8"><label>Figure 7—source data 8.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7e</xref> (IP: EGFP; WB: CEP164).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-data8-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig7sdata9"><label>Figure 7—source data 9.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7e</xref> (IP: EGFP; WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-data9-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig7sdata10"><label>Figure 7—source data 10.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7e</xref> (Lysates, WB: CEP164).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-data10-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig7sdata11"><label>Figure 7—source data 11.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7g</xref> (IP: EGFP; WB: Flag).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-data11-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig7sdata12"><label>Figure 7—source data 12.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7g</xref> (IP: EGFP; WB: EGFP).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-data12-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig7sdata13"><label>Figure 7—source data 13.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7">Figure 7g</xref> (Lysates, WB: Flag).</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-data13-v1.tif"/></supplementary-material></p><p><supplementary-material id="fig7sdata14"><label>Figure 7—source data 14.</label><caption><title>Source data from <xref ref-type="fig" rid="fig7">Figure 7b</xref>.</title><p>Data from n=7 experiments.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78383-fig7-data14-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata15"><label>Figure 7—source data 15.</label><caption><title>Source data from <xref ref-type="fig" rid="fig7">Figure 7f</xref>.</title><p>Data from n=5 experiments.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78383-fig7-data15-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>CSNK2A1 regulates INPP5E ciliary targeting without strongly interacting with it.</title><p>(<bold>a</bold>) Csnk2a1-WT and KO MEFs were stained with antibodies against Arl13b (green), gamma-tubulin (red), and Inpp5e (magenta). Scale bar, 1 µm. (<bold>b</bold>) Quantitation of Inpp5e ciliary intensity in Csnk2a1 WT and KO MEFs. Data are mean ± SEM. Statistical significance in Mann-Whitney non-parametric two-tailed test is shown. (<bold>c</bold>) The indicated EGFP-INPP5E variants were coexpressed in HEK293T cells with CSNK2A1-myc as indicated. Lysates were immunoprecipitated with GFP-Trap beads and analyzed by western blot with the indicated antibodies. No interaction was detected between EGFP-INPP5E and CSNK2A1-myc. Asterisks indicate non-specific bands. Molecular weight markers are shown on the right.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Uncropped immunoblots from <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1c</xref>.</title><p>Relevant bands are inside rectangles. EGFP bands also visible on Myc immunoblot on the left. See <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig7-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig7s1sdata2"><label>Figure 7—figure supplement 1—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1c</xref> (IP: EGFP; WB: Myc).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig7-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7s1sdata3"><label>Figure 7—figure supplement 1—source data 3.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1c</xref> (IP: EGFP; WB: EGFP).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig7-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7s1sdata4"><label>Figure 7—figure supplement 1—source data 4.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1c</xref> (Lysates; WB: Myc).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig7-figsupp1-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig7-figsupp1-v1.tif"/></fig></fig-group><p>TULP3 functions as an adapter by connecting the IFT trafficking machinery (which it binds via its N-terminal domain, NTD: aa 1–183) to membrane proteins (which it binds via its phosphoinositide-binding C-terminal Tubby domain, CTD: aa 184–442) (<xref ref-type="bibr" rid="bib70">Mukhopadhyay et al., 2010</xref>). To test how TULP3 binds INPP5E, we assessed co-IP of Flag-INPP5E by different EGFP-TULP3 constructs (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). Flag-INPP5E specifically co-IPed with full length TULP3, an interaction that was largely dependent on TULP3’s CTD, even though weak binding to NTD was also observed (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). In addition, we tested Flag-INPP5E binding to two TULP3 mutants, namely K268A+R270 A and K389A. The former cannot bind phosphoinositides, and may also be hypoacetylated (<xref ref-type="bibr" rid="bib70">Mukhopadhyay et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Kerek et al., 2021</xref>), whereas the latter removes a key lysine needed for TULP3 to interact with ARL13B and target it to cilia, according to a recent preprint (<xref ref-type="bibr" rid="bib75">Palicharla et al., 2021</xref>). Interestingly, both mutations clearly reduced INPP5E binding, though none abolished it completely (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). Therefore, our data show that INPP5E interacts with TULP3, and that this interaction is dependent on: (i) CLS2 and CLS3 in INPP5E’s catalytic domain, and (ii) TULP3’s Tubby domain and its ability to bind ARL13B and phosphoinositides (<xref ref-type="fig" rid="fig7">Figure 7d</xref>).</p></sec><sec id="s2-10"><title>INPP5E-CEP164 interaction is downregulated by CLS2-3</title><p>INPP5E also interacts with CEP164, a ciliary base protein essential for ciliogenesis. In CEP164-silenced non-ciliated cells, INPP5E fails to accumulate at the centrosome (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). This suggests that CEP164, by recruiting INPP5E to the ciliary base, may contribute to its ciliary targeting. Because of this, we also examined the INPP5E-CEP164 interaction. To do this, we looked at how EGFP-INPP5E and its mutants co-IP endogenous CEP164 in HEK293T cells. Interestingly, while WT, ΔCLS1, ΔCLS4 and ΔCLS1+4 all co-IPed similar amounts of CEP164, the ΔCLS2 and ΔCLS3 mutants displayed a stronger interaction, suggesting that CLS2 and CLS3 downregulate CEP164 binding (<xref ref-type="fig" rid="fig7">Figure 7e</xref>). This effect of CLS2-3 was confirmed after quantitation of five similar experiments (<xref ref-type="fig" rid="fig7">Figure 7f</xref>). Moreover, CEP164 strongly interacted with INPP5E’s N-terminal fragment (1-283), but not with the CLS2/3-containing C-terminal one (251-644; <xref ref-type="fig" rid="fig7">Figure 7e</xref>). Since much more CEP164 was pulled down by EGFP-INPP5E(1-283) than EGFP-INPP5E(WT), despite both fusion proteins being expressed similarly, this further indicates that CLS2-3 antagonize CEP164 binding, which is mediated by INPP5E’s N-terminal region (<xref ref-type="fig" rid="fig7">Figure 7e</xref>).</p><p>CEP164 contains a WW domain near its N-terminus and several coiled coils in the rest of its long sequence (1460 aa) (<xref ref-type="bibr" rid="bib12">Cajanek and Nigg, 2014</xref>; <xref ref-type="bibr" rid="bib85">Schmidt et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Graser et al., 2007</xref>). Since WW domains, like SH3 domains, interact with proline-rich ligands, we hypothesized that CEP164’s WW might interact with INPP5E’s proline-rich N-terminus (<xref ref-type="bibr" rid="bib66">Macias et al., 2002</xref>). To test this, we first checked whether Flag-INPP5E was co-IPed by three CEP164 fragments spanning its N-terminal (NT, aa 1–467), middle (Mid, aa 468–1135) and C-terminal (CT, aa 1136–1460) regions (<xref ref-type="bibr" rid="bib12">Cajanek and Nigg, 2014</xref>). Consistent with our hypothesis, CEP164(NT)-EGFP strongly interacted with Flag-INPP5E, as did full-length CEP164-EGFP (<xref ref-type="fig" rid="fig7">Figure 7g</xref>). Instead, no interaction was seen with CEP164(Mid)-EGFP and only a very weak one with CEP164(CT)-EGFP. Moreover, a mutation disrupting CEP164’s WW domain (WWmut: Y73A+Y74 A) abolished INPP5E binding to CEP164(NT)-EGFP (<xref ref-type="fig" rid="fig7">Figure 7g</xref>; <xref ref-type="bibr" rid="bib12">Cajanek and Nigg, 2014</xref>). Hence, CEP164’s NT is sufficient for INPP5E binding, and CEP164’s WW domain is required for it.</p><p>Altogether, these data suggest a model of CLS2-3 action: presumably, excessively strong binding to CEP164 would retain INPP5E at the ciliary base and prevent its translocation into the ciliary compartment. CLS2-3 might overcome this by loosening the CEP164-INPP5E interaction. If this is the main reason why CLS2-3 are required for INPP5E ciliary targeting, then deletion of the CEP164-interacting N-terminal region should rescue ciliary targeting of INPP5E-ΔCLS2 and INPP5E-ΔCLS3, as CLS2-3 would no longer be needed for CEP164 dissociation. To test this, we combined the ΔCLS2 and ΔCLS3 mutations with the Δ1–273 deletion, thereby generating the 274-644(ΔCLS2) and 274-644(ΔCLS3) mutants. Unlike the 274–644 control, which readily accumulated in cilia, both 274-644(ΔCLS2) and 274-644(ΔCLS3) completely failed to accumulate in cilia, just as the single ΔCLS2 and ΔCLS3 mutants (<xref ref-type="fig" rid="fig7">Figure 7h</xref>). Hence, even though CLS2-3 promote CEP164 dissociation, this is not sufficient for INPP5E ciliary targeting (<xref ref-type="fig" rid="fig7">Figure 7i</xref>). This might be due to CLS2-3 being required for binding to other ciliary trafficking proteins, such as TULP3 (<xref ref-type="fig" rid="fig7">Figure 7a–d</xref>).</p><p>The INPP5E-CEP164 interaction is also known to regulate ciliogenesis. Specifically, INPP5E prevents ectopic ciliogenesis by regulating the interaction between CEP164 and TTBK2, a key ciliogenic kinase that is in turn regulated by casein kinase 2 (CSNK2A1) (<xref ref-type="bibr" rid="bib102">Xu et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Loukil et al., 2021</xref>). Since both TTBK2-CEP164 and INPP5E-CEP164 interactions involve CEP164’s WW domain, we reasoned that the CSNK2A1-TTBK2 pathway might also regulate INPP5E-CEP164 binding and hence INPP5E ciliary targeting (<xref ref-type="bibr" rid="bib102">Xu et al., 2016</xref>). Indeed, we found INPP5E ciliary levels significantly reduced in CSNK2A1-null fibroblasts (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1a-b</xref>). Also consistent with the above hypothesis, CSNK2A1 did not co-IP with INPP5E, suggesting that CSNK2A1’s effect is indirect (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1c</xref>). Whether it is mediated by TTBK2 awaits further study.</p></sec><sec id="s2-11"><title>INPP5E-ATG16L1 interaction is modulated by CLS1 and CLS4</title><p>Recent work shows that INPP5E ciliary targeting requires ATG16L1, an autophagy protein that forms a complex with IFT-B complex component IFT20 (<xref ref-type="bibr" rid="bib10">Boukhalfa et al., 2021</xref>; <xref ref-type="bibr" rid="bib30">Finetti et al., 2021</xref>). Moreover, ATG16L1 was shown to interact with INPP5E and its product PI4P (<xref ref-type="bibr" rid="bib10">Boukhalfa et al., 2021</xref>). We therefore assessed the CLS-dependence of the ATG16L1-INPP5E interaction. Interestingly, although the single ΔCLS1, ΔCLS2, ΔCLS3, and ΔCLS4 mutants did not noticeably alter binding between EGFP-INPP5E and Flag-ATG16L1, a reduction was observed with the ΔCLS1 +4 mutant, suggesting that CLS1 and CLS4 may cooperate in ATG16L1 binding, thus mirroring their cooperation in INPP5E ciliary targeting (<xref ref-type="fig" rid="fig8">Figure 8a</xref>). Consistent with CLS1 and CLS4 partaking in the interaction, the C-terminal INPP5E fragment (251–644, containing both CLS1 and CLS4) was sufficient for binding, whereas the N-terminal fragment (1–283, containing only CLS1) interacted only weakly (<xref ref-type="fig" rid="fig8">Figure 8a</xref>). In three independent experiments, the ΔCLS1 +4 mutant was always found to interact less than the corresponding single mutants or WT (<xref ref-type="fig" rid="fig8">Figure 8b</xref>). However, despite the strong tendency, one-way ANOVA did not show a significant reduction with ΔCLS1 +4 (<xref ref-type="fig" rid="fig8">Figure 8b</xref>). Therefore, more independent experiments will be needed to clarify this point. In any case, these data suggest that CLS1 and CLS4 may jointly be implicated in how ATG16L1 targets INPP5E to cilia (<xref ref-type="fig" rid="fig8">Figure 8c</xref>). On the other hand, CLS2 and CLS3 would act via CEP164, TULP3, and ARL13B, with the latter also acting via CLS4, like PDE6D and RPGR (<xref ref-type="fig" rid="fig8">Figure 8c</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>CLS1 and CLS4 jointly modulate the ATG16L1-INPP5E interaction.</title><p>(<bold>a</bold>) The indicated EGFP-INPP5E constructs were coexpressed in HEK293T cells with Flag-ATG16L1, as shown. Lysates were immunoprecipitated with GFP-Trap beads and analyzed by Western blot with the indicated antibodies. (<bold>b</bold>) Quantitation of Flag-ATG16L1 co-IP by the indicated EGFP-INPP5E constructs in HEK293T cells. Co-IP levels, expressed as percentage of WT, are normalized by the amounts of both immunoprecipitated EGFP-INPP5Es and Flag-ATG16L1 lysate levels. Data are mean ± SEM of n=3 independent experiments and were analyzed by one-way ANOVA followed by Dunnett tests relative to WT. Significance is shown as p&lt;0.01(**). (<bold>c</bold>) Schema of INPP5E structure depicting CLS1-4 and the proteins through which they regulate INPP5E ciliary targeting, as shown herein.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Uncropped immunoblots from <xref ref-type="fig" rid="fig8">Figure 8a</xref>.</title><p>Relevant bands are inside rectangles. See <xref ref-type="fig" rid="fig8">Figure 8</xref> for more details.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-78383-fig8-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig8sdata2"><label>Figure 8—source data 2.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig8">Figure 8a</xref> (IP: EGFP; WB: ATG16L1).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig8-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata3"><label>Figure 8—source data 3.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig8">Figure 8a</xref> (IP: EGFP; WB: EGFP).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig8-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata4"><label>Figure 8—source data 4.</label><caption><title>Uncropped immunoblot from <xref ref-type="fig" rid="fig8">Figure 8a</xref> (Lysates, WB: ATG16L1).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78383-fig8-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata5"><label>Figure 8—source data 5.</label><caption><title>Source data from <xref ref-type="fig" rid="fig8">Figure 8b</xref>.</title><p>Data from n=3 experiments.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78383-fig8-data5-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>INPP5E targeting to the T-cell immune synapse is CLS-independent.</title><p>(<bold>a</bold>) Schema depicting an immune synapse (IS) between an antigen-presenting cell (APC) and a T-cell. Herein, Raji and Jurkat cells were used as APC and T-cells, respectively. F-actin is a marker well known to accumulate in productive immune synapses. (<bold>b</bold>) Jurkat cells were challenged with CMAC-labelled SEE-pulsed Raji cells to induce synaptic conjugate formation. Cells were fixed, permeabilized and stained with Alexa Fluor 546-conjugated phalloidin (F-actin, red) and anti-INPP5E antibody (green). CMAC (7-amino-4-chloromethylcoumarin) is shown in blue. Scale bar, 10 µm. (<bold>c</bold>) Jurkat cells expressing the indicated EGFP fusion proteins were challenged and stained as in (<bold>b</bold>), except that an anti-EGFP antibody (green) was used instead of anti-INPP5E. Scale bar, 10 µm. Cells in (<bold>b–c</bold>) were imaged by epifluorescence microscopy.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78383-fig8-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-12"><title>INPP5E immune synapse targeting is CLS-independent</title><p>Most cell types form primary cilia when their centrosomes are not engaged in cell division. The main exception to this is the hematopoietic lineage, where the centrosome is often engaged in other specialized structures, such as the immune synapse (IS) in lymphocytes (<xref ref-type="bibr" rid="bib89">Stinchcombe and Griffiths, 2014</xref>). Interestingly, numerous parallels exist between primary cilia and the IS, such as the use of IFT trafficking machinery (<xref ref-type="bibr" rid="bib89">Stinchcombe and Griffiths, 2014</xref>; <xref ref-type="bibr" rid="bib29">Finetti et al., 2015</xref>). ARL13B and ARL3 were shown to localize to the IS, and a recent preprint has shown that INPP5E does as well (<xref ref-type="bibr" rid="bib78">Powell et al., 2021</xref>; <xref ref-type="bibr" rid="bib88">Stephen et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Chiu et al., 2021</xref>). With advice from the preprint authors, we confirmed that endogenous INPP5E accumulates at the IS between Jurkat T-cells and Raji antigen-presenting cells, a well-established IS model (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1a-b</xref>; <xref ref-type="bibr" rid="bib16">Chiu et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Herranz et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Montoya et al., 2002</xref>; <xref ref-type="bibr" rid="bib13">Calvo and Izquierdo, 2021</xref>). Given the parallels between cilia and IS, we wondered whether IS targeting of INPP5E shares the same mechanisms that INPP5E uses for ciliary targeting in other cell types. To test this, we assessed the CLS-dependence of INPP5E IS targeting. As also reported in the preprint, EGFP-INPP5E WT is also detected at the Jurkat-Raji IS (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1c</xref>; <xref ref-type="bibr" rid="bib16">Chiu et al., 2021</xref>). This localization was not noticeably perturbed in the ΔCLS1, ΔCLS2, ΔCLS3, ΔCLS4, or ΔCLS1+4 mutants (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1c</xref>). Therefore, INPP5E IS targeting does not follow the same mechanisms as INPP5E ciliary targeting.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this work, we have demonstrated that INPP5E ciliary targeting is complex, requiring the interplay of four different CLSs. We have also made inroads into the mechanisms of action of these CLSs. <xref ref-type="table" rid="table1">Table 1</xref> summarizes our findings regarding how each CLS affects INPP5E’s interactions with ciliary trafficking regulators PDE6D, RPGR, ARL13B, TULP3, CEP164, and ATG16L1.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>CLS-dependence of INPP5E protein-protein interactions.</title><p>Cilia localization and the indicated interactions are shown for each EGFP-INPP5E construct on the left column. For both localization and interactions, meaning of arrows is as follows: two upward green arrows (strong), one upward green arrow (moderate), one downward red arrow (low), and two downward red arrows (undetectable).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2">INPP5E construct</th><th align="left" valign="bottom" rowspan="2">Ciliary?</th><th align="left" valign="bottom" colspan="6">INPP5E interactors</th></tr><tr><th align="left" valign="bottom">PDE6D</th><th align="left" valign="bottom">RPGR</th><th align="left" valign="bottom">ARL13B</th><th align="left" valign="bottom">TULP3</th><th align="left" valign="bottom">CEP164</th><th align="left" valign="bottom">ATG16L1</th></tr></thead><tbody><tr><td align="left" valign="bottom">WT</td><td align="left" valign="bottom"><bold>↑↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td></tr><tr><td align="left" valign="bottom">ΔCLS1</td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td></tr><tr><td align="left" valign="bottom">ΔCLS2</td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↓</bold></td><td align="left" valign="bottom"><bold>↑↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td></tr><tr><td align="left" valign="bottom">ΔCLS3</td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↓</bold></td><td align="left" valign="bottom"><bold>↑↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td></tr><tr><td align="left" valign="bottom">ΔCLS4</td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↓</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td></tr><tr><td align="left" valign="bottom">ΔCLS1+4</td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↓</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↓</bold></td></tr><tr><td align="left" valign="bottom">CT (251-644)</td><td align="left" valign="bottom"><bold>↑↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↑</bold></td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↑</bold></td></tr><tr><td align="left" valign="bottom">NT (1-283)</td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↓↓</bold></td><td align="left" valign="bottom"><bold>↓</bold></td><td align="left" valign="bottom"><bold>↑↑</bold></td><td align="left" valign="bottom"><bold>↓</bold></td></tr></tbody></table></table-wrap><p>Two of the CLSs (CLS2-3) are part of the catalytic domain, whose integrity is essential for ciliary localization. Moreover, mutations in CLS2-3 reduced enzyme activity (<xref ref-type="fig" rid="fig2">Figure 2e</xref>), raising the question of whether these are bona fide CLSs, actively engaging ciliary trafficking machinery, as opposed to simply maintaining overall domain architecture. We believe we have sufficiently demonstrated the former to be the case. Without being exhaustive, some observations proving this point include: (i) deleting CLS2 or CLS3 reduced activity and protein stability by about twofold, yet ciliary targeting was not merely reduced by half, but completely abolished (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplements 2</xref>–<xref ref-type="fig" rid="fig2s4">4</xref>); (ii) a similar twofold loss of activity and protein levels was seen for the R379A mutant, located directly adjacent to CLS2-3 in the catalytic domain, yet R379A was readily observed in cilia (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>); and (iii) CLS2-3 specifically affect association of INPP5E to some ciliary trafficking regulators, but not others (<xref ref-type="fig" rid="fig6">Figures 6</xref>—<xref ref-type="fig" rid="fig8">8</xref>).</p><p>Together with our data showing CLS1 and CLS4 affect ciliary targeting without any effects on activity or protein stability (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s2">2</xref>), we feel confident that CLS1, 2, 3, and 4 are all bona fide CLSs. In support of this, all these CLSs are highly conserved, and they affect INPP5E function (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>Although mutations in many other JBTS genes disrupt INPP5E ciliary localization, JBTS-causative mutations in the <italic>INPP5E</italic> gene itself had not been reported to do so (<xref ref-type="bibr" rid="bib37">Garcia-Gonzalo and Reiter, 2017</xref>; <xref ref-type="bibr" rid="bib4">Bachmann-Gagescu et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Garcia-Gonzalo et al., 2011</xref>; <xref ref-type="bibr" rid="bib82">Roberson et al., 2015</xref>; <xref ref-type="bibr" rid="bib87">Slaats et al., 2016</xref>; <xref ref-type="bibr" rid="bib1">Alkanderi et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib74">Ning et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Dowdle et al., 2011</xref>). Instead, some of these <italic>INPP5E</italic> mutations, which invariably affect the catalytic domain, were shown to impair enzyme activity without affecting ciliary targeting (<xref ref-type="bibr" rid="bib8">Bielas et al., 2009</xref>; <xref ref-type="bibr" rid="bib21">de Goede et al., 2016</xref>). Here, we show for the first time that JBTS-causing <italic>INPP5E</italic> gene mutations do sometimes prevent ciliary accumulation (<xref ref-type="fig" rid="fig5">Figure 5</xref>). However, this does not appear to be due to specific inactivation of any CLS, as none of the mutations located near CLS2-3 prevented ciliary targeting. Rather, ciliary accumulation was lost in mutants likely to compromise catalytic domain integrity, such as G286R, V303M and W474R (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Interestingly, both G286R and W474R are homozygous mutations, suggesting a complete lack of INPP5E in the cilia of these patients. Whether and how this contributed to JBTS manifestations in these patients, as compared to patients with activity-impaired but still ciliary INPP5E, remains an open question.</p><p>Besides discovering two novel CLSs in INPP5E (CLS1-2), we also shed light into how these novel CLSs relate to the previously identified ones (CLS3-4). Specifically, we found that CLS1 and CLS4 are partially redundant, with ciliary targeting moderately impaired in the single mutants, yet completely abolished in the double mutant (<xref ref-type="fig" rid="fig3">Figure 3a–c</xref>). Although the mechanisms of CLS4 action are fairly well understood, how CLS1 can partially substitute for it remains unclear (<xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib39">Gotthardt et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Fansa et al., 2016</xref>). In this regard, we tested several hypotheses, such as CLS1 also mediating binding to PDE6D, RPGR, or ARL13B, but none of this was the case (<xref ref-type="fig" rid="fig6">Figure 6</xref>; <xref ref-type="bibr" rid="bib105">Zhang et al., 2019</xref>; <xref ref-type="bibr" rid="bib80">Rao et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Dutta and Seo, 2016</xref>; <xref ref-type="bibr" rid="bib62">Lee and Seo, 2015</xref>; <xref ref-type="bibr" rid="bib27">Fansa et al., 2015</xref>; <xref ref-type="bibr" rid="bib98">Wätzlich et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Khanna, 2018</xref>). ARL3 and BART are also involved in the CLS4 pathway, but we found that they do not co-IP with INPP5E (data not shown) (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Gotthardt et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Fansa et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Ivanova et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">ElMaghloob et al., 2021</xref>).</p><p>Partial redundancy between CLS1 and CLS4 might be partly explained by their effects on ATG16L1 binding (<xref ref-type="fig" rid="fig8">Figure 8a–b</xref>). ATG16L1 is an autophagy protein without which INPP5E cannot accumulate in cilia (<xref ref-type="bibr" rid="bib10">Boukhalfa et al., 2021</xref>). As previously reported, we detected INPP5E-ATG16L1 binding, which appeared reduced with ΔCLS1 +4, but not ΔCLS1 or ΔCLS4. However, despite consistent results in three independent experiments and a strong statistical tendency in the ANOVA, the reduction in ΔCLS1 +4 was not statistically significant, so more experiments will be needed to clarify this point. Since ATG16L1 is involved in the Golgi exit of IFT20, an IFT-B component that traffics from Golgi to cilia base, one could speculate that ATG16L1 is needed for INPP5E Golgi exit (<xref ref-type="bibr" rid="bib10">Boukhalfa et al., 2021</xref>). This would be consistent with previous reports of INPP5E Golgi localization, and with post-prenylation processing of CaaX box proteins occurring on the ER-Golgi surface (<xref ref-type="bibr" rid="bib57">Kong et al., 2000</xref>; <xref ref-type="bibr" rid="bib100">Wright and Philips, 2006</xref>). However, if ATG16L1 indeed works through CLS1 and CLS4, then this hypothesis predicts that INPP5E ΔCLS1 +4 will be retained at the Golgi. This is clearly not the case, though, as our data clearly show that ΔCLS1 +4 accumulates at the ciliary transition zone (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Therefore, CLS1-4 exert their main functions at the transition zone, and how ATG16L1 mediates INPP5E ciliary targeting remains poorly understood.</p><p>Besides the functional CLS1-CLS4 connection, we also uncovered a CLS2-CLS3 link. Given their steric proximity (<xref ref-type="fig" rid="fig2">Figure 2b</xref>), we hypothesize CLS2 and CLS3 work together as a functional unit to recruit ciliary trafficking proteins like ARL13B and TULP3 (<xref ref-type="fig" rid="fig8">Figure 8c</xref>). Consistent with this, CLS2 and CLS3 behaved largely equivalently in all our interaction experiments (<xref ref-type="fig" rid="fig6">Figures 6</xref>—<xref ref-type="fig" rid="fig8">8</xref>). Moreover, the need to keep CLS2-3 together also explains why a folded catalytic domain is critical for ciliary targeting (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Future structural studies should further clarify these issues.</p><p>ARL13B regulates INPP5E ciliary targeting by functioning as an ARL3-GEF, thereby promoting INPP5E release from PDE6D inside cilia (<xref ref-type="bibr" rid="bib90">Thomas et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Fujisawa et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Qiu et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Gotthardt et al., 2015</xref>). However, this indirect connection does not suffice to explain why CLS4 promotes association between ARL13B and INPP5E, as we and others have found (<xref ref-type="fig" rid="fig6">Figure 6</xref>; <xref ref-type="bibr" rid="bib32">Fujisawa et al., 2021</xref>). The explanation for this might be that, by mediating INPP5E membrane insertion, CLS4-dependent farnesylation facilitates access to ARL13B, a fatty acylated protein (<xref ref-type="bibr" rid="bib14">Cevik et al., 2013</xref>; <xref ref-type="bibr" rid="bib83">Roy et al., 2017</xref>). If so, an alternative membrane anchor in ΔCLS4 should restore the interaction. ARL13B has also been shown to directly interact with INPP5E in a CLS3-dependent manner, an interaction that is essential for ARL13B to mediate INPP5E ciliary retention (<xref ref-type="bibr" rid="bib32">Fujisawa et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Qiu et al., 2021</xref>). Although CLS2-3 mutants did not affect INPP5E-ARL13B co-IP in our conditions, our co-recruitment assays did show a strong effect of both CLS2 and CLS3 on this interaction. Given that CLS2-3 likely form a functional unit as mentioned above, CLS2 probably affects the direct ARL13B-INPP5E interaction, as previously reported for CLS3 (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>).</p><p>TULP3 is essential for ciliary targeting of both ARL13B and INPP5E, among other ciliary membrane proteins (<xref ref-type="bibr" rid="bib43">Han et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Palicharla et al., 2021</xref>). Through its C-terminal Tubby domain, TULP3 directly interacts with ARL13B, targeting it to cilia, which in turn allows INPP5E ciliary targeting (<xref ref-type="bibr" rid="bib75">Palicharla et al., 2021</xref>). However, whether TULP3 and INPP5E interact with each other had not been reported. Our co-IPs show that they do, in a CLS2-3 and Tubby domain-dependent manner (<xref ref-type="fig" rid="fig7">Figure 7a–c</xref>). Tubby domain’s mutations K389A and K268A+R270 A reduced but not abolished the interaction. K389 is important for direct TULP3-ARL13B binding, and critical for ciliary targeting of both ARL13B and INPP5E (<xref ref-type="bibr" rid="bib75">Palicharla et al., 2021</xref>). This suggests the TULP3-INPP5E interaction might be mediated by ARL13B. However, if INPP5E associates to TULP3 indirectly via ARL13B, then it is hard to explain why ΔCLS4 reduces INPP5E-ARL13B but not INPP5E-TULP3 co-IP, and why ΔCLS2-3 do the opposite (<xref ref-type="fig" rid="fig6">Figures 6</xref>–<xref ref-type="fig" rid="fig7">7</xref>). Thus, INPP5E-TULP3 probably do not interact via ARL13B. Whether or not they interact directly remains to be determined. On the other hand, the K268A+R270 A mutation, which interferes with TULP3’s ability to bind phosphoinositides and target transmembrane receptors to cilia, has no effect on TULP3’s ability to target ARL13B and INPP5E to cilia (<xref ref-type="bibr" rid="bib75">Palicharla et al., 2021</xref>). Whether this mutation affects other functional aspects of the TULP3-INPP5E interaction we observe remains an open possibility.</p><p>CEP164 binds INPP5E and recruits it to the ciliary base (<xref ref-type="bibr" rid="bib48">Humbert et al., 2012</xref>). Herein, we show that this interaction involves the N-termini of both proteins, with the WW domain in CEP164 being critical (<xref ref-type="fig" rid="fig7">Figure 7e–i</xref>). Since WW domains typically interact with proline-rich motifs, which abound in INPP5E’s N-terminal region, it seems likely that the CEP164-INPP5E interaction also involves these motifs (<xref ref-type="bibr" rid="bib66">Macias et al., 2002</xref>). We also provide evidence that this interaction is negatively regulated by CLS2-3 (<xref ref-type="fig" rid="fig7">Figure 7e–f</xref>). This is interesting, as the CEP164-INPP5E interaction may need to be loosened for INPP5E to efficiently enter cilia. Such loosening, however, cannot be the main function of CLS2-3, as they were still required for ciliary targeting of INPP5E mutants unable to bind CEP164 (<xref ref-type="fig" rid="fig7">Figure 7h</xref>). Still, even if the loosening up of the CEP164-INPP5E interaction is not sufficient, it may still be necessary for INPP5E ciliary targeting. This remains to be determined. If so, one possible mechanism would be competition between Tau tubulin kinase 2 (TTBK2) and INPP5E for CEP164’s WW domain, which they both bind through proline-rich regions (<xref ref-type="bibr" rid="bib102">Xu et al., 2016</xref>). If so, this could explain our observation that casein kinase CSNK2A1, a recently reported upstream regulator of TTBK2, promotes INPP5E ciliary targeting without interacting with it (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib65">Loukil et al., 2021</xref>).</p><p>Finally, given the known parallels between primary cilia and immune synapses, with the latter containing, among other ciliary proteins, ARL13B and INPP5E, we asked whether CLS1-4 also drive INPP5E targeting to the IS (<xref ref-type="bibr" rid="bib88">Stephen et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Chiu et al., 2021</xref>). The answer was no, pointing to clearly distinct mechanisms for targeting to both structures (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). This may mean that INPP5E targeting to cilia and IS evolved independently of each other or, alternatively, that a common evolutionary origin has been blurred by a long history of evolutionary divergence. The fact that INPP5E IS targeting is quickly induced upon assembly of the highly dynamic IS also suggests a more transient role for INPP5E at the IS, as opposed to its more constitutive ciliary localization. The mechanisms of INPP5E targeting to the IS await further investigation.</p><p>Altogether, our data show that INPP5E ciliary targeting is a surprisingly complex process involving four different cis-acting sequences (CLS1-4), and multiple trans-acting factors (like PDE6D, RPGR, ARL13B, TULP3, CEP164, and ATG16L1). This level of complexity is unusual, especially when compared to other ciliary cargoes, whose targeting typically involves a single CLS (<xref ref-type="bibr" rid="bib73">Nachury and Mick, 2019</xref>; <xref ref-type="bibr" rid="bib35">Garcia-Gonzalo and Reiter, 2012</xref>; <xref ref-type="bibr" rid="bib6">Barbeito and Garcia-Gonzalo, 2021</xref>; <xref ref-type="bibr" rid="bib72">Mukhopadhyay et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">McIntyre et al., 2016</xref>). The complexity and redundancy in INPP5E ciliary targeting suggest this is an important process, subject to fine regulation. This is consistent with the surprisingly wide range of functions INPP5E plays at the cilium, controlling among others their lipid and protein composition, assembly and disassembly, exovesicle release, and signaling (<xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Bielas et al., 2009</xref>; <xref ref-type="bibr" rid="bib41">Guo et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Garcia-Gonzalo et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Chávez et al., 2015</xref>; <xref ref-type="bibr" rid="bib5">Badgandi et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Dyson et al., 2017</xref>; <xref ref-type="bibr" rid="bib77">Phua et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Hakim et al., 2016</xref>; <xref ref-type="bibr" rid="bib102">Xu et al., 2016</xref>; <xref ref-type="bibr" rid="bib103">Xu et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Constable et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Hasenpusch-Theil et al., 2020</xref>; <xref ref-type="bibr" rid="bib86">Sharif et al., 2021</xref>; <xref ref-type="bibr" rid="bib93">Ukhanov et al., 2022</xref>; <xref ref-type="bibr" rid="bib104">Yue et al., 2021</xref>). With the broader view of INPP5E ciliary targeting provided herein, the stage is now set for a deeper molecular understanding of these processes and their regulation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">hTERT-RPE1</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat #<break/>CRL-4000</td><td align="left" valign="bottom">Derived from retinal pigmented epithelium</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Puromycin-sensitive hTERT-RPE1</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Puromycin Acetyltransferase (PAC)-KO cells</td><td align="left" valign="bottom">Also used in <xref ref-type="bibr" rid="bib38">Gonçalves et al., 2021</xref></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">INPP5E-KO hTERT-RPE1</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Clone 3</td><td align="left" valign="bottom">Derived from puromycin-sensitive hTERT-RPE1</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">INPP5E-KO hTERT-RPE1</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Clone 12</td><td align="left" valign="bottom">Derived from puromycin-sensitive hTERT-RPE1</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="char" char="." valign="bottom">293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat #<break/>CRL-3216</td><td align="left" valign="bottom">Derived from human embryonic kidney</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HeLa</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat #<break/>CCL-2</td><td align="left" valign="bottom">Derived from cervical carcinoma</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Jurkat, Clone E6-1</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat #<break/>TIB-152</td><td align="left" valign="bottom">T lymphoblasts from acute T cell leukemia</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Raji</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat #<break/>CCL-86</td><td align="left" valign="bottom">Lymphoblast-like cells from Burkitt’s lymphoma</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Csnk2a1-WT MEFs</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib65">Loukil et al., 2021</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Control mouse embryonic fibroblasts (MEFs)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Csnk2a1-KO MEFs</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib65">Loukil et al., 2021</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Casein kinase 2 subunit alpha-null MEFs</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-acetylated<break/>α-tubulin (mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich (Merck)</td><td align="left" valign="bottom">Cat #<break/>T7451<break/>(clone 6-11B-1)</td><td align="left" valign="bottom">IF: 1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-α-tubulin (mouse monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #<break/>66031–1-Ig</td><td align="left" valign="bottom">WB: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-γ-tubulin (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat # sc-17787</td><td align="left" valign="bottom">IF: 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-EGFP (mouse monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #<break/>66002–1-Ig</td><td align="left" valign="bottom">WB: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-EGFP (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat # sc-9996</td><td align="left" valign="bottom">IF: 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-ARL13B (mouse monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #<break/>66739–1-Ig</td><td align="left" valign="bottom">WB: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Flag (mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich (Merck)</td><td align="left" valign="bottom">Cat #<break/>F3165<break/>(clone M2)</td><td align="left" valign="bottom">WB: 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-polyglutamylated tubulin (mouse monoclonal)</td><td align="left" valign="bottom">Adipogen</td><td align="left" valign="bottom">Cat #<break/>GT335</td><td align="left" valign="bottom">IF: 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-EGFP (rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #<break/>50430–2-AP</td><td align="left" valign="bottom">IF: 1:200<break/>WB: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-RPGR (rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #<break/>16891–1-AP</td><td align="left" valign="bottom">WB: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-TULP3 (rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #<break/>13637–1-AP</td><td align="left" valign="bottom">IF: 1:750<break/>WB: 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CEP164<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #<break/>22227–1-AP</td><td align="left" valign="bottom">WB: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-ATG16L<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">MBL</td><td align="left" valign="bottom">Cat #<break/>PM040</td><td align="left" valign="bottom">WB: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Myc<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #<break/>16286–1-AP</td><td align="left" valign="bottom">WB: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-INPP5E<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #<break/>17797–1-AP</td><td align="left" valign="bottom">IF: 1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti- γ-tubulin<break/>(goat polyclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat # sc-7396<break/>(discontinued)</td><td align="left" valign="bottom">IF: 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 donkey anti-rabbit IgG (donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A21206</td><td align="left" valign="bottom">IF: 1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 555 donkey anti-mouse IgG (donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A31570</td><td align="left" valign="bottom">IF: 1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 647 donkey anti-goat IgG (donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A21447</td><td align="left" valign="bottom">IF: 1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 goat anti-mouse IgG2a (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A21131</td><td align="left" valign="bottom">IF: 1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 555 goat anti-mouse IgG1 (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A21127</td><td align="left" valign="bottom">IF: 1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 555 goat anti-mouse IgG2b (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A21147</td><td align="left" valign="bottom">IF: 1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 647 goat anti-mouse IgG2a (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A21241</td><td align="left" valign="bottom">IF: 1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-conjugated goat anti-mouse IgG (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A16072</td><td align="left" valign="bottom">WB: 62 ng/ml</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-conjugated goat anti-rabbit IgG (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A16104</td><td align="left" valign="bottom">WB: 62 ng/ml</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GFP-Trap_MA magnetic agarose beads (alpaca monoclonal)</td><td align="left" valign="bottom">Chromotek (Proteintech)</td><td align="left" valign="bottom">Cat # gtma-20</td><td align="left" valign="bottom">IP: 10 µl slurry for 500 µl lysate (1:50)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref></td><td align="left" valign="bottom">Human INPP5E<break/>NM_019892.6<break/>(644 amino acids)</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (MORM)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib51">Jacoby et al., 2009</xref></td><td align="left" valign="bottom">1–626<break/>(MORM: Δ627–644)</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (D477N)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Garcia-Gonzalo et al., 2015</xref></td><td align="left" valign="bottom">D477N</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (1-623)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">1–623</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (1-621)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">1–621</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (1-618)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">1–618</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (1-616)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">1–616</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (1-608)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">1–608</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (1-283)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">1–283</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (Δ297–599)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Δ297–599</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (100-644)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">100–644</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (200-644)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">200–644</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (251-644)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">251–644</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (274-644)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">274–644</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (288-644)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">288–644</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (351-644)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">351–644</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (451-644)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">451–644</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (551-644)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">551–644</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (FDR609AAA)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">F609A+D610A+R611 A<break/>(aka ΔCLS3 or FDR &gt;AAA)</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (LYL613AAA)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">L613A+Y614A+L615 A<break/>(aka LYL &gt;AAA)</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (F609A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">F609A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (D610A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">D610A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (R611A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">R611A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (E612A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">E612A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (L613A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">L613A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (Y614A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Y614A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (L615A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">L615A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (R345A+R346 A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">R345A+R346 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (E347A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">E347A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (W348A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W348A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (E349A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">E349A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (Q353A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Q353A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (E354A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">E354A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (Y360A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Y360A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (Y360F)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Y360F</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (V361A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">V361A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (R378A+R379 A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">R378A+R379 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (R378A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">R378A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (R379A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">R379A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (D380A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">D380A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (I382A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">I382A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (W383A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W383A<break/>(aka ΔCLS2)</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (W383F)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W383F</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (W383I)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W383I</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (W383L)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W383L</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (W383M)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W383M</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (W383V)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W383V</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (W383E)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W383E</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (W383R)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W383R</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (F384A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">F384A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (E387A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">E387A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (Δ251–273)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Δ251–273<break/>(aka ΔCLS1)</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (C641S)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">C641S<break/>(aka ΔCLS4)</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (Δ251–273+C641 S)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Δ251–273+C641 S (aka ΔCLS1+4)</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (288-626)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">288–626</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (274-626)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">274–626</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (269-626)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">269–626</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (264-626)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">264–626</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">257–626</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (251-626)</td><td align="left" valign="bottom">This study</td><td align="char" char="ndash" valign="bottom">251–626</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+FS257AA</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+F257A+S258 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+LL259AA</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+L259A+L260 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+PIR262AAA</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+P262A+I263A+R264 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+SK265AA</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+S265A+K266 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+DV267AA</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+D267A+V268 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+L259 A</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+L259 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+L260 A</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+L260 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+P262 A</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+P262 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+I263 A</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+I263 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E (257-626)<break/>+R264 A</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(257-626)+R264 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(G286R)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">G286R</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(V303M)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">V303M</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(R345S)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">R345S</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(T355M)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">T355M</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(R378C)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">R378C</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(C385Y)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">C385Y</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(V388L)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">V388L</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(W474R)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">W474R</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(D490Y)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">D490Y</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(R621Q)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">R621Q</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(R621W)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">R621W</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(C641R)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">C641R</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(274-644) + ΔCLS2</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(274-644)+W383 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-INPP5E<break/>(274-644) + ΔCLS3</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(274-644)+F609A+D610A+R611 A</td><td align="left" valign="bottom">XhoI-KpnI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Flag-INPP5E</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human INPP5E<break/>NM_019892.6<break/>(644 amino acids)</td><td align="left" valign="bottom">EcoRI-KpnI cloning into pFlag-CMV4</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">mVenus-PDE6D</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human PDE6D<break/>NM_002601.4<break/>(150 amino acids)</td><td align="left" valign="bottom">Cloned into p-mVenus-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Flag-PDE6D</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human PDE6D<break/>NM_002601.4<break/>(150 amino acids)</td><td align="left" valign="bottom">mVenus-PDE6D cassette from eponymous plasmid excised with AgeI-EcoRI and replaced by Flag-PDE6D</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1(+)-N-DYK-RPGR</td><td align="left" valign="bottom">GenScript</td><td align="left" valign="bottom">Human RPGR NM_000328.3<break/>(815 amino acids)</td><td align="left" valign="bottom">Plasmid, expresses Flag-RPGR (aka DYK-RPGR)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">ARL13B-EYFP</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human ARL13B<break/>NM_001174150.2<break/>(428 amino acids)</td><td align="left" valign="bottom">Cloned into pEYFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">ARL13B-EGFP</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human ARL13B<break/>NM_001174150.2<break/>(428 amino acids)</td><td align="left" valign="bottom">XhoI-BamHI cloning into pEGFP-N1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">ARL13B-Flag</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human ARL13B<break/>NM_001174150.2<break/>(428 amino acids)</td><td align="left" valign="bottom">EGFP in ARL13B-EGFP was swapped by Flag using AgeI-NotI and pre-annealed Flag-encoding primers.</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1-TULP3-myc-his</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib6">Barbeito and Garcia-Gonzalo, 2021</xref></td><td align="left" valign="bottom">Human TULP3 NP_003315.2<break/>(442 amino acids)</td><td align="left" valign="bottom">XhoI-BamHI into pcDNA3.1-myc-his(-)C</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pG-LAP1-TULP3</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib70">Mukhopadhyay et al., 2010</xref></td><td align="left" valign="bottom">Human TULP3 NP_003315.2<break/>(442 amino acids)</td><td align="left" valign="bottom">Expresses<break/>EGFP-Stag-TULP3 (LAP-TULP3)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pG-LAP1-TULP3-KR</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib70">Mukhopadhyay et al., 2010</xref></td><td align="left" valign="bottom">TULP3 (K268A+R270 A)</td><td align="left" valign="bottom">Phosphoinositide binding-defective mutant</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-TULP3 (NTD)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">TULP3 (1–183)</td><td align="left" valign="bottom">KpnI-BamHI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-TULP3 (CTD)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">TULP3 (184–442)<break/>(aka Tubby domain)</td><td align="left" valign="bottom">KpnI-BamHI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">EGFP-TULP3 (K389A)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human TULP3 NP_003315.2<break/>(442 amino acids)</td><td align="left" valign="bottom">KpnI-BamHI cloning into pEGFP-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CEP164-EGFP</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene plasmid; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:addgene_41149">Addgene_41149</ext-link></td><td align="left" valign="bottom">Human CEP164<break/>NM_014956.5<break/>(1460 amino acids)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CEP164-EGFP (1-467)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">CEP164-NT<break/>(aka N-term in <xref ref-type="bibr" rid="bib12">Cajanek and Nigg, 2014</xref>)</td><td align="left" valign="bottom">CEP164-NT replaces full length in CEP164-EGFP (EcoRI-KpnI)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CEP164-EGFP (1-467)+WWmut</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">(1-467)<break/>+Y73A+Y74 A</td><td align="left" valign="bottom">Mutant of WW domain</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CEP164-EGFP (468–1135)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">CEP164-Mid<break/>(aka M-part in<break/><xref ref-type="bibr" rid="bib12">Cajanek and Nigg, 2014</xref>)</td><td align="left" valign="bottom">CEP164-Mid replaces full length in CEP164-EGFP (EcoRI-KpnI)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CEP164-EGFP (1136–1460)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">CEP164-CT<break/>(aka C-term in <xref ref-type="bibr" rid="bib12">Cajanek and Nigg, 2014</xref>)</td><td align="left" valign="bottom">CEP164-CT replaces full length in CEP164-EGFP (EcoRI-KpnI)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMRX-IP-SECFP-hATG16A1</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene plasmid; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:addgene_58994">Addgene_58994</ext-link></td><td align="left" valign="bottom">Human ATG16L1<break/>NP_060444.3<break/>(588 amino acids)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Flag-ATG16L1</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human ATG16L1<break/>NP_060444.3<break/>(588 amino acids)</td><td align="left" valign="bottom">EcoRI insert from pMRX-IP-SECFP-hATG16A1 transferred to pFlagCMV4</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CSNK2A1-myc</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Mouse CSNK2A1<break/>NP_031814.2<break/>(391 amino acids)</td><td align="left" valign="bottom">XhoI-BamHI into pcDNA3.1-myc-his(-)C</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">FRB-CFP-CaaX</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib84">Roy et al., 2020</xref> Biorxiv</td><td align="left" valign="bottom">FRB* domain of human mTOR<break/>(as in RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:addgene20148">Addgene_20148</ext-link>)</td><td align="left" valign="bottom">CaaX box of K-Ras targets FRB-CFP to inner leaflet of plasma membrane</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">mCherry-FKBP</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human FKBP1A<break/>(aka FKBP12)<break/>NP_000792.1<break/>(108 amino acids)</td><td align="left" valign="bottom">Cloned into p-mCherry-C1</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">mCherry-FKBP-INPP5E(WT)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Human INPP5E<break/>NM_019892.6<break/>(644 amino acids)</td><td align="left" valign="bottom">Cloned into mCherry-FKBP</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">mCherry-FKBP-INPP5E(ΔCLS1)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">INPP5E<break/>Δ251–273</td><td align="left" valign="bottom">Cloned into mCherry-FKBP</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">mCherry-FKBP-INPP5E(ΔCLS2)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">INPP5E<break/>W383A</td><td align="left" valign="bottom">Cloned into mCherry-FKBP</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">mCherry-FKBP-INPP5E(ΔCLS3)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">INPP5E<break/>F609A+D610A+R611 A</td><td align="left" valign="bottom">Cloned into mCherry-FKBP</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">mCherry-FKBP-INPP5E(ΔCLS4)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">INPP5E<break/>C641S</td><td align="left" valign="bottom">Cloned into mCherry-FKBP</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">mCherry-FKBP-INPP5E (ΔCLS1+4)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">INPP5E<break/>Δ251–273+C641 S</td><td align="left" valign="bottom">Cloned into mCherry-FKBP</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSpCas9-sgPAC1</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PAC gRNA#1<break/>plasmid</td><td align="left" valign="bottom">PAC gRNA#1: ACGCGCGUCGGGCTCGACAUCGG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSpCas9-sgPAC3</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PAC gRNA#3<break/>plasmid</td><td align="left" valign="bottom">PAC gRNA#3: CACGCGCCACACCGUCGAUCCGG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSpCas9-sgPAC6</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PAC gRNA#3<break/>plasmid</td><td align="left" valign="bottom">PAC gRNA#6: GGCGGGGUAGUCGGCGAACGCGG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSpCas9-hINPP5E-gRNA1</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">INPP5E gRNA#1<break/>plasmid</td><td align="left" valign="bottom">INPP5E gRNA#1: CGGAGCCCGGAGCAUCGGGUGGG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSpCas9-hINPP5E-gRNA2</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">INPP5E gRNA#2<break/>plasmid</td><td align="left" valign="bottom">INPP5E gRNA#2: UGGAGCGUCCUCCCUUCCGGCGG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSpCas9-hINPP5E-gRNA3</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">INPP5E gRNA#3<break/>plasmid</td><td align="left" valign="bottom">INPP5E gRNA#3:<break/>ACAGCUUCCCGGCGCUCCGCCGG</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Malachite Green Assay Kit</td><td align="left" valign="bottom">Echelon Biosciences (Tebu-Bio)</td><td align="left" valign="bottom">Cat #<break/>K-1500</td><td align="left" valign="bottom">For measurement of phosphate release in activity assays.</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PtdIns(4,5)P2-diC8</td><td align="left" valign="bottom">Echelon Biosciences (Tebu-Bio)</td><td align="left" valign="bottom">Cat #<break/>P-4508</td><td align="left" valign="bottom">Activity assays:<break/>120 µM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">n-octyl-β-D-glucopyranoside</td><td align="left" valign="bottom">Alfa Aesar</td><td align="left" valign="bottom">Cat #<break/>J67390.03</td><td align="left" valign="bottom">Activity assays:<break/>0.1%</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Alexa Fluor 546<break/>Phalloidin</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #<break/>A22283</td><td align="left" valign="bottom">IF: 1:100</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 9.4.0</td><td align="left" valign="bottom">GraphPad Software Inc</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Fiji (Image J)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib85">Schmidt et al., 2012</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">SCR_002285</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://imagej.net/Fiji">http://imagej.net/Fiji</ext-link></td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Plasmids and mutagenesis</title><p>For information on all the plasmids used in this study, see the Key Resources Table. Site-directed mutagenesis was performed by overlap extension PCR. Amplifications for all cloning were performed with Platinum SuperFi DNA polymerase (Thermofisher), and all finished constructs were validated by DNA sequencing (Eurofins Genomics).</p></sec><sec id="s4-2"><title>Cell culture and transfections</title><p>All cell lines were grown at 37 °C and 5% CO<sub>2</sub> in a humidified atmosphere and were regularly tested to ensure they were mycoplasma-free. hTERT-RPE1 cells were cultured in DMEM/F12 basal medium supplemented with 10% fetal bovine serum (FBS) and were reverse transfected using JetPrime (Polyplus-transfection), and their cilia analyzed 48 hr later, after 24 hr of serum starvation. HEK293T cells were maintained in DMEM +10% FBS, transfected using the calcium phosphate method, and lysed 40–48 hr later. HeLa cells were cultured in DMEM +10% FBS +Penicillin/Streptomycin and transfected using FuGENE 6 (Promega). Co-recruitment assays were performed 24 hr after transfection. CRISPR-engineered control and <italic>Csnk2a1</italic>-null mouse embryonic fibroblasts have been described elsewhere (<xref ref-type="bibr" rid="bib65">Loukil et al., 2021</xref>). Raji B and Jurkat T (clone JE6.1) cell lines from ATCC were cultured in RPMI-1640 medium containing L-glutamine, penicillin/streptomycin, and 10% heat-inactivated FBS. All cell lines used in this study have been validated and used extensively in previous publications, with the exception of CRISPR cell lines, whose validation is described below.</p></sec><sec id="s4-3"><title>Immunofluorescence microscopy</title><p>For information on all the antibodies used in this study, see the Key Resources Table. hTERT-RPE1 cells grown to confluence on coverslips were fixed 5 min in PBS +4% paraformaldehyde (PFA) at room temperature (RT), followed by freezer-cold methanol for 3 min at −20 °C. Cells were then blocked and permeabilized for 30–60 min at RT in PBS +0.1% Triton X100 +2% donkey serum +0.02% sodium azide (blocking solution). Coverslips were then incubated in a humidified chamber for 2 hr at RT (or overnight, 4 °C) with blocking solution-diluted primary antibodies. After three PBS washes, PBS-diluted secondary antibodies and DAPI (1 µg/ml, Thermofisher) were added for 1 hr at RT in the dark. After three more PBS washes, coverslips were mounted on slides using Prolong Diamond (Thermofisher), incubated overnight at 4 °C, and imaged with a Nikon Ti fluorescence microscope. Brightness and contrast of microscopic images were adjusted for optimal visualization using Adobe Photoshop or Fiji (Image J). For methanol-only fixation (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>), cells were fixed 5 min in freezer-cold methanol at –20 °C, washed thrice in PBS, blocked as above but without Triton X100, and stained with antibodies as above.</p></sec><sec id="s4-4"><title>Generation of CRISPR cell lines</title><p>Puromycin-sensitive PAC-KO hTERT-RPE1 cells, and from them INPP5E-KO cells, were generated using CRISPR/Cas9 methods essentially as we described previously (<xref ref-type="bibr" rid="bib7">Barbeito et al., 2021</xref>). The sequences of guide RNAs and information on the plasmids encoding them are in the Key Resources Table. PAC-KO cells were not analyzed genomically, but their puromycin sensitivity was confirmed in dose-response assays as shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b-c</xref>. The genomic analysis of INPP5E-KO cells was performed as previously reported (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2a</xref>; <xref ref-type="bibr" rid="bib7">Barbeito et al., 2021</xref>).</p></sec><sec id="s4-5"><title>TULP3 rescue assays in INPP5E-KO cells</title><p>For the rescue assays, INPP5E-KO hTERT-RPE1 cells were reverse transfected on coverslips using JetPrime (500 ng DNA and 1 µl JetPrime reagent, in 50 µl JetPrime buffer, were prepared following manufacturer’s instructions and added to 2·10<sup>5</sup> suspended cells in 1 ml serum-containing medium, per well). Transfection medium was replaced 4 hr post-transfection (hpt). At 24 hpt, cells were starved with DMEM:F12 +0.2% FBS. At 48 hpt, cells were fixed (PFA +methanol), stained and visualized as described above. For quantitation, transfected-cell cilia without visible TULP3 staining were expressed as percentage relative to total transfected-cell cilia.</p></sec><sec id="s4-6"><title>Immunoprecipitation and western blot</title><p>HEK293T cells were lysed 40–48 hr post-transfection in buffer containing 50 mM Tris-HCl pH = 7.5, 150 mM NaCl, 1% Igepal CA-630 (Sigma-Aldrich) and 1 X Halt protease inhibitor cocktail (Thermofisher, #78429). Lysates were then rotated (15 min, 4 °C) and centrifuged (10 min, 20,000 g, 4 °C), and protein levels in the postnuclear supernatants measured with Pierce BCA Protein Assay Kit (Thermofisher). After equalizing protein amount and concentration in all samples, EGFP fusion proteins were immunoprecipitated with GFP-Trap magnetic agarose (GFP-Trap_MA, Chromotek) beads for 2 hr or overnight at 4 °C with rotation. Beads were then washed thrice in lysis buffer without protease inhibitors, eluted with 2 X Laemmli buffer containing 200 mM DTT, and boiled 5 min at 95 °C. SDS-PAGE and Western blots were performed as previously described (<xref ref-type="bibr" rid="bib7">Barbeito et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Martin-Hurtado et al., 2019</xref>). For information on all antibodies used for western blot, see the Key Resources Table.</p></sec><sec id="s4-7"><title>Phosphoinositide phosphatase assays</title><p>Activity assays were performed essentially as described (<xref ref-type="bibr" rid="bib8">Bielas et al., 2009</xref>). Briefly, HEK293T cell lysates were obtained as above, and their protein levels measured with Pierce BCA Protein Assay kit (Thermofisher). EGFP-INPP5E or its mutants were then immunoprecipitated from 1 mg of cell lysate by overnight rotation at 4 °C with GFP-Trap_MA beads (Chromotek). Beads were then washed thrice in buffer containing 50 mM Tris-HCl pH = 7.5 and 150 mM NaCl buffer (no protease inhibitors or detergent), and twice more in activity buffer (50 mM Tris-HCl pH = 7.5, 150 mM NaCl, 3 mM MgCl<sub>2</sub> and 0.1% octyl-β-D-glucopyranoside (Alfa Aesar)). For the activity assays, beads were incubated in activity buffer supplemented with 120 µM diC8-PtdIns(4,5)P2, from Echelon Biosciences. After incubating the enzyme reactions for 20 min at 37 °C, the supernatant was retrieved from the beads and its phosphate concentration measured at 620 nm using the Malachite Green Assay Kit (Echelon Biosciences). Beads were then processed for western blot as above.</p></sec><sec id="s4-8"><title>Co-recruitment assays</title><p>Co-recruitment assays were performed using Eclipse Ti microscope (Nikon, Japan) with a 100 X TIRF objective (1.0 X zoom and 4X4 binning) in TIRF mode and PCO-Edge 4.2 BI sCMOS camera (PCO, Germany), driven by NIS Elements software (Nikon) and equipped with 440 nm, 514 nm, and 561 nm laser lines. Time lapse imaging was performed at 2 min intervals for 20 min, with 100 nM rapamycin addition after the fifth time point. All live cell imaging was conducted at 37 °C, 5% CO<sub>2</sub> and 90% humidity with a stage top incubation system (Tokai Hit). Vitamin and phenol red-free media (US Biological) supplemented with 2% FBS were used in imaging to reduce background and photobleaching. Adequate co-expression of all relevant plasmids was confirmed by fluorescent imaging at appropriate wavelengths. To minimize variability due to relative expression levels, only cells showing at least 30% increase in mCherry intensity after addition of rapamycin were considered for quantification. All image processing and analyses for co-recruitment assays were performed using Metamorph (Molecular Devices, Sunnyvale, CA, USA) and FIJI software (NIH, Bethesda, MD, USA). Co-recruitment assay graphs show means ±95% confidence interval with n≥40 different cells pooled from at least three independent experiments. For information on plasmids used in these assays, see the Key Resources Table.</p></sec><sec id="s4-9"><title>Immune synapse analyses</title><p>Raji cells were attached to glass-bottom microwell culture dishes (IBIDI) using poly-L-lysine (20 µg/mL). Raji cells were then labeled with 10 µM CMAC (7-amino-4-chloromethylcoumarin, Molecular Probes), pulsed with 1 µg/ml SEE (Staphylococcus enterotoxin E, Toxin Technologies), and mixed with Jurkat T cells (clone JE6.1) (ATCC). To promote synaptic conjugate formation, cell-containing dishes were centrifuged at low speed (200xg, 30 seg) and incubated 5 min at 37 °C. For recombinant protein expression, exponentially growing Jurkat T cells were electroporated with 20–30 µg of plasmid as previously reported (<xref ref-type="bibr" rid="bib46">Herranz et al., 2019</xref>), and Raji cells were added as above 40–48 hr post-electroporation. Cell conjugates were then fixed, first with PBS +2% PFA (10 min, RT), then with cold acetone (10 min at –20 °C). Immunofluorescence staining was done as previously described (<xref ref-type="bibr" rid="bib46">Herranz et al., 2019</xref>). Imaging was performed using a Nikon Eclipse TiE microscope equipped with a DS-Qi1MC digital camera, a PlanApo VC 60 x NA 1.4 objective, and NIS-AR software (all from Nikon). Epifluorescence images were then deconvolved with Huygens Deconvolution Software from Scientific Volume Image (SVI), using the ‘widefield’ optical option.</p></sec><sec id="s4-10"><title>Structural analyses</title><p>Swiss PDB Viewer was used to visualize the crystallographic structure of INPP5E aa 282–623 (Protein Data Bank (PDB) ID: 2xsw) in order to identify candidate CLS or ciliopathy residues near the FDRxLYL motif (<xref ref-type="bibr" rid="bib92">Tresaugues et al., 2010</xref>). Final figures were rendered using the PyMOL Molecular Graphics System (Version 2.0 Schrödinger), from either the PDB structure or the full length AlphaFold model (AF-Q9NRR6-F1) (<xref ref-type="bibr" rid="bib52">Jumper et al., 2021</xref>).</p></sec><sec id="s4-11"><title>Quantitations and statistical analyses</title><p>For quantitation of Western blot levels, including co-IP experiments, Fiji/Image J was used. Using 8-bit blot images, average pixel intensity (API) and surface area of a rectangular region of interest (ROI) containing the protein band or background region was obtained using the <italic>Measure</italic> function. Data were then transferred to an Excel file, where API values were inverted (so that blacker in blot means higher intensity: API’=255 API), background-subtracted, and the resulting specific intensity multiplied by the corresponding ROI’s surface area to get the band’s total specific intensity. Ratios were then calculated for each sample as appropriate (e.g. EGFP-INPP5E construct levels normalized to tubulin, or co-IPed protein normalized to IPed protein, and to its own levels in lysates). Specific details for each experiment are described in figure legends. Quantitation of intensities along cilia length in the methanol immunofluorescence stainings were obtained using Fiji/Image J’s <italic>Plot Profile</italic> function. For graphs and statistical analyses, GraphPad Prism 9 software was used. Details of statistical analyses are found in the corresponding figure legends.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>has consulted for Arvinas Inc</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-78383-transrepform1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated during this study are included in the manuscript and associated files. Source data files are provided for Figures 2,3,4,5,6,7,8, and for Figure Supplements 1-1, 2-2, 2-3, 2-4, 3-1, 3-2, 7-1.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Jung-Chi Liao for advice with INPP5E immune synapse stainings. This publication is part of grants PID2019-104941RB-I00 (to FRGG) and PID2020-114148RB-I00 (to MI), both funded by MCIN/AEI/ 10.13039/501100011033, and the latter also funded by ERDF, a way of making Europe. FRGG is also recipient of an ACCI-2020 grant from CIBERER. This work was also funded by NIH grant R01HD099784 (SCG), discretionary funds (TI), American Heart Association fellowship 20POST35220046 (ADR), Community of Madrid contract PEJD-2016/BMD-2341 (BSR), and MICINN predoctoral grant BES2016-077828 (RMM).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkanderi</surname><given-names>S</given-names></name><name><surname>Molinari</surname><given-names>E</given-names></name><name><surname>Shaheen</surname><given-names>R</given-names></name><name><surname>Elmaghloob</surname><given-names>Y</given-names></name><name><surname>Stephen</surname><given-names>LA</given-names></name><name><surname>Sammut</surname><given-names>V</given-names></name><name><surname>Ramsbottom</surname><given-names>SA</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Cairns</surname><given-names>G</given-names></name><name><surname>Edwards</surname><given-names>N</given-names></name><name><surname>Rice</surname><given-names>SJ</given-names></name><name><surname>Ewida</surname><given-names>N</given-names></name><name><surname>Alhashem</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>K</given-names></name><name><surname>Miles</surname><given-names>CG</given-names></name><name><surname>Steel</surname><given-names>DH</given-names></name><name><surname>Alkuraya</surname><given-names>FS</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name><name><surname>Sayer</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ARL3 mutations cause joubert syndrome by disrupting ciliary protein composition</article-title><source>American Journal of Human Genetics</source><volume>103</volume><fpage>612</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2018.08.015</pub-id><pub-id pub-id-type="pmid">30269812</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Mochizuki</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Takenawa</surname><given-names>T</given-names></name><name><surname>Endo</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Pharbin, a novel inositol polyphosphate 5-phosphatase, induces dendritic appearances in fibroblasts</article-title><source>Biochemical and Biophysical Research Communications</source><volume>261</volume><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1999.0998</pub-id><pub-id pub-id-type="pmid">10405344</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmann-Gagescu</surname><given-names>R</given-names></name><name><surname>Dempsey</surname><given-names>JC</given-names></name><name><surname>Phelps</surname><given-names>IG</given-names></name><name><surname>O’Roak</surname><given-names>BJ</given-names></name><name><surname>Knutzen</surname><given-names>DM</given-names></name><name><surname>Rue</surname><given-names>TC</given-names></name><name><surname>Ishak</surname><given-names>GE</given-names></name><name><surname>Isabella</surname><given-names>CR</given-names></name><name><surname>Gorden</surname><given-names>N</given-names></name><name><surname>Adkins</surname><given-names>J</given-names></name><name><surname>Boyle</surname><given-names>EA</given-names></name><name><surname>de Lacy</surname><given-names>N</given-names></name><name><surname>O’Day</surname><given-names>D</given-names></name><name><surname>Alswaid</surname><given-names>A</given-names></name><name><surname>Ramadevi A</surname><given-names>R</given-names></name><name><surname>Lingappa</surname><given-names>L</given-names></name><name><surname>Lourenço</surname><given-names>C</given-names></name><name><surname>Martorell</surname><given-names>L</given-names></name><name><surname>Garcia-Cazorla</surname><given-names>À</given-names></name><name><surname>Ozyürek</surname><given-names>H</given-names></name><name><surname>Haliloğlu</surname><given-names>G</given-names></name><name><surname>Tuysuz</surname><given-names>B</given-names></name><name><surname>Topçu</surname><given-names>M</given-names></name><collab>University of Washington Center for Mendelian Genomics</collab><name><surname>Chance</surname><given-names>P</given-names></name><name><surname>Parisi</surname><given-names>MA</given-names></name><name><surname>Glass</surname><given-names>IA</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Doherty</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Joubert syndrome: a model for untangling recessive disorders with extreme genetic heterogeneity</article-title><source>Journal of Medical Genetics</source><volume>52</volume><fpage>514</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103087</pub-id><pub-id pub-id-type="pmid">26092869</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmann-Gagescu</surname><given-names>R</given-names></name><name><surname>Dempsey</surname><given-names>JC</given-names></name><name><surname>Bulgheroni</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>ML</given-names></name><name><surname>D’Arrigo</surname><given-names>S</given-names></name><name><surname>Glass</surname><given-names>IA</given-names></name><name><surname>Heller</surname><given-names>T</given-names></name><name><surname>Héon</surname><given-names>E</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name><name><surname>Joshi</surname><given-names>N</given-names></name><name><surname>Knutzen</surname><given-names>D</given-names></name><name><surname>Kroes</surname><given-names>HY</given-names></name><name><surname>Mack</surname><given-names>SH</given-names></name><name><surname>Nuovo</surname><given-names>S</given-names></name><name><surname>Parisi</surname><given-names>MA</given-names></name><name><surname>Snow</surname><given-names>J</given-names></name><name><surname>Summers</surname><given-names>AC</given-names></name><name><surname>Symons</surname><given-names>JM</given-names></name><name><surname>Zein</surname><given-names>WM</given-names></name><name><surname>Boltshauser</surname><given-names>E</given-names></name><name><surname>Sayer</surname><given-names>JA</given-names></name><name><surname>Gunay-Aygun</surname><given-names>M</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name><name><surname>Doherty</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Healthcare recommendations for joubert syndrome</article-title><source>American Journal of Medical Genetics. Part A</source><volume>182</volume><fpage>229</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.61399</pub-id><pub-id pub-id-type="pmid">31710777</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badgandi</surname><given-names>HB</given-names></name><name><surname>Hwang</surname><given-names>SH</given-names></name><name><surname>Shimada</surname><given-names>IS</given-names></name><name><surname>Loriot</surname><given-names>E</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tubby family proteins are adapters for ciliary trafficking of integral membrane proteins</article-title><source>The Journal of Cell Biology</source><volume>216</volume><fpage>743</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1083/jcb.201607095</pub-id><pub-id pub-id-type="pmid">28154160</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbeito</surname><given-names>P</given-names></name><name><surname>Garcia-Gonzalo</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>HTR6 and SSTR3 targeting to primary cilia</article-title><source>Biochemical Society Transactions</source><volume>49</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1042/BST20191005</pub-id><pub-id pub-id-type="pmid">33599752</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbeito</surname><given-names>P</given-names></name><name><surname>Tachibana</surname><given-names>Y</given-names></name><name><surname>Martin-Morales</surname><given-names>R</given-names></name><name><surname>Moreno</surname><given-names>P</given-names></name><name><surname>Mykytyn</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Garcia-Gonzalo</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>HTR6 and SSTR3 ciliary targeting relies on both IC3 loops and C-terminal tails</article-title><source>Life Science Alliance</source><volume>4</volume><elocation-id>e202000746</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.202000746</pub-id><pub-id pub-id-type="pmid">33372037</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bielas</surname><given-names>SL</given-names></name><name><surname>Silhavy</surname><given-names>JL</given-names></name><name><surname>Brancati</surname><given-names>F</given-names></name><name><surname>Kisseleva</surname><given-names>MV</given-names></name><name><surname>Al-Gazali</surname><given-names>L</given-names></name><name><surname>Sztriha</surname><given-names>L</given-names></name><name><surname>Bayoumi</surname><given-names>RA</given-names></name><name><surname>Zaki</surname><given-names>MS</given-names></name><name><surname>Abdel-Aleem</surname><given-names>A</given-names></name><name><surname>Rosti</surname><given-names>RO</given-names></name><name><surname>Kayserili</surname><given-names>H</given-names></name><name><surname>Swistun</surname><given-names>D</given-names></name><name><surname>Scott</surname><given-names>LC</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Boltshauser</surname><given-names>E</given-names></name><name><surname>Fazzi</surname><given-names>E</given-names></name><name><surname>Travaglini</surname><given-names>L</given-names></name><name><surname>Field</surname><given-names>SJ</given-names></name><name><surname>Gayral</surname><given-names>S</given-names></name><name><surname>Jacoby</surname><given-names>M</given-names></name><name><surname>Schurmans</surname><given-names>S</given-names></name><name><surname>Dallapiccola</surname><given-names>B</given-names></name><name><surname>Majerus</surname><given-names>PW</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name><name><surname>Gleeson</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies</article-title><source>Nature Genetics</source><volume>41</volume><fpage>1032</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1038/ng.423</pub-id><pub-id pub-id-type="pmid">19668216</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>H-Y</given-names></name><name><surname>Chuguransky</surname><given-names>S</given-names></name><name><surname>Grego</surname><given-names>T</given-names></name><name><surname>Kandasaamy</surname><given-names>S</given-names></name><name><surname>Mitchell</surname><given-names>A</given-names></name><name><surname>Nuka</surname><given-names>G</given-names></name><name><surname>Paysan-Lafosse</surname><given-names>T</given-names></name><name><surname>Qureshi</surname><given-names>M</given-names></name><name><surname>Raj</surname><given-names>S</given-names></name><name><surname>Richardson</surname><given-names>L</given-names></name><name><surname>Salazar</surname><given-names>GA</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Bridge</surname><given-names>A</given-names></name><name><surname>Gough</surname><given-names>J</given-names></name><name><surname>Haft</surname><given-names>DH</given-names></name><name><surname>Letunic</surname><given-names>I</given-names></name><name><surname>Marchler-Bauer</surname><given-names>A</given-names></name><name><surname>Mi</surname><given-names>H</given-names></name><name><surname>Natale</surname><given-names>DA</given-names></name><name><surname>Necci</surname><given-names>M</given-names></name><name><surname>Orengo</surname><given-names>CA</given-names></name><name><surname>Pandurangan</surname><given-names>AP</given-names></name><name><surname>Rivoire</surname><given-names>C</given-names></name><name><surname>Sigrist</surname><given-names>CJA</given-names></name><name><surname>Sillitoe</surname><given-names>I</given-names></name><name><surname>Thanki</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>PD</given-names></name><name><surname>Tosatto</surname><given-names>SCE</given-names></name><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Bateman</surname><given-names>A</given-names></name><name><surname>Finn</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The interpro protein families and domains database: 20 years on</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D344</fpage><lpage>D354</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa977</pub-id><pub-id pub-id-type="pmid">33156333</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boukhalfa</surname><given-names>A</given-names></name><name><surname>Roccio</surname><given-names>F</given-names></name><name><surname>Dupont</surname><given-names>N</given-names></name><name><surname>Codogno</surname><given-names>P</given-names></name><name><surname>Morel</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The autophagy protein ATG16L1 cooperates with IFT20 and INPP5E to regulate the turnover of phosphoinositides at the primary cilium</article-title><source>Cell Reports</source><volume>35</volume><elocation-id>109045</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109045</pub-id><pub-id pub-id-type="pmid">33910006</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>DA</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ciliopathies</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>9</volume><elocation-id>a028191</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a028191</pub-id><pub-id pub-id-type="pmid">27793968</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cajanek</surname><given-names>L</given-names></name><name><surname>Nigg</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cep164 triggers ciliogenesis by recruiting tau tubulin kinase 2 to the mother centriole</article-title><source>PNAS</source><volume>111</volume><fpage>E2841</fpage><lpage>E2850</lpage><pub-id pub-id-type="doi">10.1073/pnas.1401777111</pub-id><pub-id pub-id-type="pmid">24982133</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvo</surname><given-names>V</given-names></name><name><surname>Izquierdo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Role of actin cytoskeleton reorganization in polarized secretory traffic at the immunological synapse</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>629097</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.629097</pub-id><pub-id pub-id-type="pmid">33614660</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cevik</surname><given-names>S</given-names></name><name><surname>Sanders</surname><given-names>A</given-names></name><name><surname>Van Wijk</surname><given-names>E</given-names></name><name><surname>Boldt</surname><given-names>K</given-names></name><name><surname>Clarke</surname><given-names>L</given-names></name><name><surname>van Reeuwijk</surname><given-names>J</given-names></name><name><surname>Hori</surname><given-names>Y</given-names></name><name><surname>Horn</surname><given-names>N</given-names></name><name><surname>Hetterschijt</surname><given-names>L</given-names></name><name><surname>Wdowicz</surname><given-names>A</given-names></name><name><surname>Mullins</surname><given-names>A</given-names></name><name><surname>Kida</surname><given-names>K</given-names></name><name><surname>Kaplan</surname><given-names>OI</given-names></name><name><surname>van Beersum</surname><given-names>SEC</given-names></name><name><surname>Man Wu</surname><given-names>K</given-names></name><name><surname>Letteboer</surname><given-names>SJF</given-names></name><name><surname>Mans</surname><given-names>DA</given-names></name><name><surname>Katada</surname><given-names>T</given-names></name><name><surname>Kontani</surname><given-names>K</given-names></name><name><surname>Ueffing</surname><given-names>M</given-names></name><name><surname>Roepman</surname><given-names>R</given-names></name><name><surname>Kremer</surname><given-names>H</given-names></name><name><surname>Blacque</surname><given-names>OE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Active transport and diffusion barriers restrict joubert syndrome-associated ARL13B/ARL-13 to an inv-like ciliary membrane subdomain</article-title><source>PLOS Genetics</source><volume>9</volume><elocation-id>e1003977</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003977</pub-id><pub-id pub-id-type="pmid">24339792</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chávez</surname><given-names>M</given-names></name><name><surname>Ena</surname><given-names>S</given-names></name><name><surname>Van Sande</surname><given-names>J</given-names></name><name><surname>de Kerchove d’Exaerde</surname><given-names>A</given-names></name><name><surname>Schurmans</surname><given-names>S</given-names></name><name><surname>Schiffmann</surname><given-names>SN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Modulation of ciliary phosphoinositide content regulates trafficking and sonic hedgehog signaling output</article-title><source>Developmental Cell</source><volume>34</volume><fpage>338</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.06.016</pub-id><pub-id pub-id-type="pmid">26190144</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>TY</given-names></name><name><surname>Yang</surname><given-names>FH</given-names></name><name><surname>Chong</surname><given-names>WM</given-names></name><name><surname>Tsai</surname><given-names>HC</given-names></name><name><surname>Wang</surname><given-names>WJ</given-names></name><name><surname>Liao</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>INPP5E Regulates CD3ζ Enrichment at the Immune Synapse by Phosphoinositide Distribution Control</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.01.06.425541</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conduit</surname><given-names>SE</given-names></name><name><surname>Ramaswamy</surname><given-names>V</given-names></name><name><surname>Remke</surname><given-names>M</given-names></name><name><surname>Watkins</surname><given-names>DN</given-names></name><name><surname>Wainwright</surname><given-names>BJ</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name><name><surname>Dyson</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote sonic hedgehog medulloblastoma</article-title><source>Oncogene</source><volume>36</volume><fpage>5969</fpage><lpage>5984</lpage><pub-id pub-id-type="doi">10.1038/onc.2017.208</pub-id><pub-id pub-id-type="pmid">28650469</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conduit</surname><given-names>SE</given-names></name><name><surname>Davies</surname><given-names>EM</given-names></name><name><surname>Fulcher</surname><given-names>AJ</given-names></name><name><surname>Oorschot</surname><given-names>V</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Superresolution microscopy reveals distinct phosphoinositide subdomains within the cilia transition zone</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>634649</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.634649</pub-id><pub-id pub-id-type="pmid">33996795</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constable</surname><given-names>S</given-names></name><name><surname>Long</surname><given-names>AB</given-names></name><name><surname>Floyd</surname><given-names>KA</given-names></name><name><surname>Schurmans</surname><given-names>S</given-names></name><name><surname>Caspary</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The ciliary phosphatidylinositol phosphatase inpp5e plays positive and negative regulatory roles in shh signaling</article-title><source>Development</source><volume>147</volume><elocation-id>dev183301</elocation-id><pub-id pub-id-type="doi">10.1242/dev.183301</pub-id><pub-id pub-id-type="pmid">31964774</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dafinger</surname><given-names>C</given-names></name><name><surname>Liebau</surname><given-names>MC</given-names></name><name><surname>Elsayed</surname><given-names>SM</given-names></name><name><surname>Hellenbroich</surname><given-names>Y</given-names></name><name><surname>Boltshauser</surname><given-names>E</given-names></name><name><surname>Korenke</surname><given-names>GC</given-names></name><name><surname>Fabretti</surname><given-names>F</given-names></name><name><surname>Janecke</surname><given-names>AR</given-names></name><name><surname>Ebermann</surname><given-names>I</given-names></name><name><surname>Nürnberg</surname><given-names>G</given-names></name><name><surname>Nürnberg</surname><given-names>P</given-names></name><name><surname>Zentgraf</surname><given-names>H</given-names></name><name><surname>Koerber</surname><given-names>F</given-names></name><name><surname>Addicks</surname><given-names>K</given-names></name><name><surname>Elsobky</surname><given-names>E</given-names></name><name><surname>Benzing</surname><given-names>T</given-names></name><name><surname>Schermer</surname><given-names>B</given-names></name><name><surname>Bolz</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mutations in KIF7 link joubert syndrome with sonic hedgehog signaling and microtubule dynamics</article-title><source>The Journal of Clinical Investigation</source><volume>121</volume><fpage>2662</fpage><lpage>2667</lpage><pub-id pub-id-type="doi">10.1172/JCI43639</pub-id><pub-id pub-id-type="pmid">21633164</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Goede</surname><given-names>C</given-names></name><name><surname>Yue</surname><given-names>WW</given-names></name><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Ariyaratnam</surname><given-names>S</given-names></name><name><surname>Chandler</surname><given-names>KE</given-names></name><name><surname>Downes</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Mohan</surname><given-names>M</given-names></name><name><surname>Lowe</surname><given-names>M</given-names></name><name><surname>Banka</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Role of reverse phenotyping in interpretation of next generation sequencing data and a review of INPP5E related disorders</article-title><source>European Journal of Paediatric Neurology</source><volume>20</volume><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2015.11.012</pub-id><pub-id pub-id-type="pmid">26748598</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Mori</surname><given-names>R</given-names></name><name><surname>Romani</surname><given-names>M</given-names></name><name><surname>D’Arrigo</surname><given-names>S</given-names></name><name><surname>Zaki</surname><given-names>MS</given-names></name><name><surname>Lorefice</surname><given-names>E</given-names></name><name><surname>Tardivo</surname><given-names>S</given-names></name><name><surname>Biagini</surname><given-names>T</given-names></name><name><surname>Stanley</surname><given-names>V</given-names></name><name><surname>Musaev</surname><given-names>D</given-names></name><name><surname>Fluss</surname><given-names>J</given-names></name><name><surname>Micalizzi</surname><given-names>A</given-names></name><name><surname>Nuovo</surname><given-names>S</given-names></name><name><surname>Illi</surname><given-names>B</given-names></name><name><surname>Chiapparini</surname><given-names>L</given-names></name><name><surname>Di Marcotullio</surname><given-names>L</given-names></name><name><surname>Issa</surname><given-names>MY</given-names></name><name><surname>Anello</surname><given-names>D</given-names></name><name><surname>Casella</surname><given-names>A</given-names></name><name><surname>Ginevrino</surname><given-names>M</given-names></name><name><surname>Leggins</surname><given-names>AS</given-names></name><name><surname>Roosing</surname><given-names>S</given-names></name><name><surname>Alfonsi</surname><given-names>R</given-names></name><name><surname>Rosati</surname><given-names>J</given-names></name><name><surname>Schot</surname><given-names>R</given-names></name><name><surname>Mancini</surname><given-names>GMS</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name><name><surname>Mazza</surname><given-names>T</given-names></name><name><surname>Gleeson</surname><given-names>JG</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hypomorphic recessive variants in SUFU impair the sonic hedgehog pathway and cause joubert syndrome with cranio-facial and skeletal defects</article-title><source>American Journal of Human Genetics</source><volume>101</volume><fpage>552</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.08.017</pub-id><pub-id pub-id-type="pmid">28965847</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowdle</surname><given-names>WE</given-names></name><name><surname>Robinson</surname><given-names>JF</given-names></name><name><surname>Kneist</surname><given-names>A</given-names></name><name><surname>Sirerol-Piquer</surname><given-names>MS</given-names></name><name><surname>Frints</surname><given-names>SGM</given-names></name><name><surname>Corbit</surname><given-names>KC</given-names></name><name><surname>Zaghloul</surname><given-names>NA</given-names></name><name><surname>Zaghloul</surname><given-names>NA</given-names></name><name><surname>van Lijnschoten</surname><given-names>G</given-names></name><name><surname>Mulders</surname><given-names>L</given-names></name><name><surname>Verver</surname><given-names>DE</given-names></name><name><surname>Zerres</surname><given-names>K</given-names></name><name><surname>Reed</surname><given-names>RR</given-names></name><name><surname>Attié-Bitach</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>García-Verdugo</surname><given-names>JM</given-names></name><name><surname>Katsanis</surname><given-names>N</given-names></name><name><surname>Bergmann</surname><given-names>C</given-names></name><name><surname>Reiter</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Disruption of a ciliary B9 protein complex causes meckel syndrome</article-title><source>American Journal of Human Genetics</source><volume>89</volume><fpage>94</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.06.003</pub-id><pub-id pub-id-type="pmid">21763481</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>N</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RPGR, a prenylated retinal ciliopathy protein, is targeted to cilia in a prenylation- and PDE6D-dependent manner</article-title><source>Biology Open</source><volume>5</volume><fpage>1283</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1242/bio.020461</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyson</surname><given-names>JM</given-names></name><name><surname>Conduit</surname><given-names>SE</given-names></name><name><surname>Feeney</surname><given-names>SJ</given-names></name><name><surname>Hakim</surname><given-names>S</given-names></name><name><surname>DiTommaso</surname><given-names>T</given-names></name><name><surname>Fulcher</surname><given-names>AJ</given-names></name><name><surname>Sriratana</surname><given-names>A</given-names></name><name><surname>Ramm</surname><given-names>G</given-names></name><name><surname>Horan</surname><given-names>KA</given-names></name><name><surname>Gurung</surname><given-names>R</given-names></name><name><surname>Wicking</surname><given-names>C</given-names></name><name><surname>Smyth</surname><given-names>I</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>INPP5E regulates phosphoinositide-dependent cilia transition zone function</article-title><source>The Journal of Cell Biology</source><volume>216</volume><fpage>247</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1083/jcb.201511055</pub-id><pub-id pub-id-type="pmid">27998989</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ElMaghloob</surname><given-names>Y</given-names></name><name><surname>Sot</surname><given-names>B</given-names></name><name><surname>McIlwraith</surname><given-names>MJ</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Yelland</surname><given-names>T</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ARL3 activation requires the co-GEF BART and effector-mediated turnover</article-title><source>eLife</source><volume>10</volume><elocation-id>e64624</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.64624</pub-id><pub-id pub-id-type="pmid">33438581</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fansa</surname><given-names>EK</given-names></name><name><surname>O’Reilly</surname><given-names>NJ</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name><name><surname>Wittinghofer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The N- and C-terminal ends of RPGR can bind to pde6δ</article-title><source>EMBO Reports</source><volume>16</volume><fpage>1583</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.15252/embr.201541404</pub-id><pub-id pub-id-type="pmid">26553937</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fansa</surname><given-names>EK</given-names></name><name><surname>Kosling</surname><given-names>SK</given-names></name><name><surname>Zent</surname><given-names>E</given-names></name><name><surname>Wittinghofer</surname><given-names>A</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PDE6delta-mediated sorting of INPP5E into the cilium is determined by cargo-carrier affinity</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11366</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11366</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finetti</surname><given-names>F</given-names></name><name><surname>Onnis</surname><given-names>A</given-names></name><name><surname>Baldari</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of vesicular traffic at the T cell immune synapse: lessons from the primary cilium</article-title><source>Traffic</source><volume>16</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1111/tra.12241</pub-id><pub-id pub-id-type="pmid">25393976</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finetti</surname><given-names>F</given-names></name><name><surname>Cassioli</surname><given-names>C</given-names></name><name><surname>Cianfanelli</surname><given-names>V</given-names></name><name><surname>Zevolini</surname><given-names>F</given-names></name><name><surname>Onnis</surname><given-names>A</given-names></name><name><surname>Gesualdo</surname><given-names>M</given-names></name><name><surname>Brunetti</surname><given-names>J</given-names></name><name><surname>Cecconi</surname><given-names>F</given-names></name><name><surname>Baldari</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The intraflagellar transport protein IFT20 recruits ATG16L1 to early endosomes to promote autophagosome formation in T cells</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>634003</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.634003</pub-id><pub-id pub-id-type="pmid">33829015</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frikstad</surname><given-names>K-AM</given-names></name><name><surname>Molinari</surname><given-names>E</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Ramsbottom</surname><given-names>SA</given-names></name><name><surname>Hughes</surname><given-names>F</given-names></name><name><surname>Letteboer</surname><given-names>SJF</given-names></name><name><surname>Gilani</surname><given-names>S</given-names></name><name><surname>Schink</surname><given-names>KO</given-names></name><name><surname>Stokke</surname><given-names>T</given-names></name><name><surname>Geimer</surname><given-names>S</given-names></name><name><surname>Pedersen</surname><given-names>LB</given-names></name><name><surname>Giles</surname><given-names>RH</given-names></name><name><surname>Akhmanova</surname><given-names>A</given-names></name><name><surname>Roepman</surname><given-names>R</given-names></name><name><surname>Sayer</surname><given-names>JA</given-names></name><name><surname>Patzke</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A CEP104-CSPP1 complex is required for formation of primary cilia competent in hedgehog signaling</article-title><source>Cell Reports</source><volume>28</volume><fpage>1907</fpage><lpage>1922</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.07.025</pub-id><pub-id pub-id-type="pmid">31412255</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujisawa</surname><given-names>S</given-names></name><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Nozaki</surname><given-names>S</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name><name><surname>Katoh</surname><given-names>Y</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ARL3 and ARL13B gtpases participate in distinct steps of INPP5E targeting to the ciliary membrane</article-title><source>Biology Open</source><volume>10</volume><elocation-id>bio058843</elocation-id><pub-id pub-id-type="doi">10.1242/bio.058843</pub-id><pub-id pub-id-type="pmid">34447983</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallego</surname><given-names>O</given-names></name><name><surname>Specht</surname><given-names>T</given-names></name><name><surname>Brach</surname><given-names>T</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Gavin</surname><given-names>A-C</given-names></name><name><surname>Kaksonen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Detection and characterization of protein interactions in vivo by a simple live-cell imaging method</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e62195</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0062195</pub-id><pub-id pub-id-type="pmid">23658712</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Gonzalo</surname><given-names>FR</given-names></name><name><surname>Corbit</surname><given-names>KC</given-names></name><name><surname>Sirerol-Piquer</surname><given-names>MS</given-names></name><name><surname>Ramaswami</surname><given-names>G</given-names></name><name><surname>Otto</surname><given-names>EA</given-names></name><name><surname>Noriega</surname><given-names>TR</given-names></name><name><surname>Seol</surname><given-names>AD</given-names></name><name><surname>Robinson</surname><given-names>JF</given-names></name><name><surname>Bennett</surname><given-names>CL</given-names></name><name><surname>Josifova</surname><given-names>DJ</given-names></name><name><surname>García-Verdugo</surname><given-names>JM</given-names></name><name><surname>Katsanis</surname><given-names>N</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name><name><surname>Reiter</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A transition zone complex regulates mammalian ciliogenesis and ciliary membrane composition</article-title><source>Nature Genetics</source><volume>43</volume><fpage>776</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/ng.891</pub-id><pub-id pub-id-type="pmid">21725307</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Gonzalo</surname><given-names>FR</given-names></name><name><surname>Reiter</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Scoring a backstage pass: mechanisms of ciliogenesis and ciliary access</article-title><source>The Journal of Cell Biology</source><volume>197</volume><fpage>697</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1083/jcb.201111146</pub-id><pub-id pub-id-type="pmid">22689651</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Gonzalo</surname><given-names>FR</given-names></name><name><surname>Phua</surname><given-names>SC</given-names></name><name><surname>Roberson</surname><given-names>EC</given-names></name><name><surname>Abedin</surname><given-names>M</given-names></name><name><surname>Schurmans</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Reiter</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phosphoinositides regulate ciliary protein trafficking to modulate hedgehog signaling</article-title><source>Developmental Cell</source><volume>34</volume><fpage>400</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.08.001</pub-id><pub-id pub-id-type="pmid">26305592</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Gonzalo</surname><given-names>FR</given-names></name><name><surname>Reiter</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Open sesame: how transition fibers and the transition zone control ciliary composition</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>9</volume><elocation-id>a028134</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a028134</pub-id><pub-id pub-id-type="pmid">27770015</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonçalves</surname><given-names>AB</given-names></name><name><surname>Hasselbalch</surname><given-names>SK</given-names></name><name><surname>Joensen</surname><given-names>BB</given-names></name><name><surname>Patzke</surname><given-names>S</given-names></name><name><surname>Martens</surname><given-names>P</given-names></name><name><surname>Ohlsen</surname><given-names>SK</given-names></name><name><surname>Quinodoz</surname><given-names>M</given-names></name><name><surname>Nikopoulos</surname><given-names>K</given-names></name><name><surname>Suleiman</surname><given-names>R</given-names></name><name><surname>Damsø Jeppesen</surname><given-names>MP</given-names></name><name><surname>Weiss</surname><given-names>C</given-names></name><name><surname>Christensen</surname><given-names>ST</given-names></name><name><surname>Rivolta</surname><given-names>C</given-names></name><name><surname>Andersen</surname><given-names>JS</given-names></name><name><surname>Farinelli</surname><given-names>P</given-names></name><name><surname>Pedersen</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CEP78 functions downstream of CEP350 to control biogenesis of primary cilia by negatively regulating CP110 levels</article-title><source>eLife</source><volume>10</volume><elocation-id>e63731</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.63731</pub-id><pub-id pub-id-type="pmid">34259627</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotthardt</surname><given-names>K</given-names></name><name><surname>Lokaj</surname><given-names>M</given-names></name><name><surname>Koerner</surname><given-names>C</given-names></name><name><surname>Falk</surname><given-names>N</given-names></name><name><surname>Gießl</surname><given-names>A</given-names></name><name><surname>Wittinghofer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A G-protein activation cascade from arl13b to arl3 and implications for ciliary targeting of lipidated proteins</article-title><source>eLife</source><volume>4</volume><elocation-id>e11859</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.11859</pub-id><pub-id pub-id-type="pmid">26551564</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graser</surname><given-names>S</given-names></name><name><surname>Stierhof</surname><given-names>Y-D</given-names></name><name><surname>Lavoie</surname><given-names>SB</given-names></name><name><surname>Gassner</surname><given-names>OS</given-names></name><name><surname>Lamla</surname><given-names>S</given-names></name><name><surname>Le Clech</surname><given-names>M</given-names></name><name><surname>Nigg</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cep164, a novel centriole appendage protein required for primary cilium formation</article-title><source>The Journal of Cell Biology</source><volume>179</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1083/jcb.200707181</pub-id><pub-id pub-id-type="pmid">17954613</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Otis</surname><given-names>JM</given-names></name><name><surname>Suciu</surname><given-names>SK</given-names></name><name><surname>Catalano</surname><given-names>C</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Constable</surname><given-names>S</given-names></name><name><surname>Wachten</surname><given-names>D</given-names></name><name><surname>Gupton</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Blackley</surname><given-names>KH</given-names></name><name><surname>Ptacek</surname><given-names>T</given-names></name><name><surname>Simon</surname><given-names>JM</given-names></name><name><surname>Schurmans</surname><given-names>S</given-names></name><name><surname>Stuber</surname><given-names>GD</given-names></name><name><surname>Caspary</surname><given-names>T</given-names></name><name><surname>Anton</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Primary cilia signaling promotes axonal tract development and is disrupted in joubert syndrome-related disorders models</article-title><source>Developmental Cell</source><volume>51</volume><fpage>759</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.11.005</pub-id><pub-id pub-id-type="pmid">31846650</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakim</surname><given-names>S</given-names></name><name><surname>Dyson</surname><given-names>JM</given-names></name><name><surname>Feeney</surname><given-names>SJ</given-names></name><name><surname>Davies</surname><given-names>EM</given-names></name><name><surname>Sriratana</surname><given-names>A</given-names></name><name><surname>Koenig</surname><given-names>MN</given-names></name><name><surname>Plotnikova</surname><given-names>OV</given-names></name><name><surname>Smyth</surname><given-names>IM</given-names></name><name><surname>Ricardo</surname><given-names>SD</given-names></name><name><surname>Hobbs</surname><given-names>RM</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inpp5e suppresses polycystic kidney disease via inhibition of PI3K/akt-dependent mtorc1 signaling</article-title><source>Human Molecular Genetics</source><volume>25</volume><fpage>2295</fpage><lpage>2313</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw097</pub-id><pub-id pub-id-type="pmid">27056978</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Miyoshi</surname><given-names>K</given-names></name><name><surname>Shikada</surname><given-names>S</given-names></name><name><surname>Amano</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yoshimura</surname><given-names>T</given-names></name><name><surname>Katayama</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TULP3 is required for localization of membrane-associated proteins ARL13B and INPP5E to primary cilia</article-title><source>Biochemical and Biophysical Research Communications</source><volume>509</volume><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.12.109</pub-id><pub-id pub-id-type="pmid">30583862</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>J</given-names></name><name><surname>Iwamoto</surname><given-names>R</given-names></name><name><surname>Otomo</surname><given-names>T</given-names></name><name><surname>Nezu</surname><given-names>A</given-names></name><name><surname>Hamasaki</surname><given-names>M</given-names></name><name><surname>Yoshimori</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Autophagosome-lysosome fusion in neurons requires INPP5E, a protein associated with joubert syndrome</article-title><source>The EMBO Journal</source><volume>35</volume><fpage>1853</fpage><lpage>1867</lpage><pub-id pub-id-type="doi">10.15252/embj.201593148</pub-id><pub-id pub-id-type="pmid">27340123</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasenpusch-Theil</surname><given-names>K</given-names></name><name><surname>Laclef</surname><given-names>C</given-names></name><name><surname>Colligan</surname><given-names>M</given-names></name><name><surname>Fitzgerald</surname><given-names>E</given-names></name><name><surname>Howe</surname><given-names>K</given-names></name><name><surname>Carroll</surname><given-names>E</given-names></name><name><surname>Abrams</surname><given-names>SR</given-names></name><name><surname>Reiter</surname><given-names>JF</given-names></name><name><surname>Schneider-Maunoury</surname><given-names>S</given-names></name><name><surname>Theil</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A transient role of the ciliary gene <italic>inpp5e</italic> in controlling direct versus indirect neurogenesis in cortical development</article-title><source>eLife</source><volume>9</volume><elocation-id>e58162</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.58162</pub-id><pub-id pub-id-type="pmid">32840212</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herranz</surname><given-names>G</given-names></name><name><surname>Aguilera</surname><given-names>P</given-names></name><name><surname>Dávila</surname><given-names>S</given-names></name><name><surname>Sánchez</surname><given-names>A</given-names></name><name><surname>Stancu</surname><given-names>B</given-names></name><name><surname>Gómez</surname><given-names>J</given-names></name><name><surname>Fernández-Moreno</surname><given-names>D</given-names></name><name><surname>de Martín</surname><given-names>R</given-names></name><name><surname>Quintanilla</surname><given-names>M</given-names></name><name><surname>Fernández</surname><given-names>T</given-names></name><name><surname>Rodríguez-Silvestre</surname><given-names>P</given-names></name><name><surname>Márquez-Expósito</surname><given-names>L</given-names></name><name><surname>Bello-Gamboa</surname><given-names>A</given-names></name><name><surname>Fraile-Ramos</surname><given-names>A</given-names></name><name><surname>Calvo</surname><given-names>V</given-names></name><name><surname>Izquierdo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Protein kinase C δ regulates the depletion of actin at the immunological synapse required for polarized exosome secretion by T cells</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>851</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00851</pub-id><pub-id pub-id-type="pmid">31105694</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilgendorf</surname><given-names>KI</given-names></name><name><surname>Johnson</surname><given-names>CT</given-names></name><name><surname>Mezger</surname><given-names>A</given-names></name><name><surname>Rice</surname><given-names>SL</given-names></name><name><surname>Norris</surname><given-names>AM</given-names></name><name><surname>Demeter</surname><given-names>J</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name><name><surname>Reiter</surname><given-names>JF</given-names></name><name><surname>Kopinke</surname><given-names>D</given-names></name><name><surname>Jackson</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Omega-3 fatty acids activate ciliary FFAR4 to control adipogenesis</article-title><source>Cell</source><volume>179</volume><fpage>1289</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.11.005</pub-id><pub-id pub-id-type="pmid">31761534</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humbert</surname><given-names>MC</given-names></name><name><surname>Weihbrecht</surname><given-names>K</given-names></name><name><surname>Searby</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Pope</surname><given-names>RM</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ARL13B, PDE6D, and CEP164 form a functional network for INPP5E ciliary targeting</article-title><source>PNAS</source><volume>109</volume><fpage>19691</fpage><lpage>19696</lpage><pub-id pub-id-type="doi">10.1073/pnas.1210916109</pub-id><pub-id pub-id-type="pmid">23150559</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>S-H</given-names></name><name><surname>Somatilaka</surname><given-names>BN</given-names></name><name><surname>Badgandi</surname><given-names>H</given-names></name><name><surname>Palicharla</surname><given-names>VR</given-names></name><name><surname>Walker</surname><given-names>R</given-names></name><name><surname>Shelton</surname><given-names>JM</given-names></name><name><surname>Qian</surname><given-names>F</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tulp3 regulates renal cystogenesis by trafficking of cystoproteins to cilia</article-title><source>Current Biology</source><volume>29</volume><fpage>790</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2019.01.047</pub-id><pub-id pub-id-type="pmid">30799239</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanova</surname><given-names>AA</given-names></name><name><surname>Caspary</surname><given-names>T</given-names></name><name><surname>Seyfried</surname><given-names>NT</given-names></name><name><surname>Duong</surname><given-names>DM</given-names></name><name><surname>West</surname><given-names>AB</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Kahn</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Biochemical characterization of purified mammalian ARL13B protein indicates that it is an atypical gtpase and ARL3 guanine nucleotide exchange factor (GEF)</article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>11091</fpage><lpage>11108</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.784025</pub-id><pub-id pub-id-type="pmid">28487361</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacoby</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>JJ</given-names></name><name><surname>Gayral</surname><given-names>S</given-names></name><name><surname>Hampshire</surname><given-names>DJ</given-names></name><name><surname>Ayub</surname><given-names>M</given-names></name><name><surname>Blockmans</surname><given-names>M</given-names></name><name><surname>Pernot</surname><given-names>E</given-names></name><name><surname>Kisseleva</surname><given-names>MV</given-names></name><name><surname>Compère</surname><given-names>P</given-names></name><name><surname>Schiffmann</surname><given-names>SN</given-names></name><name><surname>Gergely</surname><given-names>F</given-names></name><name><surname>Riley</surname><given-names>JH</given-names></name><name><surname>Pérez-Morga</surname><given-names>D</given-names></name><name><surname>Woods</surname><given-names>CG</given-names></name><name><surname>Schurmans</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>INPP5E mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and mouse</article-title><source>Nature Genetics</source><volume>41</volume><fpage>1027</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1038/ng.427</pub-id><pub-id pub-id-type="pmid">19668215</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Romera-Paredes</surname><given-names>B</given-names></name><name><surname>Nikolov</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Pacholska</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>T</given-names></name><name><surname>Bodenstein</surname><given-names>S</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Vinyals</surname><given-names>O</given-names></name><name><surname>Senior</surname><given-names>AW</given-names></name><name><surname>Kavukcuoglu</surname><given-names>K</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Highly accurate protein structure prediction with alphafold</article-title><source>Nature</source><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerek</surname><given-names>EM</given-names></name><name><surname>Yoon</surname><given-names>KH</given-names></name><name><surname>Luo</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Valencia</surname><given-names>R</given-names></name><name><surname>Julien</surname><given-names>O</given-names></name><name><surname>Waskiewicz</surname><given-names>AJ</given-names></name><name><surname>Hubbard</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A conserved acetylation switch enables pharmacological control of tubby-like protein stability</article-title><source>The Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100073</elocation-id><pub-id pub-id-type="doi">10.1074/jbc.RA120.015839</pub-id><pub-id pub-id-type="pmid">33187986</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>More than meets the eye: current understanding of RPGR function</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1074</volume><fpage>521</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-75402-4_64</pub-id><pub-id pub-id-type="pmid">29721984</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ki</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Won</surname><given-names>SY</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>IY</given-names></name><name><surname>Bae</surname><given-names>Y-K</given-names></name><name><surname>Chung</surname><given-names>KW</given-names></name><name><surname>Choi</surname><given-names>B-O</given-names></name><name><surname>Park</surname><given-names>B</given-names></name><name><surname>Choi</surname><given-names>E-J</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CEP41-mediated ciliary tubulin glutamylation drives angiogenesis through AURKA-dependent deciliation</article-title><source>EMBO Reports</source><volume>21</volume><elocation-id>e48290</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201948290</pub-id><pub-id pub-id-type="pmid">31885126</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisseleva</surname><given-names>MV</given-names></name><name><surname>Wilson</surname><given-names>MP</given-names></name><name><surname>Majerus</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The isolation and characterization of a cdna encoding phospholipid-specific inositol polyphosphate 5-phosphatase</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>20110</fpage><lpage>20116</lpage><pub-id pub-id-type="doi">10.1074/jbc.M910119199</pub-id><pub-id pub-id-type="pmid">10764818</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>AM</given-names></name><name><surname>Speed</surname><given-names>CJ</given-names></name><name><surname>O’Malley</surname><given-names>CJ</given-names></name><name><surname>Layton</surname><given-names>MJ</given-names></name><name><surname>Meehan</surname><given-names>T</given-names></name><name><surname>Loveland</surname><given-names>KL</given-names></name><name><surname>Cheema</surname><given-names>S</given-names></name><name><surname>Ooms</surname><given-names>LM</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cloning and characterization of a 72-kda inositol-polyphosphate 5-phosphatase localized to the golgi network</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>24052</fpage><lpage>24064</lpage><pub-id pub-id-type="doi">10.1074/jbc.M000874200</pub-id><pub-id pub-id-type="pmid">10806194</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>AM</given-names></name><name><surname>Horan</surname><given-names>KA</given-names></name><name><surname>Sriratana</surname><given-names>A</given-names></name><name><surname>Bailey</surname><given-names>CG</given-names></name><name><surname>Collyer</surname><given-names>LJ</given-names></name><name><surname>Nandurkar</surname><given-names>HH</given-names></name><name><surname>Shisheva</surname><given-names>A</given-names></name><name><surname>Layton</surname><given-names>MJ</given-names></name><name><surname>Rasko</surname><given-names>JEJ</given-names></name><name><surname>Rowe</surname><given-names>T</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Phosphatidylinositol 3-phosphate [ptdins3p] is generated at the plasma membrane by an inositol polyphosphate 5-phosphatase: endogenous ptdins3p can promote glut4 translocation to the plasma membrane</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>6065</fpage><lpage>6081</lpage><pub-id pub-id-type="doi">10.1128/MCB.00203-06</pub-id><pub-id pub-id-type="pmid">16880518</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kösling</surname><given-names>SK</given-names></name><name><surname>Fansa</surname><given-names>EK</given-names></name><name><surname>Maffini</surname><given-names>S</given-names></name><name><surname>Wittinghofer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanism and dynamics of INPP5E transport into and inside the ciliary compartment</article-title><source>Biological Chemistry</source><volume>399</volume><fpage>277</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1515/hsz-2017-0226</pub-id><pub-id pub-id-type="pmid">29140789</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latour</surname><given-names>BL</given-names></name><name><surname>Van De Weghe</surname><given-names>JC</given-names></name><name><surname>Rusterholz</surname><given-names>TD</given-names></name><name><surname>Letteboer</surname><given-names>SJ</given-names></name><name><surname>Gomez</surname><given-names>A</given-names></name><name><surname>Shaheen</surname><given-names>R</given-names></name><name><surname>Gesemann</surname><given-names>M</given-names></name><name><surname>Karamzade</surname><given-names>A</given-names></name><name><surname>Asadollahi</surname><given-names>M</given-names></name><name><surname>Barroso-Gil</surname><given-names>M</given-names></name><name><surname>Chitre</surname><given-names>M</given-names></name><name><surname>Grout</surname><given-names>ME</given-names></name><name><surname>van Reeuwijk</surname><given-names>J</given-names></name><name><surname>van Beersum</surname><given-names>SE</given-names></name><name><surname>Miller</surname><given-names>CV</given-names></name><name><surname>Dempsey</surname><given-names>JC</given-names></name><name><surname>Morsy</surname><given-names>H</given-names></name><collab>University of Washington Center for Mendelian Genomics</collab><name><surname>Bamshad</surname><given-names>MJ</given-names></name><collab>Genomics England Research Consortium</collab><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Neuhauss</surname><given-names>SC</given-names></name><name><surname>Boldt</surname><given-names>K</given-names></name><name><surname>Ueffing</surname><given-names>M</given-names></name><name><surname>Keramatipour</surname><given-names>M</given-names></name><name><surname>Sayer</surname><given-names>JA</given-names></name><name><surname>Alkuraya</surname><given-names>FS</given-names></name><name><surname>Bachmann-Gagescu</surname><given-names>R</given-names></name><name><surname>Roepman</surname><given-names>R</given-names></name><name><surname>Doherty</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dysfunction of the ciliary ARMC9/TOGARAM1 protein module causes joubert syndrome</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>4423</fpage><lpage>4439</lpage><pub-id pub-id-type="doi">10.1172/JCI131656</pub-id><pub-id pub-id-type="pmid">32453716</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Silhavy</surname><given-names>JL</given-names></name><name><surname>Zaki</surname><given-names>MS</given-names></name><name><surname>Schroth</surname><given-names>J</given-names></name><name><surname>Bielas</surname><given-names>SL</given-names></name><name><surname>Marsh</surname><given-names>SE</given-names></name><name><surname>Olvera</surname><given-names>J</given-names></name><name><surname>Brancati</surname><given-names>F</given-names></name><name><surname>Iannicelli</surname><given-names>M</given-names></name><name><surname>Ikegami</surname><given-names>K</given-names></name><name><surname>Schlossman</surname><given-names>AM</given-names></name><name><surname>Merriman</surname><given-names>B</given-names></name><name><surname>Attié-Bitach</surname><given-names>T</given-names></name><name><surname>Logan</surname><given-names>CV</given-names></name><name><surname>Glass</surname><given-names>IA</given-names></name><name><surname>Cluckey</surname><given-names>A</given-names></name><name><surname>Louie</surname><given-names>CM</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Raynes</surname><given-names>HR</given-names></name><name><surname>Rapin</surname><given-names>I</given-names></name><name><surname>Castroviejo</surname><given-names>IP</given-names></name><name><surname>Setou</surname><given-names>M</given-names></name><name><surname>Barbot</surname><given-names>C</given-names></name><name><surname>Boltshauser</surname><given-names>E</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>Doherty</surname><given-names>DA</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name><name><surname>Gleeson</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>CEP41 is mutated in joubert syndrome and is required for tubulin glutamylation at the cilium</article-title><source>Nature Genetics</source><volume>44</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1038/ng.1078</pub-id><pub-id pub-id-type="pmid">22246503</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PDE6D binds to the C-terminus of RPGR in a prenylation-dependent manner</article-title><source>EMBO Reports</source><volume>16</volume><fpage>1581</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.15252/embr.201541220</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legué</surname><given-names>E</given-names></name><name><surname>Liem</surname><given-names>KF</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tulp3 is a ciliary trafficking gene that regulates polycystic kidney disease</article-title><source>Current Biology</source><volume>29</volume><fpage>803</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2019.01.054</pub-id><pub-id pub-id-type="pmid">30799240</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y-C</given-names></name><name><surname>Niewiadomski</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Phua</surname><given-names>SC</given-names></name><name><surname>Jiao</surname><given-names>J</given-names></name><name><surname>Levchenko</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Rohatgi</surname><given-names>R</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Chemically inducible diffusion trap at cilia reveals molecular sieve-like barrier</article-title><source>Nature Chemical Biology</source><volume>9</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1252</pub-id><pub-id pub-id-type="pmid">23666116</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loukil</surname><given-names>A</given-names></name><name><surname>Barrington</surname><given-names>C</given-names></name><name><surname>Goetz</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A complex of distal appendage-associated kinases linked to human disease regulates ciliary trafficking and stability</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2018740118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2018740118</pub-id><pub-id pub-id-type="pmid">33846249</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macias</surname><given-names>MJ</given-names></name><name><surname>Wiesner</surname><given-names>S</given-names></name><name><surname>Sudol</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>WW and SH3 domains, two different scaffolds to recognize proline-rich ligands</article-title><source>FEBS Letters</source><volume>513</volume><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/s0014-5793(01)03290-2</pub-id><pub-id pub-id-type="pmid">11911877</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Hurtado</surname><given-names>A</given-names></name><name><surname>Martin-Morales</surname><given-names>R</given-names></name><name><surname>Robledinos-Antón</surname><given-names>N</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Palacios-Blanco</surname><given-names>I</given-names></name><name><surname>Lastres-Becker</surname><given-names>I</given-names></name><name><surname>Cuadrado</surname><given-names>A</given-names></name><name><surname>Garcia-Gonzalo</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NRF2-dependent gene expression promotes ciliogenesis and hedgehog signaling</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>13896</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-50356-0</pub-id><pub-id pub-id-type="pmid">31554934</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>JC</given-names></name><name><surname>Hege</surname><given-names>MM</given-names></name><name><surname>Berbari</surname><given-names>NF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Trafficking of ciliary G protein-coupled receptors</article-title><source>Methods in Cell Biology</source><volume>132</volume><fpage>35</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/bs.mcb.2015.11.009</pub-id><pub-id pub-id-type="pmid">26928538</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montoya</surname><given-names>MC</given-names></name><name><surname>Sancho</surname><given-names>D</given-names></name><name><surname>Bonello</surname><given-names>G</given-names></name><name><surname>Collette</surname><given-names>Y</given-names></name><name><surname>Langlet</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>HT</given-names></name><name><surname>Aparicio</surname><given-names>P</given-names></name><name><surname>Alcover</surname><given-names>A</given-names></name><name><surname>Olive</surname><given-names>D</given-names></name><name><surname>Sánchez-Madrid</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Role of ICAM-3 in the initial interaction of T lymphocytes and apcs</article-title><source>Nature Immunology</source><volume>3</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1038/ni753</pub-id><pub-id pub-id-type="pmid">11812993</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Chih</surname><given-names>B</given-names></name><name><surname>Nelson</surname><given-names>CD</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Scales</surname><given-names>SJ</given-names></name><name><surname>Jackson</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TULP3 bridges the IFT-A complex and membrane phosphoinositides to promote trafficking of G protein-coupled receptors into primary cilia</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>2180</fpage><lpage>2193</lpage><pub-id pub-id-type="doi">10.1101/gad.1966210</pub-id><pub-id pub-id-type="pmid">20889716</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Ratti</surname><given-names>N</given-names></name><name><surname>Loktev</surname><given-names>A</given-names></name><name><surname>Rangell</surname><given-names>L</given-names></name><name><surname>Scales</surname><given-names>SJ</given-names></name><name><surname>Jackson</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The ciliary G-protein-coupled receptor gpr161 negatively regulates the sonic hedgehog pathway via camp signaling</article-title><source>Cell</source><volume>152</volume><fpage>210</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.12.026</pub-id><pub-id pub-id-type="pmid">23332756</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name><surname>Badgandi</surname><given-names>HB</given-names></name><name><surname>Hwang</surname><given-names>S-H</given-names></name><name><surname>Somatilaka</surname><given-names>B</given-names></name><name><surname>Shimada</surname><given-names>IS</given-names></name><name><surname>Pal</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Trafficking to the primary cilium membrane</article-title><source>Molecular Biology of the Cell</source><volume>28</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1091/mbc.E16-07-0505</pub-id><pub-id pub-id-type="pmid">28082521</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachury</surname><given-names>MV</given-names></name><name><surname>Mick</surname><given-names>DU</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Establishing and regulating the composition of cilia for signal transduction</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>20</volume><fpage>389</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/s41580-019-0116-4</pub-id><pub-id pub-id-type="pmid">30948801</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Sendayen</surname><given-names>BE</given-names></name><name><surname>Prosseda</surname><given-names>PP</given-names></name><name><surname>Chang</surname><given-names>K-C</given-names></name><name><surname>Ghaffarieh</surname><given-names>A</given-names></name><name><surname>Alvarado</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Haider</surname><given-names>KM</given-names></name><name><surname>Berbari</surname><given-names>NF</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Defective INPP5E distribution in NPHP1-related senior-loken syndrome</article-title><source>Molecular Genetics &amp; Genomic Medicine</source><volume>9</volume><elocation-id>e1566</elocation-id><pub-id pub-id-type="doi">10.1002/mgg3.1566</pub-id><pub-id pub-id-type="pmid">33306870</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Palicharla</surname><given-names>VR</given-names></name><name><surname>Hwang</surname><given-names>SH</given-names></name><name><surname>Somatilaka</surname><given-names>BN</given-names></name><name><surname>Badgandi</surname><given-names>HB</given-names></name><name><surname>Legué</surname><given-names>E</given-names></name><name><surname>Tran</surname><given-names>VM</given-names></name><name><surname>Woodruff</surname><given-names>JB</given-names></name><name><surname>Liem</surname><given-names>KF</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Interactions between TULP3 Tubby Domain Cargo Site and ARL13B Amphipathic Helix Promote Lipidated Protein Transport to Cilia</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.05.25.445488</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pampliega</surname><given-names>O</given-names></name><name><surname>Orhon</surname><given-names>I</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Sridhar</surname><given-names>S</given-names></name><name><surname>Díaz-Carretero</surname><given-names>A</given-names></name><name><surname>Beau</surname><given-names>I</given-names></name><name><surname>Codogno</surname><given-names>P</given-names></name><name><surname>Satir</surname><given-names>BH</given-names></name><name><surname>Satir</surname><given-names>P</given-names></name><name><surname>Cuervo</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Functional interaction between autophagy and ciliogenesis</article-title><source>Nature</source><volume>502</volume><fpage>194</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/nature12639</pub-id><pub-id pub-id-type="pmid">24089209</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phua</surname><given-names>SC</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>E</given-names></name><name><surname>Roberson</surname><given-names>EC</given-names></name><name><surname>Pusapati</surname><given-names>GV</given-names></name><name><surname>Schurmans</surname><given-names>S</given-names></name><name><surname>Setou</surname><given-names>M</given-names></name><name><surname>Rohatgi</surname><given-names>R</given-names></name><name><surname>Reiter</surname><given-names>JF</given-names></name><name><surname>Ikegami</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dynamic remodeling of membrane composition drives cell cycle through primary cilia excision</article-title><source>Cell</source><volume>168</volume><fpage>264</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.032</pub-id><pub-id pub-id-type="pmid">28086093</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>L</given-names></name><name><surname>Samarakoon</surname><given-names>YH</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name><name><surname>Sayer</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ARL3, a small gtpase with a functionally conserved role in primary cilia and immune synapses</article-title><source>Small GTPases</source><volume>12</volume><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1080/21541248.2019.1703466</pub-id><pub-id pub-id-type="pmid">31826708</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Fujisawa</surname><given-names>S</given-names></name><name><surname>Nozaki</surname><given-names>S</given-names></name><name><surname>Katoh</surname><given-names>Y</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Interaction of INPP5E with ARL13B is essential for its ciliary membrane retention but dispensable for its ciliary entry</article-title><source>Biology Open</source><volume>10</volume><elocation-id>bio057653</elocation-id><pub-id pub-id-type="doi">10.1242/bio.057653</pub-id><pub-id pub-id-type="pmid">33372066</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>KN</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Anand</surname><given-names>M</given-names></name><name><surname>Khanna</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prenylated retinal ciliopathy protein RPGR interacts with pde6δ and regulates ciliary localization of joubert syndrome-associated protein INPP5E</article-title><source>Human Molecular Genetics</source><volume>25</volume><fpage>4533</fpage><lpage>4545</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw281</pub-id><pub-id pub-id-type="pmid">28172980</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiter</surname><given-names>JF</given-names></name><name><surname>Leroux</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genes and molecular pathways underpinning ciliopathies</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>18</volume><fpage>533</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.60</pub-id><pub-id pub-id-type="pmid">28698599</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberson</surname><given-names>EC</given-names></name><name><surname>Dowdle</surname><given-names>WE</given-names></name><name><surname>Ozanturk</surname><given-names>A</given-names></name><name><surname>Garcia-Gonzalo</surname><given-names>FR</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Halbritter</surname><given-names>J</given-names></name><name><surname>Elkhartoufi</surname><given-names>N</given-names></name><name><surname>Porath</surname><given-names>JD</given-names></name><name><surname>Cope</surname><given-names>H</given-names></name><name><surname>Ashley-Koch</surname><given-names>A</given-names></name><name><surname>Gregory</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Sayer</surname><given-names>JA</given-names></name><name><surname>Saunier</surname><given-names>S</given-names></name><name><surname>Otto</surname><given-names>EA</given-names></name><name><surname>Katsanis</surname><given-names>N</given-names></name><name><surname>Davis</surname><given-names>EE</given-names></name><name><surname>Attié-Bitach</surname><given-names>T</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name><name><surname>Leroux</surname><given-names>MR</given-names></name><name><surname>Reiter</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TMEM231, mutated in orofaciodigital and meckel syndromes, organizes the ciliary transition zone</article-title><source>The Journal of Cell Biology</source><volume>209</volume><fpage>129</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1083/jcb.201411087</pub-id><pub-id pub-id-type="pmid">25869670</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>K</given-names></name><name><surname>Jerman</surname><given-names>S</given-names></name><name><surname>Jozsef</surname><given-names>L</given-names></name><name><surname>McNamara</surname><given-names>T</given-names></name><name><surname>Onyekaba</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Marin</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Palmitoylation of the ciliary gtpase arl13b is necessary for its stability and its role in cilia formation</article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>17703</fpage><lpage>17717</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.792937</pub-id><pub-id pub-id-type="pmid">28848045</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>AD</given-names></name><name><surname>Gross</surname><given-names>EG</given-names></name><name><surname>Pillai</surname><given-names>GS</given-names></name><name><surname>Seetharaman</surname><given-names>S</given-names></name><name><surname>Etienne-Manneville</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A phospho-regulated signal motif determines subcellular localization of α-TAT1 for dynamic microtubule acetylation</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.09.23.310235</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>KN</given-names></name><name><surname>Kuhns</surname><given-names>S</given-names></name><name><surname>Neuner</surname><given-names>A</given-names></name><name><surname>Hub</surname><given-names>B</given-names></name><name><surname>Zentgraf</surname><given-names>H</given-names></name><name><surname>Pereira</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cep164 mediates vesicular docking to the mother centriole during early steps of ciliogenesis</article-title><source>The Journal of Cell Biology</source><volume>199</volume><fpage>1083</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1083/jcb.201202126</pub-id><pub-id pub-id-type="pmid">23253480</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname><given-names>AS</given-names></name><name><surname>Gerstner</surname><given-names>CD</given-names></name><name><surname>Cady</surname><given-names>MA</given-names></name><name><surname>Arshavsky</surname><given-names>VY</given-names></name><name><surname>Mitchell</surname><given-names>C</given-names></name><name><surname>Ying</surname><given-names>G</given-names></name><name><surname>Frederick</surname><given-names>JM</given-names></name><name><surname>Baehr</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Deletion of the phosphatase INPP5E in the murine retina impairs photoreceptor axoneme formation and prevents disc morphogenesis</article-title><source>The Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100529</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100529</pub-id><pub-id pub-id-type="pmid">33711342</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slaats</surname><given-names>GG</given-names></name><name><surname>Isabella</surname><given-names>CR</given-names></name><name><surname>Kroes</surname><given-names>HY</given-names></name><name><surname>Dempsey</surname><given-names>JC</given-names></name><name><surname>Gremmels</surname><given-names>H</given-names></name><name><surname>Monroe</surname><given-names>GR</given-names></name><name><surname>Phelps</surname><given-names>IG</given-names></name><name><surname>Duran</surname><given-names>KJ</given-names></name><name><surname>Adkins</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>SA</given-names></name><name><surname>Knutzen</surname><given-names>DM</given-names></name><name><surname>Knoers</surname><given-names>NV</given-names></name><name><surname>Mendelsohn</surname><given-names>NJ</given-names></name><name><surname>Neubauer</surname><given-names>D</given-names></name><name><surname>Mastroyianni</surname><given-names>SD</given-names></name><name><surname>Vogt</surname><given-names>J</given-names></name><name><surname>Worgan</surname><given-names>L</given-names></name><name><surname>Karp</surname><given-names>N</given-names></name><name><surname>Bowdin</surname><given-names>S</given-names></name><name><surname>Glass</surname><given-names>IA</given-names></name><name><surname>Parisi</surname><given-names>MA</given-names></name><name><surname>Otto</surname><given-names>EA</given-names></name><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name><name><surname>van Haaften</surname><given-names>G</given-names></name><name><surname>Giles</surname><given-names>RH</given-names></name><name><surname>Doherty</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MKS1 regulates ciliary INPP5E levels in joubert syndrome</article-title><source>Journal of Medical Genetics</source><volume>53</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103250</pub-id><pub-id pub-id-type="pmid">26490104</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephen</surname><given-names>LA</given-names></name><name><surname>ElMaghloob</surname><given-names>Y</given-names></name><name><surname>McIlwraith</surname><given-names>MJ</given-names></name><name><surname>Yelland</surname><given-names>T</given-names></name><name><surname>Castro Sanchez</surname><given-names>P</given-names></name><name><surname>Roda-Navarro</surname><given-names>P</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The ciliary machinery is repurposed for T cell immune synapse trafficking of LCK</article-title><source>Developmental Cell</source><volume>47</volume><fpage>122</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2018.08.012</pub-id><pub-id pub-id-type="pmid">30220567</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stinchcombe</surname><given-names>JC</given-names></name><name><surname>Griffiths</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Communication, the centrosome and the immunological synapse</article-title><source>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</source><volume>369</volume><elocation-id>20130463</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2013.0463</pub-id><pub-id pub-id-type="pmid">25047617</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>KJ</given-names></name><name><surname>Le Corre</surname><given-names>S</given-names></name><name><surname>Micalizzi</surname><given-names>A</given-names></name><name><surname>Romani</surname><given-names>M</given-names></name><name><surname>Abhyankar</surname><given-names>A</given-names></name><name><surname>Saada</surname><given-names>J</given-names></name><name><surname>Perrault</surname><given-names>I</given-names></name><name><surname>Amiel</surname><given-names>J</given-names></name><name><surname>Litzler</surname><given-names>J</given-names></name><name><surname>Filhol</surname><given-names>E</given-names></name><name><surname>Elkhartoufi</surname><given-names>N</given-names></name><name><surname>Kwong</surname><given-names>M</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name><name><surname>Boddaert</surname><given-names>N</given-names></name><name><surname>Baehr</surname><given-names>W</given-names></name><name><surname>Lyonnet</surname><given-names>S</given-names></name><name><surname>Munnich</surname><given-names>A</given-names></name><name><surname>Burglen</surname><given-names>L</given-names></name><name><surname>Chassaing</surname><given-names>N</given-names></name><name><surname>Encha-Ravazi</surname><given-names>F</given-names></name><name><surname>Vekemans</surname><given-names>M</given-names></name><name><surname>Gleeson</surname><given-names>JG</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name><name><surname>Jackson</surname><given-names>PK</given-names></name><name><surname>Drummond</surname><given-names>IA</given-names></name><name><surname>Saunier</surname><given-names>S</given-names></name><name><surname>Attié-Bitach</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A homozygous PDE6D mutation in joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium</article-title><source>Human Mutation</source><volume>35</volume><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1002/humu.22470</pub-id><pub-id pub-id-type="pmid">24166846</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Travaglini</surname><given-names>L</given-names></name><name><surname>Brancati</surname><given-names>F</given-names></name><name><surname>Silhavy</surname><given-names>J</given-names></name><name><surname>Iannicelli</surname><given-names>M</given-names></name><name><surname>Nickerson</surname><given-names>E</given-names></name><name><surname>Elkhartoufi</surname><given-names>N</given-names></name><name><surname>Scott</surname><given-names>E</given-names></name><name><surname>Spencer</surname><given-names>E</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Ben-Zeev</surname><given-names>B</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Boltshauser</surname><given-names>E</given-names></name><name><surname>Chaouch</surname><given-names>M</given-names></name><name><surname>Cilio</surname><given-names>MR</given-names></name><name><surname>de Jong</surname><given-names>MM</given-names></name><name><surname>Kayserili</surname><given-names>H</given-names></name><name><surname>Ogur</surname><given-names>G</given-names></name><name><surname>Poretti</surname><given-names>A</given-names></name><name><surname>Signorini</surname><given-names>S</given-names></name><name><surname>Uziel</surname><given-names>G</given-names></name><name><surname>Zaki</surname><given-names>MS</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Attié-Bitach</surname><given-names>T</given-names></name><name><surname>Gleeson</surname><given-names>JG</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name><collab>International JSRD Study Group</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Phenotypic spectrum and prevalence of INPP5E mutations in joubert syndrome and related disorders</article-title><source>European Journal of Human Genetics</source><volume>21</volume><fpage>1074</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2012.305</pub-id><pub-id pub-id-type="pmid">23386033</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tresaugues</surname><given-names>L</given-names></name><name><surname>Schutz</surname><given-names>P</given-names></name><name><surname>Arrowsmith</surname><given-names>CH</given-names></name><name><surname>Berglund</surname><given-names>H</given-names></name><name><surname>Bountra</surname><given-names>C</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>AM</given-names></name><name><surname>Flodin</surname><given-names>S</given-names></name><name><surname>Flores</surname><given-names>A</given-names></name><name><surname>Graslund</surname><given-names>S</given-names></name><name><surname>Hammarstrom</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>I</given-names></name><name><surname>Karlberg</surname><given-names>T</given-names></name><name><surname>Kol</surname><given-names>S</given-names></name><name><surname>Kotenyova</surname><given-names>T</given-names></name><name><surname>Kouznetsova</surname><given-names>E</given-names></name><name><surname>Moche</surname><given-names>M</given-names></name><name><surname>Nyman</surname><given-names>T</given-names></name><name><surname>Persson</surname><given-names>C</given-names></name><name><surname>Schuler</surname><given-names>H</given-names></name><name><surname>Siponen</surname><given-names>MI</given-names></name><name><surname>Thorsell</surname><given-names>AG</given-names></name><name><surname>Berg</surname><given-names>VD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Crystal structure of human INPP5E</article-title><source>Protein Data Bank</source><volume>10</volume><elocation-id>2xsw</elocation-id><pub-id pub-id-type="doi">10.2210/pdb2XSW/pdb</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ukhanov</surname><given-names>K</given-names></name><name><surname>Uytingco</surname><given-names>C</given-names></name><name><surname>Green</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Schurmans</surname><given-names>S</given-names></name><name><surname>Martens</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>INPP5E controls ciliary localization of phospholipids and the odor response in olfactory sensory neurons</article-title><source>Journal of Cell Science</source><volume>135</volume><elocation-id>jcs258364</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.258364</pub-id><pub-id pub-id-type="pmid">33771931</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van De Weghe</surname><given-names>JC</given-names></name><name><surname>Rusterholz</surname><given-names>TDS</given-names></name><name><surname>Latour</surname><given-names>B</given-names></name><name><surname>Grout</surname><given-names>ME</given-names></name><name><surname>Aldinger</surname><given-names>KA</given-names></name><name><surname>Shaheen</surname><given-names>R</given-names></name><name><surname>Dempsey</surname><given-names>JC</given-names></name><name><surname>Maddirevula</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>Y-HH</given-names></name><name><surname>Phelps</surname><given-names>IG</given-names></name><name><surname>Gesemann</surname><given-names>M</given-names></name><name><surname>Goel</surname><given-names>H</given-names></name><name><surname>Birk</surname><given-names>OS</given-names></name><name><surname>Alanzi</surname><given-names>T</given-names></name><name><surname>Rawashdeh</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>AO</given-names></name><collab>University of Washington Center for Mendelian Genomics</collab><name><surname>Bamshad</surname><given-names>MJ</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Neuhauss</surname><given-names>SCF</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name><name><surname>Alkuraya</surname><given-names>FS</given-names></name><name><surname>Roepman</surname><given-names>R</given-names></name><name><surname>Bachmann-Gagescu</surname><given-names>R</given-names></name><name><surname>Doherty</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mutations in ARMC9, which encodes a basal body protein, cause joubert syndrome in humans and ciliopathy phenotypes in zebrafish</article-title><source>American Journal of Human Genetics</source><volume>101</volume><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.05.010</pub-id><pub-id pub-id-type="pmid">28625504</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vössing</surname><given-names>C</given-names></name><name><surname>Atigbire</surname><given-names>P</given-names></name><name><surname>Eilers</surname><given-names>J</given-names></name><name><surname>Markus</surname><given-names>F</given-names></name><name><surname>Stieger</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Neidhardt</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The major ciliary isoforms of RPGR build different interaction complexes with INPP5E and RPGRIP1L</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>3583</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22073583</pub-id><pub-id pub-id-type="pmid">33808286</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ijuin</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Takenawa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulation of IGF-1/PI3K/akt signalling by the phosphoinositide phosphatase pharbin</article-title><source>Journal of Biochemistry</source><volume>150</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1093/jb/mvr037</pub-id><pub-id pub-id-type="pmid">21436142</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>V</given-names></name><name><surname>Tuan</surname><given-names>H-F</given-names></name><name><surname>Keser</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Lopez</surname><given-names>I</given-names></name><name><surname>Zaneveld</surname><given-names>JE</given-names></name><name><surname>Siddiqui</surname><given-names>S</given-names></name><name><surname>Bowles</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Salvo</surname><given-names>J</given-names></name><name><surname>Jacobson</surname><given-names>SG</given-names></name><name><surname>Iannaccone</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Birch</surname><given-names>D</given-names></name><name><surname>Heckenlively</surname><given-names>JR</given-names></name><name><surname>Fishman</surname><given-names>GA</given-names></name><name><surname>Traboulsi</surname><given-names>EI</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wheaton</surname><given-names>D</given-names></name><name><surname>Koenekoop</surname><given-names>RK</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Comprehensive molecular diagnosis of 179 leber congenital amaurosis and juvenile retinitis pigmentosa patients by targeted next generation sequencing</article-title><source>Journal of Medical Genetics</source><volume>50</volume><fpage>674</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2013-101558</pub-id><pub-id pub-id-type="pmid">23847139</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wätzlich</surname><given-names>D</given-names></name><name><surname>Vetter</surname><given-names>I</given-names></name><name><surname>Gotthardt</surname><given-names>K</given-names></name><name><surname>Miertzschke</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y-X</given-names></name><name><surname>Wittinghofer</surname><given-names>A</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The interplay between RPGR, pdeδ and arl2/3 regulate the ciliary targeting of farnesylated cargo</article-title><source>EMBO Reports</source><volume>14</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1038/embor.2013.37</pub-id><pub-id pub-id-type="pmid">23559067</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whisstock</surname><given-names>JC</given-names></name><name><surname>Romero</surname><given-names>S</given-names></name><name><surname>Gurung</surname><given-names>R</given-names></name><name><surname>Nandurkar</surname><given-names>H</given-names></name><name><surname>Ooms</surname><given-names>LM</given-names></name><name><surname>Bottomley</surname><given-names>SP</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The inositol polyphosphate 5-phosphatases and the apurinic/apyrimidinic base excision repair endonucleases share a common mechanism for catalysis</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>37055</fpage><lpage>37061</lpage><pub-id pub-id-type="doi">10.1074/jbc.M006244200</pub-id><pub-id pub-id-type="pmid">10962003</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>LP</given-names></name><name><surname>Philips</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of ras</article-title><source>Journal of Lipid Research</source><volume>47</volume><fpage>883</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1194/jlr.R600004-JLR200</pub-id><pub-id pub-id-type="pmid">16543601</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutation analysis in 129 genes associated with other forms of retinal dystrophy in 157 families with retinitis pigmentosa based on exome sequencing</article-title><source>Molecular Vision</source><volume>21</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">25999675</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Ling</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phosphatidylinositol phosphate kinase pipkiγ and phosphatase INPP5E coordinate initiation of ciliogenesis</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10777</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10777</pub-id><pub-id pub-id-type="pmid">26916822</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The joubert syndrome protein inpp5e controls ciliogenesis by regulating phosphoinositides at the apical membrane</article-title><source>Journal of the American Society of Nephrology</source><volume>28</volume><fpage>118</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1681/ASN.2015080906</pub-id><pub-id pub-id-type="pmid">27401686</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Lyu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><name><surname>Zhong</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Down-regulation of <italic>inpp5e</italic> associated with abnormal ciliogenesis during embryonic neurodevelopment under inositol deficiency</article-title><source>Frontiers in Neurology</source><volume>12</volume><elocation-id>579998</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2021.579998</pub-id><pub-id pub-id-type="pmid">34093381</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Giacalone</surname><given-names>JC</given-names></name><name><surname>Searby</surname><given-names>C</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Tucker</surname><given-names>BA</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Disruption of RPGR protein interaction network is the common feature of RPGR missense variations that cause XLRP</article-title><source>PNAS</source><volume>116</volume><fpage>1353</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1073/pnas.1817639116</pub-id><pub-id pub-id-type="pmid">30622176</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78383.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pedersen</surname><given-names>Lotte B</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035b05819</institution-id><institution>University of Copenhagen</institution></institution-wrap><country>Denmark</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.01.25.477585" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.01.25.477585"/></front-stub><body><p>This manuscript is of interest to readers in the field of cilia biology and ciliopathies. The authors address the molecular mechanisms by which INPP5E, a ciliary phosphoinositide phosphatase mutated in multiple ciliopathies, is targeted to the primary cilium of cultured mammalian cells. By combining cell-based analysis of various INPP5E mutant constructs with biochemical assays and structure prediction, the authors show that ciliary targeting of INPP5E requires its folded catalytic domain and is controlled by four ciliary localization signals. The work clarifies and extends previous work in the field and reveals a complex ciliary targeting mechanism unparalleled among other known ciliary cargoes. The claims are generally well supported by the data.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78383.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Pedersen</surname><given-names>Lotte B</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035b05819</institution-id><institution>University of Copenhagen</institution></institution-wrap><country>Denmark</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Pedersen</surname><given-names>Lotte B</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035b05819</institution-id><institution>University of Copenhagen</institution></institution-wrap><country>Denmark</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Lorentzen</surname><given-names>Esben</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01aj84f44</institution-id><institution>Aarhus University</institution></institution-wrap><country>Denmark</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.01.25.477585">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.01.25.477585v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Multiple Ciliary Localization Signals Control INPP5E Ciliary Targeting&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Lotte B Pedersen as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Piali Sengupta as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Esben Lorentzen (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The functional significance of the identified CLSs should be addressed in more detail (for example, examination of the role the CLSs play in cilia protein or phosphoinositide composition, cilia-dependent signaling pathways, cilia assembly or disassembly), which would provide stronger evidence of their biological significance and provide a conceptual advance in the cilia field essential to development and disease. This is particularly important considering that INPP5E mutations associated with JBTS have variable effects on INPP5E cilia localization.</p><p>2) Indirect immunofluorescence analysis in fixed cells has been used extensively here to demonstrate the identification and characterization of cilia localization signals in INPP5E. A recent publication in this field has reported possible artifactual INPP5E localization issues dependent upon fixation conditions (doi:10.3389/fcell.2021.634649). The authors should assess their data in the context of this new report and repeat a part of their principal localization experiments with alternative fixation conditions to address any possible artifactual issues with INPP5E ciliary localization. This would increase confidence in the co-localization studies.</p><p>3) For all IFM figures comparing cilia localization of various EGFP- INPP5E mutants, the authors should provide information about how many times experiments were repeated, and how many cells/cilia were analyzed in each case. In Figures 2d and 3c, the authors do provide a quantitative analysis of cilia localization of selected mutants, but the number of cells examined is not stated in the legend, nor in the Methods section. Furthermore, it is unclear whether relative expression levels and/or stability of the different INPP5E mutant constructs in RPE1 cells are similar? This is important to clarify as it could influence their cilia localization.</p><p>4) The claim that the authors have elucidated the mechanisms of INPP5E ciliary targeting requires further evidence that has not been addressed in the immunoprecipitation studies described within the manuscript. The authors use the terminology &quot;decreased binding&quot; when actually referring to &quot;decreased immunoprecipitation&quot;. This language needs to be clarified in the text as a reduction in co-immunoprecipitation could also be due to protein misfolding in the mutants. Furthermore, it would be desirable if authors could somehow quantify the IP results, e.g. by measuring band intensities and quantifying ARL13B levels in each IP pellet relative to the amount of EGFP- INPP5E levels in the same IP pellets. Before a claim of &quot;decreased binding&quot; can be substantiated, the authors also need to validate that the mutant proteins are correctly folding and confirm immunoprecipitation data with direct binding studies; alternatively, this claim needs to be adjusted/toned down.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78383.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The functional significance of the identified CLSs should be addressed in more detail (for example, examination of the role the CLSs play in cilia protein or phosphoinositide composition, cilia-dependent signaling pathways, cilia assembly or disassembly), which would provide stronger evidence of their biological significance and provide a conceptual advance in the cilia field essential to development and disease. This is particularly important considering that INPP5E mutations associated with JBTS have variable effects on INPP5E cilia localization.</p></disp-quote><p>To address this great point, we have assessed CLS function in a rescue assay of TULP3 ciliary accumulation in INPP5E-KO cells (Figure 4c-d). This assay is based on the known fact that INPP5E-KO cilia have abnormally high levels of TULP3, as we and others showed some years ago (refs. 33-34). The results and quantitation of these rescue experiments show that all CLS mutants failing to localize to cilia also have significantly reduced activity in this rescue assay, as compared to INPP5E WT (Figure 4c-d). Therefore, these CLSs are indeed important regulators of INPP5E ciliary function.</p><p>To carry out these assays, we have used INPP5E-KO hTERT-RPE1 cells that we have generated using CRISPR-Cas9 technology. Generation of these cells is described in Figure 4—figure supplement 2. These INPP5E-KO cells were in turn generated from puromycin-sensitive hTERT-RPE1 cells, which we previously generated by inactivating, also via CRISPR, the puromycin acetyltransferase (PAC) gene in the original hTERT-RPE1 cell line (which contains this gene as a remnant of their immortalization procedure). The generation of these PAC-KO hTERT-RPE1 cells, which can be a useful resource for other labs, is described in Figure 4—figure supplement 1.</p><p>The manuscript text has been updated to incorporate all these changes. In addition to the cited figures and their legends, the changes can be found in Results (lines 326-353), Discussion (lines 594-595), and Methods (lines 731-745).</p><disp-quote content-type="editor-comment"><p>2) Indirect immunofluorescence analysis in fixed cells has been used extensively here to demonstrate the identification and characterization of cilia localization signals in INPP5E. A recent publication in this field has reported possible artifactual INPP5E localization issues dependent upon fixation conditions (doi:10.3389/fcell.2021.634649). The authors should assess their data in the context of this new report and repeat a part of their principal localization experiments with alternative fixation conditions to address any possible artifactual issues with INPP5E ciliary localization. This would increase confidence in the co-localization studies.</p></disp-quote><p>As suggested, we have repeated our key INPP5E localization experiments using alternative fixation conditions. Specifically, we have looked at all CLS mutants with methanol fixation. In agreement with the above-mentioned paper, in methanol-fixed hTERT-RPE1 cells, we often see EGFP-INPP5E WT accumulated at the ciliary base, with some staining also seen along the axoneme. In contrast, CLS mutants are never seen inside the axoneme under these conditions, confirming that these CLSs grant INPP5E access to the axonemal compartment (Figure 4—figure supplement 3a-b).</p><p>Three of the five CLS mutants (∆CLS1, ∆CLS4 and ∆CLS1+4) strongly accumulate at the transition zone (TZ) under these fixation conditions (Figure 4—figure supplement 3c), indicating that these CLSs play a role in INPP5E’s TZ crossing. This is no surprise for CLS4 (CaaX box), which was already known to function at the TZ (as explained in lines 83-85 of the introduction). It also makes sense for CLS1, as we show its function is partially redundant with CLS4 (Figure 3a-c). Instead, ∆CLS3 is never seen at the ciliary base in methanol-fixed cells, and ∆CLS2 only occasionally so. This suggests a different mechanism of action for these CLSs, perhaps in retaining INPP5E inside cilia, or in reaching the ciliary base.</p><p>Regarding possible artefacts, it seems clear (from the aforementioned Conduit et al., 2021 paper, and from our own data) that the different ciliary pools of INPP5E are better seen with different fixations. Thus, as the above paper shows, the ciliary base accumulation of EGFP-INPP5E seen in live hTERT-RPE1 cells is largely lost with paraformaldehyde (PFA) fixation. On the other hand, our data with ∆CLS1 and ∆CLS4 suggest that methanol fixation is worse at preserving axonemal staining (since we see these mutants inside the axoneme with PFA (Figure 3b-c), but not methanol (Figure 4—figure supplement 3a-b)). In summary, we think that each fixation method has its own pros and cons when it comes to visualizing INPP5E.</p><p>In addition to Figure 4—figure supplement 3 and its legend, associated changes in the manuscript can be found in Results (lines 354-373), Discussion (lines 625-629), and Methods (lines 727-730 and 814-816). Thanks for raising this excellent point.</p><disp-quote content-type="editor-comment"><p>3) For all IFM figures comparing cilia localization of various EGFP- INPP5E mutants, the authors should provide information about how many times experiments were repeated, and how many cells/cilia were analyzed in each case. In Figures 2d and 3c, the authors do provide a quantitative analysis of cilia localization of selected mutants, but the number of cells examined is not stated in the legend, nor in the Methods section. Furthermore, it is unclear whether relative expression levels and/or stability of the different INPP5E mutant constructs in RPE1 cells are similar? This is important to clarify as it could influence their cilia localization.</p></disp-quote><p>We have added to the figure legends all the information regarding number of independent experiments and of cells and cilia analyzed.</p><p>We have also analyzed protein levels of the EGFP-INPP5E mutants we use throughout the paper. To do this, we have performed Western blots of transfected HEK293T cells, and quantitated the levels of each EGFP-INPP5E protein relative to tubulin expression. These data are found in Figure 1—figure supplement 1, Figure 2—figure supplement 2, Figure 3—figure supplement 2, and Figure 5d.</p><p>In the text, these data have been incorporated to Results (lines 163-181, 220-224, 290-293, 304-305 and 383-399), Discussion (lines 581-595), and Methods (lines 755-756 and 806-814) sections.</p><p>Thanks for these great points, which have clearly improved the quality of our data.</p><disp-quote content-type="editor-comment"><p>4) The claim that the authors have elucidated the mechanisms of INPP5E ciliary targeting requires further evidence that has not been addressed in the immunoprecipitation studies described within the manuscript. The authors use the terminology &quot;decreased binding&quot; when actually referring to &quot;decreased immunoprecipitation&quot;. This language needs to be clarified in the text as a reduction in co-immunoprecipitation could also be due to protein misfolding in the mutants. Furthermore, it would be desirable if authors could somehow quantify the IP results, e.g. by measuring band intensities and quantifying ARL13B levels in each IP pellet relative to the amount of EGFP- INPP5E levels in the same IP pellets. Before a claim of &quot;decreased binding&quot; can be substantiated, the authors also need to validate that the mutant proteins are correctly folding and confirm immunoprecipitation data with direct binding studies; alternatively, this claim needs to be adjusted/toned down.</p></disp-quote><p>We agree that the claim in the abstract that “<italic>we elucidate the mechanisms</italic>” of INPP5E ciliary targeting sounded excessive. We have replaced it by “<italic>we shed light on the mechanisms</italic>”, which we believe it indicates simply that we know more now than we did before. This sentence not only refers to the co-IPs, but also to our identification of novel CLSs.</p><p>Regarding our claims of “<italic>decreased binding</italic>” (or similar expressions), we have replaced many of them by “<italic>decreased co-IP</italic>” (or equivalent). That said, when we speak of <italic>binding</italic>, <italic>interaction</italic> or <italic>association</italic> in the context of our co-IPs, we do not intend to make any mechanistic presumptions as to how the interaction occurs (e.g. whether direct or not). Therefore, we see no need to prove that an interaction is direct in order to speak in terms of <italic>decreased binding</italic> (but of course, this depends on how one defines the word <italic>binding</italic>).</p><p>Moreover, although we agree in principle that lack of co-IP may be due to misfolding, we do not think this is a major issue in our data. For CLS1 and CLS4, we show that their mutants are fully enzymatically active (Figure 3—figure supplement 1), and must hence be properly folded. For CLS2-3, although it is true that their mutation reduces enzyme activity, they still preserve significant activity (Figure 2e), their protein levels and stability are not strongly reduced (Figure 2—figure supplements 2-3), and they co-IP with all proteins analyzed except TULP3 (Figures 6-8). Therefore, on this count we also think it is reasonable for us to speak in terms of binding/interaction/association, as we do sometimes.</p><p>Still, as mentioned above, we have replaced these terms in multiple places for “co-IP” (as a result, searching the manuscript for “co-IP” now retrieves 50 hits, as opposed to 23 in the previous version).</p><p>Lastly, we have quantified all co-IP results throughout the paper. We have done it as suggested by the reviewer: normalizing co-IPed protein by amount of EGFP-INPP5E IPed in the same sample (and by lysate levels of the co-IPed protein). These quantitations have been incorporated into Figure 6a (PDE6D), Figure 6b (RPGR), Figure 6d (ARL13B), Figure 7b-c (TULP3), Figure 7f (CEP164), and Figure 8b (ATG16L1). Details on each quantitation are found in the figure legends, and in Methods (lines 806-814). The corresponding Results subsections (lines 456-466, 481-482, 505-506 and 553-557), and the Discussion (lines 617-620), have been updated accordingly.</p><p>Thanks for the great point. We think it has greatly improved the quality of our work.</p></body></sub-article></article>